

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number
WO 2004/099228 A2

(51) International Patent Classification⁷: **C07H**

(21) International Application Number:
PCT/US2004/013401

(22) International Filing Date: 30 April 2004 (30.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/467,767 2 May 2003 (02.05.2003) US
60/528,342 9 December 2003 (09.12.2003) US

(71) Applicant: **NOVOZYMES BIOTECH, INC.** [US/US];
1445 Drew Avenue, Davis, CA 95616 (US).

(72) Inventors: **LAMSA, Michael**; 2635 Duchamp Street,
Davis, CA 95616 (US). **FIDANTSEF, Ana**; 3836 Alegre
Way, Davis, CA 95616 (US). **GORRE-CLANCY, Brian**;
8766 Torrey Way, Elk Grove, CA 95616 (US).

(74) Agent: **STARNES, Robert**; Novozymes Biotech, Inc.,
1445 Drew Avenue, Davis, CA 95616 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report*
- *with (an) indication(s) in relation to deposited biological
material furnished under Rule 13bis separately from the
description*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: VARIANTS OF BETA-GLUCOSIDASES

(57) Abstract: The present invention relates to variants of a parent beta-glucosidase, comprising a substitution at one or more po-
sitions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions
142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity. The present
invention also relates to nucleotide sequences encoding the variant beta-glucosidases and to nucleic acid constructs, vectors, and host
cells comprising the nucleotide sequences.



WO 2004/099228 A2

VARIANTS OF BETA-GLUCOSIDASES

Statement as to Rights to Inventions Made Under Federally Sponsored Research and Development

This invention was made with Government support under NREL Subcontract No. ZCO-30017-02, Prime Contract DE-AC36-98GO10337 awarded by the Department of Energy. The government has certain rights in this invention.

Background of the Invention

Field of the Invention

The present invention relates to variants of beta-glucosidases having one or more improved properties relative to its parent enzyme, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.

Description of the Related Art

Cellulose is a polymer of the simple sugar glucose covalently bonded by beta-1,4-linkages. Many microorganisms produce enzymes that hydrolyze beta-linked glucans. These enzymes include endoglucanases, cellobiohydrolases, and beta-glucosidases. Endoglucanases digest the cellulose polymer at random locations, opening it to attack by cellobiohydrolases. Cellobiohydrolases sequentially release molecules of cellobiose from the ends of the cellulose polymer. Cellobiose is a water-soluble beta-1,4-linked dimer of glucose. Beta-glucosidases hydrolyze cellobiose to glucose.

The conversion of cellulosic feedstocks into ethanol has the advantages of the ready availability of large amounts of feedstock, the desirability of avoiding burning or land filling the materials, and the cleanliness of the ethanol fuel. Wood, agricultural residues, herbaceous crops, and municipal solid wastes have been considered as feedstocks for ethanol production. These materials primarily consist of cellulose, hemicellulose, and lignin.

Once the cellulose is converted to glucose, the glucose is easily fermented by yeast into ethanol. Since glucose is readily fermented to ethanol by a variety of yeasts while cellobiose is not, any cellobiose remaining at the end of the hydrolysis represents a loss of yield of ethanol. More importantly, cellobiose is a potent inhibitor of endoglucanases and cellobiohydrolases. The accumulation of cellobiose during hydrolysis is extremely undesirable for ethanol production.

Cellobiose accumulation has been a major problem in enzymatic hydrolysis because

cellulase-producing microorganisms produce little beta-glucosidase. The low amount of beta-glucosidase results in a shortage of capacity to hydrolyze the cellobiose to glucose. Several approaches have been used to increase the amount of beta-glucosidase in cellulose conversion to glucose.

5 One approach is to produce beta-glucosidase using microorganisms that produce little cellulase, and add the beta-glucosidase exogenously to endoglucanase and cellobiohydrolase to enhance the hydrolysis. However, the quantities required are too costly for a commercial biomass to ethanol operation.

10 A second approach is to carry out cellulose hydrolysis simultaneously with fermentation of the glucose by yeast. This process is known as simultaneous saccharification and fermentation (SSF). In an SSF system, fermentation of the glucose removes it from solution. However, SSF systems are not yet commercially viable because the operating temperature for yeast of 28°C is too low for the 50°C conditions required.

15 A third approach to overcome the shortage of beta-glucosidase is to overexpress the beta-glucosidase in a host, thereby increasing the yield of beta-glucosidase.

20 It would be an advantage in the art to provide beta-glucosidase variants with improved properties for converting cellulosic materials to monosaccharides, disaccharides, and polysaccharides. Improved properties include altered temperature-dependent activity profiles, thermostability, pH activity, pH stability, substrate specificity, product specificity, and chemical stability.

 It is an object of the present invention to provide variants of beta-glucosidases with improved properties compared to their parent enzymes.

Summary of the Invention

25 The present invention relates to isolated variants of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity.

30 The present invention also relates to isolated polypeptides having beta-glucosidase activity, wherein the amino acid sequence of the polypeptide differs from amino acids 1 to 842 of SEQ ID NO:2 or amino acids 1 to 844 of SEQ ID NO: 70 at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

35

The present invention also relates to isolated nucleotide sequences encoding the variant beta-glucosidases or polypeptides having beta-glucosidase activity and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.

5 The present invention also relates to methods for producing a variant of a parent beta-glucosidase or polypeptides having beta-glucosidase activity in a host cell.

The present invention also relates to methods for obtaining a variant of a parent beta-glucosidase, comprising:

(a) introducing a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to
10 positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity; and

(b) recovering the variant.

The present invention also relates to detergent compositions comprising beta-glucosidase variants and polypeptides having beta-glucosidase activity.

15 The present invention also relates to plants encoding beta-glucosidase variants or polypeptides having beta-glucosidase activity.

The present invention further relates to using the beta-glucosidase variants and polypeptides having beta-glucosidase activity in the conversion of cellulose to glucose.

20 **Brief Description of the Figures**

Figure 1 shows a restriction map of pSATE101.

Figure 2 shows a restriction map of pSATE111.

Figure 3 shows a restriction map of pMJ04.

Figure 4 shows a restriction map of pCaHj527.

25 Figure 5 shows a restriction map of pMT2188.

Figure 6 shows a restriction map of pCaHj568.

Figure 7 shows a restriction map of pMJ05.

Figure 8 shows a restriction map of pSMai130.

30 Figure 9 shows the cDNA sequence of an *Aspergillus oryzae* beta-glucosidase gene (SEQ ID NO: 1) and the deduced amino acid sequence thereof (SEQ ID NO: 2).

Figure 10 shows 63 bp of the putative *Humicola insolens* endoglucanase V signal sequence (ATG start codon to Ala-21, SEQ ID NO: 29).

Figure 11 shows a restriction map of pSMai135.

Figure 12 shows a restriction map of pALFd1.

35 Figure 13 shows a restriction map of pALLo1.

Figure 14 shows a restriction map of pBANE10.

Figure 15 shows a restriction map of pALLo2.

Figure 16 shows a restriction map of pALFd3BG41.

Figure 17 shows a restriction map of pALFd3BG48.

5 Figure 18 shows a thermostability determination of *Aspergillus oryzae* beta-glucosidase variants BG41 and BG48.

Figure 19 shows the thermostability effects of mutations G142S and H266Q individually and combined.

Figure 20 shows a restriction map of pEJG97.

10 Figure 21 shows the genomic DNA sequence and the deduced amino acid sequence of an *Aspergillus fumigatus* beta-glucosidase (SEQ ID NOS: 69 and 70, respectively). The predicted signal peptide is underlined and predicted introns are italicized.

Figure 22 shows a restriction map of pCR4Blunt-TOPOAfcDNA5'.

Figure 23 shows a restriction map of pCR4Blunt-TOPOAfcDNA3'.

15 Figure 24 shows a restriction map of pCR4Blunt-TOPOAfcDNA.

Figure 25 shows a restriction map of pALFd7.

Figure 26 shows a restriction map of pALFd6.

Figure 27 shows a restriction map of pEJG97AfumFAM3AG142S.

Figure 28 shows a restriction map of pALFd7G142S.

20 Figure 29 shows a restriction map of pEJG97AfumFAM3AH266Q.

Detailed Description of the Invention

The present invention relates to isolated variants of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266,
25 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity.

Definitions

30 The term "beta-glucosidase" is defined herein as a beta-D-glucoside glucohydrolase (E.C. 3.2.1.21) which catalyzes the hydrolysis of terminal non-reducing beta-D-glucose residues with the release of beta-D-glucose. For purposes of the present invention, beta-glucosidase activity is determined according to the basic procedure described by Venturi *et al.*, 2002, *J. Basic Microbiol.* 42: 55-66, except various temperatures and pH 5 are employed
35 herein. One unit of beta-glucosidase activity is defined as 1.0 μ mole of beta-D-glucose

produced per minute at 25°C, pH 5.

The term "variant" is defined herein as a beta-glucosidase comprising one or more alterations, such as substitutions, insertions, deletions, and/or truncations of one or more specific amino acid residues at one or more specific positions in the polypeptide.

5 The term "wild-type" beta-glucosidase denotes a beta-glucosidase expressed by a naturally occurring microorganism, such as a yeast or filamentous fungus found in nature.

The term "parent" beta-glucosidase as used herein means a beta-glucosidase to which modifications, *e.g.*, substitution(s), insertion(s), deletion(s), and/or truncation(s), are made to produce the enzyme variants of the present invention. This term also refers to the polypeptide with which a variant is compared and aligned. The parent may be a naturally occurring (wild type) polypeptide, or it may even be a variant thereof, prepared by any suitable means. For instance, the parent protein may be a variant of a naturally occurring polypeptide which has been modified or altered in the amino acid sequence. A parent may also be an allelic variant which is any of two or more alternative forms of a gene occupying the same chromosomal locus. An allelic variant of a polypeptide is a polypeptide encoded by the corresponding allelic variant of a gene.

15 The term "shuffling" means recombination of nucleotide sequence(s) between two or more homologous nucleotide sequences resulting in recombined nucleotide sequences (*i.e.*, nucleotide sequences having been subjected to a shuffling cycle) having a number of nucleotides exchanged, in comparison to the starting nucleotide sequences.

20 The term "randomized library", "variant library", or "library" is defined herein as a library of variant polypeptides. Diversity in the variant library can be generated via mutagenesis of the genes encoding the variants at the DNA triplet level, such that individual codons are variegated, *e.g.*, by using primers of partially randomized sequences in a PCR reaction. Several techniques have been described, by which one can create a diverse combinatorial library by variegating several nucleotide positions in a gene and recombining them, for instance, where these positions are too far apart to be covered by a single (spiked or doped) oligonucleotide primer. These techniques include the use of *in vivo* recombination of the individually diversified gene segments as described in WO 97/07205 on page 3, lines 8 to 29. They also include the use of DNA shuffling techniques to create a library of full length genes, wherein several gene segments are combined, and wherein each segment may be diversified, *e.g.*, by spiked mutagenesis (Stemmer, 1994, *Nature* 370: 389-391; US 5,811,238; US 5,605,793; and US 5,830,721). One can use a gene encoding a protein "backbone" (wild type parent polypeptide) as a template polynucleotide, and combine this with one or more single or double-stranded oligonucleotides as described in WO 98/41623

and WO 98/41622. The single-stranded oligonucleotides can be partially randomized during synthesis. The double-stranded oligonucleotides can be PCR products incorporating diversity in a specific region. In both cases, one can dilute the diversity with corresponding segments encoding the sequence of the backbone protein in order to limit the average
5 number of changes that are introduced.

The term "recombination" is defined herein as a process wherein nucleic acids associate with each other in regions of homology, leading to interstrand DNA exchange between those sequences. For purposes of the present invention, homologous recombination is determined according to the procedures summarized by Paques and Haber,
10 1999, *Microbiology and Molecular Biology Reviews* 63: 349-404. "Homologous recombination" is defined herein as recombination in which no changes in the nucleotide sequences occurs within the regions of homology relative to the input nucleotide sequences.

For perfect homologous recombination, the regions should contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most
15 preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding nucleic acid sequence to enhance the probability of homologous recombination. The recombination may also occur by non-homologous recombination. "Non-homologous recombination" is defined herein as recombination where any mode of DNA repair incorporating strand exchange results in a nucleotide sequence different from any of the
20 recombining sequences.

The term "improved property" is defined herein as a characteristic associated with a variant which is improved compared to the parent beta-glucosidase. Such improved properties include, but are not limited to, altered temperature-dependent activity profile, thermostability, pH activity, pH stability, substrate specificity, product specificity, and
25 chemical stability.

The term "improved thermal activity" is defined herein as a variant enzyme displaying an alteration of the temperature-dependent activity profile of a beta-glucosidase variant at a specific temperature relative to the temperature-dependent activity profile of the parent beta-glucosidase. The thermal activity value provides a measure of the enzyme's
30 efficiency in performing catalysis of a hydrolysis reaction over a range of temperatures. A beta-glucosidase has a specific temperature range wherein the protein is stable and retains its enzymatic activity, but becomes less stable and thus less active with increasing temperature. Furthermore, the initial rate of a reaction catalyzed by a beta-glucosidase can be accelerated by an increase in temperature which is measured by determining thermal
35 activity of a variant. A more thermoactive variant will lead to an increase in the rate of

hydrolysis decreasing the time required and/or decreasing the enzyme concentration required for hydrolysis. Alternatively, a variant with a reduced thermal activity will catalyze a hydrolysis reaction at a temperature lower than the temperature optimum of the parent enzyme defined by the temperature-dependent activity profile of the parent.

5 The term "improved thermostability" is defined herein as a variant enzyme displaying retention of enzymatic activity after a period of incubation at elevated temperature relative to the parent enzyme. Such a variant may or may not display an altered thermal activity profile relative to the parent, *e.g.*, it may have an improved ability to refold following incubation at elevated temperature relative to the parent.

10 In a preferred embodiment, the thermal activity of the variant beta-glucosidase is at least 1.5-fold, preferably at least 2-fold, more preferably at least 5-fold, most preferably at least 7-fold, and even most preferably at least 20-fold more thermally active than the parent enzyme when residual activity is compared using methylumbelliferyl-beta-D-glucopyranoside as substrate at 60°C and pH 5 for 15 hours.

15 The term "improved product specificity" is defined herein as a variant enzyme displaying an altered product profile relative to the parent in which the altered product profile improves the performance of the variant in a given application relative to the parent. The term "product profile" is defined herein as the chemical composition of the reaction products produced by enzymatic hydrolysis.

20 The term "improved chemical stability" is defined herein as a variant enzyme displaying retention of enzymatic activity after a period of incubation in the presence of a chemical or chemicals, either naturally occurring or synthetic, that reduce the enzymatic activity of the parent enzyme. Improved chemical stability may also result in variants better able to catalyze a reaction in the presence of such chemicals.

25

Conventions for Designation of Variants

 In the present invention, a specific numbering of amino acid residue positions in the beta-glucosidase variants is employed. For example, by aligning the amino acid sequences of known beta-glucosidases, it is possible to designate an amino acid position number to any
30 amino acid residue in any beta-glucosidase enzyme.

 Using the numbering system originating from the amino acid sequence of the beta-glucosidase disclosed in SEQ ID NO: 2 or SEQ ID NO: 70, aligned with the amino acid sequence of a number of other beta-glucosidases, it is possible to indicate the position of an amino acid residue in a beta-glucosidase in regions of structural homology.

35 Multiple alignments of protein sequences may be made, for example, using

“ClustalW” (Thompson, J.D., Higgins, D.G. and Gibson, T.J., 1994, CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice, *Nucleic Acids Research* 22: 4673-4680). Multiple alignments of DNA sequences may be done using the protein alignment as
5 a template, replacing the amino acids with the corresponding codon from the DNA sequence.

Pairwise sequence comparison algorithms in common use are adequate to detect similarities between protein sequences that have not diverged beyond the point of approximately 20-30% sequence identity (Doolittle, 1992, *Protein Sci.* 1: 191-200; Brenner
10 *et al.*, 1998, *Proc. Natl. Acad. Sci. USA* 95, 6073-6078). However, truly homologous proteins with the same fold and similar biological function have often diverged to the point where traditional sequence-based comparison fails to detect their relationship (Lindahl and Elofsson, 2000, *J. Mol. Biol.* 295: 613-615). Greater sensitivity in sequence-based searching can be attained using search programs that utilize probabilistic representations of protein
15 families (profiles) to search databases. For example, the PSI-BLAST program generates profiles through an iterative database search process and is capable of detecting remote homologs (Atschul *et al.*, 1997, *Nucleic Acids Res.* 25: 3389-3402). Even greater sensitivity can be achieved if the family or superfamily for the protein of interest has one or more representatives in the protein structure databases. Programs such as GenTHREADER (Jones
20 1999, *J. Mol. Biol.* 287: 797-815; McGuffin and Jones, 2003, *Bioinformatics* 19: 874-881) utilize information from a variety of sources (PSI-BLAST, secondary structure prediction, structural alignment profiles, and solvation potentials) as input to a neural network that predicts the structural fold for a query sequence. Similarly, the method of Gough *et al.*,
2000, *J. Mol. Biol.* 313: 903-919, can be used to align a sequence of unknown structure with
25 the superfamily models present in the SCOP database. These alignments can in turn be used to generate homology models for the protein of interest, and such models can be assessed for accuracy using a variety of tools developed for that purpose.

For proteins of known structure, several tools and resources are available for retrieving and generating structural alignments. For example the SCOP superfamilies of
30 proteins have been structurally aligned, and those alignments are accessible and downloadable. These alignments can be used to predict the structurally and functionally corresponding amino acid residues in proteins within the same structural superfamily. This information, along with information derived from homology modeling and profile searches, can be used to predict which residues to mutate when moving mutations of interest from
35 one protein to a close or remote homolog.

In describing the various beta-glucosidase variants of the present invention, the nomenclature described below is adapted for ease of reference. In all cases, the accepted IUPAC single letter or triple letter amino acid abbreviations are employed.

Substitutions. For an amino acid substitution, the following nomenclature is used:
 5 [Original amino acid, position, substituted amino acid]. Accordingly, the substitution of threonine with alanine at position 226 is designated as "Thr226Ala" or "T226A". Multiple mutations are separated by addition marks ("+"), *e.g.*, "Gly205Arg + Ser411Phe" or "G205R + S411F", representing mutations at positions 205 and 411 substituting glycine (G) with arginine (R), and serine (S) with phenylalanine (F), respectively.

10 Deletions. For an amino acid deletion, the following nomenclature is used: [Original amino acid, position*]. Accordingly, the deletion of glycine at position 195 is designated as "Gly195*" or "G195*". Multiple deletions are separated by addition marks ("+"), *e.g.*, "Gly195* + Ser411*" or "G195* + S411*".

Insertions. For an amino acid insertion, the following nomenclature is used: [Original
 15 amino acid, position, original amino acid, new inserted amino acid]. Accordingly the insertion of lysine after glycine at position 195 is designated "Gly195GlyLys" or "G195GK". Multiple insertions of amino acids are designated [Original amino acid, position, original amino acid, new inserted amino acid #1, new inserted amino acid #2; etc.]. For example, the insertion of lysine and alanine after glycine at position 195 is indicated as
 20 "Gly195GlyLysAla" or "G195GKA".

In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s). In the above example the sequences would thus be:

<u>Parent:</u>	<u>Variant:</u>
195	195 195a 195b
G	G - K - A

25

Degenerate indications. For degenerate indications where an amino acid residue identical to the existing amino acid residue is inserted, degeneracy in the nomenclature arises. For example, a glycine inserted after the glycine in the above example would be indicated by "G195GG". Given that an alanine were present in position 194, the same actual
 30 change could just as well be indicated as "A194AG":

	<u>Parent:</u>	<u>Variant:</u>
Numbering I:	194 195	194 195 195a

Sequence:	A - G	A - G - G
Numbering II:		194 194a 195

Such instances will be apparent to the skilled person, and the indication "G195GG" and corresponding indications for this type of insertion is thus meant to comprise such equivalent degenerate indications.

- 5 If amino acid sequence segments are repeated in the parent polypeptide and/or in the variant, equivalent degenerate indications arise, also when alterations other than insertions are listed such as deletions and/or substitutions. For instance, the deletion of two consecutive amino acids "AG" in the sequence "AGAG" from position 194-97 may be written as "A194*+G195*" or "A196*+G197*":

	<u>Parent:</u>	<u>Variant:</u>
Numbering I:	194 195 196 197	194 195
Sequence:	A - G - A - G	A - G
Numbering II:		196 197

10

- Multiple modifications. Variants comprising multiple modifications are separated by addition marks ("+"), *e.g.*, "Arg170Tyr+Gly195Glu" or "R170Y+G195E" representing modifications in positions 170 and 195 substituting tyrosine and glutamic acid for arginine and glycine, respectively. Thus, "Tyr167Gly,Ala,Ser,Thr + Arg170Gly,Ala,Ser,Thr" designates
- 15 the following variants:

- "Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala", "Tyr167Gly+Arg170Ser",
 "Tyr167Gly+Arg170Thr", "Tyr167Ala+Arg170Gly", "Tyr167Ala+Arg170Ala",
 "Tyr167Ala+Arg170Ser", "Tyr167Ala+Arg170Thr", "Tyr167Ser+Arg170Gly",
 "Tyr167Ser+Arg170Ala", "Tyr167Ser+Arg170Ser", "Tyr167Ser+Arg170Thr",
 20 "Tyr167Thr+Arg170Gly", "Tyr167Thr+Arg170Ala", "Tyr167Thr+Arg170Ser", and
 "Tyr167Thr+Arg170Thr".

- This nomenclature is particularly relevant to modifications involving substituting, inserting or deleting amino acid residues having specific common properties. Such modifications are referred to as conservative amino acid modification(s). Examples of
- 25 conservative modifications are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid modifications, which do not generally alter

the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as the reverse (Taylor, 1986, *Journal of Theoretical Biology* 119: 205-218; <http://www.compbio.dundee.ac.uk/papers/amas/amas3d.html>).

Parent Beta-Glucosidases

In the present invention, the parent beta-glucosidase is (a) a polypeptide comprising an amino acid sequence which has at least 70% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70; or (b) a polypeptide encoded by a nucleotide sequence which hybridizes under at least low stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, or their complementary strands.

In a first aspect, the parent beta-glucosidase comprise an amino acid sequence which has a degree of identity to amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 (*i.e.*, the mature polypeptides) of at least about 70%, preferably at least about 75%, more preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97%, which have beta-glucosidase activity (hereinafter "homologous polypeptides"). In a preferred embodiment, the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. For purposes of the present invention, the degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

Substantially homologous parent beta-glucosidases may have one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions as described above and other substitutions that do not significantly affect the three-dimensional folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or

carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification (an affinity tag), such as a poly-histidine tract, or protein A (Nilsson *et al.*, 1985, *EMBO J.* 4: 1075; Nilsson *et al.*, 1991, *Methods Enzymol.* 198: 3. See, also, in general, Ford *et al.*,
5 1991, *Protein Expression and Purification* 2: 95-107.

Although the changes described above preferably are of a minor nature, such changes may also be of a substantive nature such as fusion of larger polypeptides of up to 300 amino acids or more both as amino- or carboxyl-terminal extensions.

In addition to the 20 standard amino acids, non-standard amino acids (such as 4-
10 hydroxyproline, 6-*N*-methyl lysine, 2-aminoisobutyric acid, isovaline, and alpha-methyl serine) may be substituted for amino acid residues of a wild-type beta-glucosidase. A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, and unnatural amino acids may be substituted for amino acid residues. "Unnatural amino acids" have been modified after protein synthesis, and/or have a chemical
15 structure in their side chain(s) different from that of the standard amino acids. Unnatural amino acids can be chemically synthesized, and preferably, are commercially available, and include pipercolic acid, thiazolidine carboxylic acid, dehydropyrolone, 3- and 4-methylpyrolone, and 3,3-dimethylpyrolone.

Preferably, the parent beta-glucosidase comprises the amino acid sequence of SEQ
20 ID NO: 2 or SEQ ID NO: 70; or an allelic variant thereof; or a fragment thereof that has beta-glucosidase activity. In a preferred embodiment, the parent polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 70. In another preferred embodiment, the parent polypeptide comprises amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70; or an allelic variant thereof; or a fragment thereof
25 that has beta-glucosidase activity. In another preferred embodiment, the parent polypeptide comprises amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the parent polypeptide consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 70; or an allelic variant thereof; or a fragment thereof that has beta-glucosidase activity. In another preferred embodiment, the
30 parent polypeptide consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 70.

In another preferred embodiment, the parent polypeptide consists of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 or an allelic variant thereof; or a fragment thereof that has beta-glucosidase activity. In another preferred embodiment, the parent polypeptide consists of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to
35 844 of SEQ ID NO: 70. In another preferred embodiment, the parent polypeptide is

encoded by the nucleotide sequence contained in *Escherichia coli* DSM 14240, wherein the nucleic acid sequence encodes a polypeptide having beta-glucosidase activity. In another preferred embodiment, the parent polypeptide is encoded by the mature polypeptide coding region contained in *Escherichia coli* DSM 14240. In another preferred embodiment, the parent polypeptide is encoded by the nucleotide sequence contained in plasmid pEJG113 which is contained in *Escherichia coli* NRRL B-30695, wherein the nucleic acid sequence encodes a polypeptide having beta-glucosidase activity. In another preferred embodiment, the parent polypeptide is encoded by the mature polypeptide coding region contained in plasmid pEJG113 which is contained in *Escherichia coli* NRRL B-30695.

10 A fragment of SEQ ID NO: 2 or SEQ ID NO: 70 is a polypeptide having one or more amino acids deleted from the amino and/or carboxyl terminus of this amino acid sequence. Preferably, a fragment contains at least 770 amino acid residues, more preferably at least 800 amino acid residues, and most preferably at least 830 amino acid residues.

In a second aspect, the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under low stringency conditions, preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleotide probe which hybridizes under the same conditions with (i) nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, (ii) the genomic nucleotide sequence comprising nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii) (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York). The subsequence of SEQ ID NO: 1 may be at least 100 contiguous nucleotides or preferably at least 200 contiguous nucleotides. Moreover, the subsequence may encode a polypeptide fragment which has beta-glucosidase activity.

A subsequence of SEQ ID NO: 1 or SEQ ID NO: 71, or homologue thereof, is a nucleotide sequence where one or more nucleotides have been deleted from the 5'-and/or 3'-end. Preferably, a subsequence contains at least 2310 nucleotides, more preferably at least 2400 nucleotides, and most preferably at least 2490 nucleotides.

30 The parent polypeptides may also be allelic variants of the polypeptides that have beta-glucosidase activity. An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic

variant of a gene.

The nucleotide sequence of SEQ ID NO: 1 or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 70, or a fragment thereof, may be used to design nucleotide probes to identify and clone DNA encoding parent polypeptides
5 having beta-glucosidase activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15,
10 preferably at least 25, and more preferably at least 35 nucleotides in length. Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin).

A genomic DNA or cDNA library prepared from such other organisms may be screened for DNA which hybridizes with the probes described above and which encodes a
15 parent polypeptide having beta-glucosidase activity. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with SEQ ID NO: 1 or SEQ ID NO: 71, or a subsequence
20 thereof, the carrier material is used in a Southern blot. For purposes of the present invention, hybridization indicates that the nucleotide sequence hybridizes to a labeled nucleotide probe corresponding to the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 71, its complementary strand, or a subsequence thereof, under low to very high stringency conditions. Molecules to which the radioactivity-labeled probe hybridizes can be
25 detected using, for example, X-ray film.

In a preferred embodiment, the nucleotide probe is a nucleotide sequence which encodes the polypeptide of SEQ ID NO: 2 or SEQ ID NO: 70, or a subsequence thereof. In another preferred embodiment, the nucleotide probe is SEQ ID NO: 1 or SEQ ID NO: 71. In another preferred embodiment, the nucleotide probe is nucleotides 58 to 2583 of SEQ ID
30 NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71. In another preferred embodiment, the nucleotide probe is the nucleic acid sequence contained in *Escherichia coli* DSM 14240, wherein the nucleic acid sequence encodes a polypeptide having beta-glucosidase activity. In another preferred embodiment, the nucleotide probe is the mature polypeptide coding region contained in *Escherichia coli* DSM 14240. In another preferred embodiment, the
35 nucleotide probe is the nucleic acid sequence contained in plasmid pEJG113 which is

contained in *Escherichia coli* NRRL B-30695, wherein the nucleic acid sequence encodes a polypeptide having beta-glucosidase activity. In another preferred embodiment, the nucleotide probe is the mature polypeptide coding region contained in plasmid pEJG113 which is contained in *Escherichia coli* NRRL B-30695.

5 For long probes of at least 100 nucleotides in length, low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures.

10 For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS preferably at least at least at 50°C (low stringency), more preferably at least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), most preferably at least at 65°C (high stringency), and even most preferably at least at 70°C (very high stringency).

15 For short probes which are about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at about 5°C to about 10°C below the calculated T_m using the calculation according to Bolton and McCarthy (1962, *Proceedings of the National Academy of Sciences USA* 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

For short probes which are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T_m .

25 The parent beta-glucosidase may be obtained from microorganisms of any genus. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the parent beta-glucosidase encoded by a nucleotide sequence is produced by the source or by a cell in which the nucleotide sequence from the source has been inserted. In a preferred embodiment, the parent beta-glucosidase is secreted extracellularly.

30 The parent beta-glucosidase may be a fungal beta-glucosidase. In a more preferred embodiment, the fungal beta-glucosidase is a yeast beta-glucosidase such as a *Candida*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* beta-glucosidase. In another more preferred embodiment, the fungal beta-glucosidase is a filamentous fungal beta-glucosidase such as an *Acremonium*, *Agaricus*, *Alternaria*, *Aspergillus*, *Botryosphaeria*,

Ceriporiopsis, Chaetomidium, Claviceps, Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria, Diplodia, Exidia, Fusarium, Gibberella, Holomastigotoides, Humicola, Irpex, Lentinula, Leptosphaeria, Magnaporthe, Melanocarpus, Meripilus, Myceliophthora, Neurospora, Penicillium, Phanerochaete, Poitrasia, Pseudoplectania,
 5 *Pseudotriconympha, Rhizomucor, Scytalidium, Talaromyces, Thermoascus, Thielavia, Trichoderma, Trichophaea, Verticillium, Volvariella, or Xylaria* beta-glucosidase.

In a more preferred embodiment, the parent beta-glucosidase is a *Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis, or Saccharomyces oviformis*
 10 beta-glucosidase.

In another more preferred embodiment, the parent beta-glucosidase is an *Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus fumigatus, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Fusarium bactridioides, Fusarium cerealis,*
 15 *Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium solani, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola grisea, Humicola insolens, Humicola lanuginosa, Irpex*
 20 *lacteus, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium funiculosum, Penicillium purpurogenum, Phanerochaete chrysosporium, Schizophyllum commune, Sclerotium rolfsii, Sporotrichum cellulophilum, Talaromyces emersonii, Thielavia terrestris, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma viride* beta-glucosidase.

In an even more preferred embodiment, the parent beta-glucosidase is an *Aspergillus oryzae* beta-glucosidase, and most preferably the *Aspergillus oryzae* beta-glucosidase of SEQ ID NO: 2 or the mature polypeptide thereof. In another most preferred embodiment, the parent beta-glucosidase is encoded by the nucleotide sequence contained in *E. coli* DSM 14240, wherein the nucleotide sequence encodes a polypeptide having beta-glucosidase activity. In another most preferred embodiment, the parent beta-glucosidase is encoded by the mature polypeptide coding region contained in *E. coli* DSM 14240.
 30

In an even more preferred embodiment, the parent beta-glucosidase is an *Aspergillus fumigatus* beta-glucosidase, and most preferably the *Aspergillus fumigatus* beta-glucosidase of SEQ ID NO: 70 or the mature polypeptide thereof. In another most preferred embodiment, the parent beta-glucosidase is encoded by the nucleotide sequence contained
 35

in plasmid pEJG113 which is contained in *Escherichia coli* NRRL B-30695, wherein the nucleotide sequence encodes a polypeptide having beta-glucosidase activity. In another most preferred embodiment, the parent beta-glucosidase is encoded by the mature polypeptide coding region contained in plasmid pEJG113 which is contained in *Escherichia coli* NRRL B-30695.

It will be understood that for the aforementioned species, the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, *e.g.*, anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.

Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

The parent beta-glucosidases may also be identified and obtained from other sources including microorganisms isolated from nature (*e.g.*, soil, composts, water, etc.) or DNA samples obtained directly from natural materials (*e.g.*, soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms and DNA directly from natural habitats are well known in the art. The nucleotide sequence encoding a beta-glucosidase may then be derived by similarly screening a genomic or cDNA library of another microorganism or mixed DNA sample. Once a nucleotide sequence encoding a beta-glucosidase has been detected with suitable probe(s) as described herein, the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, *e.g.*, J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York).

As defined herein, an "isolated" beta-glucosidase is a polypeptide which is essentially free of other non-beta-glucosidase polypeptides, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

The parent beta-glucosidases can also include fused polypeptides or cleavable fusion polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleotide sequence (or a portion thereof) encoding another polypeptide to a nucleotide sequence (or a portion thereof) of the present invention. Techniques for producing fusion polypeptides

are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter(s) and terminator. Fusion proteins may also be constructed using intein technology in which fusions are created post-translationally (Cooper *et al.*, 1993, *EMBO J.* 12: 2575-2583; Dawson *et al.*, 1994, *Science* 266: 776-779).

Variants

In the present invention, the isolated variants of a parent beta-glucosidase comprise a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant, having beta-glucosidase activity, comprises an amino acid sequence which has a degree of identity of at least about 70%, preferably at least about 75%, more preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97% to the amino acid sequence of the parent beta-glucosidase. For purposes of the present invention, the degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

Essential amino acids in the parent beta-glucosidase can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (*i.e.*, beta-glucosidase activity) to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton *et al.*, 1996, *J. Biol. Chem.* 271: 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos *et al.*, 1992, *Science* 255: 306-312; Smith *et al.*, 1992, *J. Mol. Biol.* 224: 899-904; Wlodaver *et al.*, 1992, *FEBS Lett.* 309:59-64. The identities of essential amino acids can also be inferred from analysis of identities with polypeptides which are related to a polypeptide according to the invention.

Single or multiple amino acid substitutions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, *Science* 241: 53-57; Bowie and Sauer, 1989, *Proc. Natl. Acad. Sci. USA* 86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (*e.g.*, Lowman *et al.*, 1991, *Biochem.* 30:10832-10837; U.S. Patent No. 5,223,409; WO 92/06204) and region-directed mutagenesis (Derbyshire *et al.*, 1986, *Gene* 46:145; Ner *et al.*, 1988, *DNA* 7:127).

Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells. Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

In a preferred embodiment, the number of amino acid substitutions in the variants of the present invention comprise preferably 4 substitutions, more preferably 3 substitutions, even more preferably 2 substitutions, and most preferably 1 substitution. In another preferred embodiment, the number of amino acid substitutions in the variants of the present invention consists of preferably 4 substitutions, more preferably 3 substitutions, even more preferably 2, and most preferably 1 substitution.

In a preferred embodiment, a variant of the present invention consists of 741 to 750, 751 to 760, 761 to 770, 771 to 780, 781 to 790, 791 to 800, 801 to 810, 811 to 820, 821 to 830, 831 to 840, 841 to 850, 851 to 860, 861 to 870, 871 to 880, 881 to 890, 891 to 900, 901 to 910, 911 to 920, 921 to 930, 931 to 940, or 941 to 950 amino acids.

The variants of the present invention may further comprise one or more deletions and/or insertions of the amino acid sequence.

In a preferred embodiment, a variant of a parent beta-glucosidase comprises a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, a variant of a parent beta-glucosidase comprises substitutions at two or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, a variant of a parent beta-glucosidase comprises substitutions at three or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1

to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, a variant of a parent beta-glucosidase comprises substitutions at least at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

In a preferred embodiment, the variant comprises a substitution at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises a substitution at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser as a substitution at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the variant comprises the substitution G142S of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises a substitution at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the variant comprises a substitution at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the variant comprises Arg as a substitution at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitution Q183R of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises a substitution at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the variant comprises a substitution at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the variant comprises Gln as a substitution at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitution H266Q of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises a substitution at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2. In another more preferred embodiment, the variant comprises a substitution at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the variant comprises Gly as a substitution at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitution D703G of amino acids 1 to 842 of SEQ ID NO: 2.

10 In another preferred embodiment, the variant comprises a substitution at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the variant comprises a substitution at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the variant comprises Gly as a substitution at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitution D705G of amino acids 1 to 844 of SEQ ID NO: 70.

20 In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser and Arg as substitutions at positions corresponding to positions 142 and 183, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

25 In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser and Gln as substitutions at positions corresponding to positions 142 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to
5 positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser and Gly as substitutions at positions corresponding to positions 142 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

10 In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142 and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even
15 more preferred embodiment, the variant comprises Ser and Gly as substitutions at positions corresponding to positions 142 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino
20 acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Arg and Gln as substitutions at positions
25 corresponding to positions 183 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to
30 positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Arg and Gly as substitutions at positions corresponding to positions 183 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

35 In another preferred embodiment, the variant comprises substitutions at positions

corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even
5 more preferred embodiment, the variant comprises Arg and Gly as substitutions at positions corresponding to positions 183 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more
10 preferred embodiment, the variant comprises substitutions at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Gln and Gly as substitutions at positions corresponding to positions 266 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO:
15 2.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp,
20 Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Gln and Gly as substitutions at positions corresponding to positions 266 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions
25 corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In
30 an even more preferred embodiment, the variant comprises Ser, Arg, and Gln as substitutions at positions corresponding to positions 142, 183, and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a
35 more preferred embodiment, the variant comprises substitutions at positions corresponding

to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser, Gln, and Gly as substitutions at positions corresponding to positions 142, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser, Gln, and Gly as substitutions at positions corresponding to positions 142, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Arg, Gln, and Gly as substitutions at positions corresponding to positions 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Arg, Gln, and Gly as substitutions at positions corresponding to positions 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser, Arg, and Gly as substitutions

at positions corresponding to positions 142, 183, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In

5 a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser, Arg, and Gly as substitutions at positions corresponding to positions 142, 183, and 705, respectively,
10 of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2
15 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Ser, Arg, Gln, and Gly as substitutions at positions corresponding to positions 142, 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the variant comprises substitutions at positions
20 corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the variant comprises substitutions at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the variant comprises Arg and Gly
25 as substitutions at positions corresponding to positions 142, 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In a more preferred embodiment, the variant comprises two or more substitutions selected from the group consisting of G142S, Q183R, H266Q, and D703G (or D705G) of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

30 In a most preferred embodiment, the variant comprises the substitutions G142S + Q183R of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions G142S + H266Q of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions G142S + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred
35 embodiment, the variant comprises the substitutions Q183R + H266Q of amino acids 1 to

842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions Q183R + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2.

5 In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions G142S + H266Q of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions G142S + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions Q183R + H266Q of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions Q183R + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions H266Q + D705G of amino acids 1 to 844 of SEQ ID NO: 70.

15 In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R + H266Q of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions G142S + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions Q183R + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R + D703G of amino acids 1 to 842 of SEQ ID NO: 2.

20 In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R + H266Q of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions G142S + H266Q + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions Q183R + H266Q + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R + D705G of amino acids 1 to 844 of SEQ ID NO: 70.

25 In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the variant comprises the substitutions G142S + Q183R + H266Q + D705G of amino acids 1 to 842 of SEQ ID NO: 70.

30 In another most preferred embodiment, the variant comprising the substitutions G142S + Q183R + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2 is encoded by the nucleotide sequence contained in pSATE111BG53 which is contained in *E. coli*/NRRL B-35

30652.

As defined herein, an "isolated variant" of a parent beta-glucosidase is a polypeptide which is essentially free of other non-beta-glucosidase polypeptides, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more
5 preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

Plasmids

The plasmid or plasmids used for preparing beta-glucosidase variants may be any
10 plasmid or vector that may be subjected to recombinant DNA procedures. The plasmid comprising a nucleotide sequence encoding a beta-glucosidase may be prepared by ligating the nucleotide sequence into a suitable plasmid, or by any other suitable method. The plasmid preferably contains one or more selectable markers described herein which permit easy selection of transformed cells. The choice of plasmid will often depend on the host cell
15 into which it is to be introduced.

In the present invention, the plasmid may be an autonomously replicating plasmid, *i.e.* a plasmid which exists as an extrachromosomal entity, the replication of which is distinct from chromosomal replication.

The plasmid replicator may be any plasmid replicator mediating autonomous
20 replication which functions in a cell. The term "plasmid replicator" is defined herein as a sequence that enables a plasmid or vector to replicate *in vivo*. Examples of a plasmid replicator useful in a yeast cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. Examples of a plasmid replicator useful in a filamentous fungal cell are AMA1 and ANS1 (Gems *et al.*, 1991,
25 *Gene* 98:61-67; Cullen *et al.*, 1987, *Nucleic Acids Research* 15: 9163-9175; WO 00/24883). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the gene can be accomplished according to the methods disclosed in WO 00/24883.

The linearizing of the plasmid(s) can be directed toward any site within the plasmid. The plasmid(s) may be linearized by any suitable methods known in the art, for example,
30 digestion with one or more restriction enzymes. The linearized ends of the plasmid may be filled-in with nucleotides as described by Pompon *et al.*, 1989, *Gene* 83: 15-24. However, it is preferred not to fill in the linearized ends as it might create a frameshift.

To facilitate the screening process, the plasmid is preferably an expression vector in which the nucleotide sequence in question is operably linked to additional segments
35 required for transcription of the DNA. In general, the expression vector is derived from a

plasmid, a cosmid or a bacteriophage, or may contain elements of any or all of these. For purposes of the present invention, the terms "plasmid" and "vector" are used interchangeably.

5 DNA Fragments

The library of DNA fragments to be randomly combined (or "shuffled") with homologous regions in the linearized plasmid(s) by *in vivo* recombination may be prepared by any suitable method. For instance, the DNA fragment may be prepared by PCR amplification (*e.g.*, error-prone PCR) of a plasmid comprising the nucleotide sequence, using
10 specific primers, for example, as described in U.S. Patent No. 4,683,202 or Saiki *et al.*, 1988, *Science* 239: 487-491. The DNA fragment may also be isolated from a plasmid comprising the desired nucleotide sequence by digestion with restriction enzymes, followed by isolation using, for example, electrophoresis.

The DNA fragment may alternatively be prepared synthetically by established
15 standard methods, *e.g.*, the phosphoamidite method described by Beaucage and Caruthers, 1981, *Tetrahedron Letters* 22: 1859-1869, or the method described by Matthes *et al.*, 1984, *EMBO Journal* 3: 801-805. According to the phosphoamidite method, oligonucleotides are synthesized in an automatic DNA synthesizer, purified, annealed, ligated, and cloned into suitable plasmids.

20 The DNA fragment may also be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origins prepared by ligating fragments of synthetic, genomic or cDNA origin, the fragments corresponding to various parts of the entire nucleotide sequence, in accordance with standard techniques.

The library of DNA fragments comprise one or more mutations of the nucleotide
25 sequence, wherein the fragments comprise at least two regions, one or more regions which are homologous to the 5'-region or the 3'-region of the gap in the linearized nucleotide sequence and/or plasmid sequence and one or more second regions which are homologous to the 5'-region or the 3'-region of the DNA fragments of the library.

The regions of the DNA fragment may be any sequence that is homologous with the
30 nucleotide sequence and/or plasmid sequence.

In a preferred embodiment, the regions of the DNA fragment are a 5'-region and/or a 3'-region that flank a gene that encodes a beta-glucosidase; or a 5'-region and/or a 3'-region of a gene that encodes a beta-glucosidase.

In another preferred embodiment of the present invention, the DNA fragment or
35 fragments are prepared under conditions resulting in a low, medium or high random

mutagenesis frequency. To obtain low mutagenesis frequency the nucleotide sequence(s) (comprising the DNA fragment(s)) may be prepared by a standard PCR amplification method (US 4,683,202 or Saiki *et al.*, 1988, *Science* 239: 487-491). A medium or high mutagenesis frequency may be obtained by performing the PCR amplification under conditions which
5 reduce the fidelity of replication by the thermostable polymerase and increase the misincorporation of nucleotides, for instance as described by Deshler, 1992, *GATA* 9: 103-106; Leung *et al.*, 1989, *BioTechniques* 1: 11-15.

The PCR amplification may be combined with a mutagenesis step using a suitable physical or chemical mutagenizing agent, *e.g.*, one which induces transitions, transversions,
10 inversions, scrambling, deletions, and/or insertions.

In a preferred embodiment, the DNA fragment(s) to be shuffled preferably have a length of about 15 bp to 8 kb, more preferably about 30 bp to 6 kb, even more preferably about 40 bp to 6 kb, even more preferably about 80 bp to 4 kb, and most preferably about 100 bp to 2 kb, to be able to interact optimally with the linearized plasmid.
15

Fungal Cells

The fungal cell, into which the mixture of plasmid/fragment nucleotide sequences are to be introduced, may be any fungal cell useful in the present invention. A "recombination fungal cell" is defined herein as a cell capable of mediating shuffling of a
20 number of homologous nucleotide sequences.

In a preferred embodiment, the fungal recombination cell is a yeast cell. In a more preferred embodiment, the yeast recombination cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

In a most preferred embodiment, the yeast recombination cell is a *Kluyveromyces*
25 *lactis*, *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis*, *Saccharomyces oviformis*, or *Yarrowia lipolytica* cell.

In another preferred embodiment, the fungal recombination cell is a filamentous fungal cell. In a more preferred embodiment, the filamentous fungal recombination cell is
30 an *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

In a most preferred embodiment, the filamentous fungal recombination cell is an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, or *Aspergillus oryzae* cell. In another most preferred embodiment, the
35 filamentous fungal recombination cell is a *Fusarium bactridioides*, *Fusarium cerealis*,

Fusarium crookwellense, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell. In another most preferred embodiment, the filamentous fungal recombination cell is a *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Thielavia terrestris*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell.

10 In another most preferred embodiment, the *Aspergillus* cell is an *Aspergillus oryzae* cell.

In another most preferred embodiment, the *Aspergillus* cell is an *Aspergillus niger* cell.

In another most preferred embodiment, the *Fusarium venenatum* cell is *Fusarium venenatum* A3/5, which was originally deposited as *Fusarium graminearum* ATCC 20334 and recently reclassified as *Fusarium venenatum* by Yoder and Christianson, 1998, *Fungal Genetics and Biology* 23: 62-80 and O'Donnell *et al.*, 1998, *Fungal Genetics and Biology* 23: 57-67; as well as taxonomic equivalents of *Fusarium venenatum* regardless of the species name by which they are currently known. In another most preferred embodiment, the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* A3/5 or *Fusarium venenatum* ATCC 20334, as disclosed in WO 97/26330.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* and *Trichoderma* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156, and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920.

***In vivo* Recombination**

35 A large number of variants or homologous genes can be combined in one

transformation to efficiently create gene chimeras from the homologous genes. The shuffling of these genes, encoding improved variants or wild type genes, results in chimeras that can be expressed and followed by screening to identify those chimeras with the optimal combination of beneficial mutations. The process increases multi-fold the number of further improved variants that can be obtained compared to a process that uses only random mutagenesis (for a review, *see* Kuchner and Arnold, 1997, *TIBTech* 15: 523-530). Random mutagenesis introduces mutations into a target nucleotide sequence, creating deleterious mutations much more frequently than beneficial ones. In iterative rounds of such mutagenesis, deleterious mutations accumulate more rapidly than beneficial ones, effectively masking the identification of beneficial mutations during screening. The random recombination between two or more homologous nucleotide sequences that contain multiple single nucleotide changes in their nucleotide sequences potentially allows all those nucleotide changes contained in one variant to be separated from one another and to be randomly combined instead with any mutations present on other variants. This shuffling of mutations provides a means by which mutations from different parent sequences can be combined with each other randomly to increase the probability of combining nucleotide changes in a single nucleotide sequence.

Efficient recombination of multiple overlapping fragments using the *in vivo* recombination method is a means to generate chimeras from variants or homologous genes. An overlap as small as 15 bp is sufficient for recombination, and may be utilized for very easy domain shuffling of even distantly related genes. In domain shuffling, larger blocks of non-homologous DNA are randomly assorted by means of stretches of homology at their termini.

It is preferred that at least one shuffling cycle is a backcrossing cycle with the initially used DNA fragment or fragments, which may be the wild-type DNA fragment. This eliminates non-essential mutations. Non-essential mutations may also be eliminated by using wild-type DNA fragments as the initially used input DNA material.

More than two nucleotide sequences can be shuffled at the same time, and can be advantageous as a vast number of quite different variants can be made rapidly without an abundance of iterative procedures. When recombining many fragments from the same region, multiple overlapping of the fragments will increase the frequency of DNA interchange by itself, but it is also important to have a relatively high number of random crossovers in overlapping regions in order to recombine closely located variants/differences.

An overlap as small as 15 bp between two fragments is sufficient to obtain an efficient recombination. Therefore, overlapping in the range from 15 to 5000 bp, preferably

from 30 bp to 500 bp, especially 30 bp to 100 bp is suitable in the present invention.

In the present invention, preferably 2 or more overlapping fragments, more preferably 2 to 50 overlapping fragments, and most preferably 2 to 10 overlapping fragments may advantageously be used as DNA fragments in a shuffling cycle.

5 Besides allowing creation of chimeric genes, employing overlapping fragments is a useful method for domain shuffling by creating small overlaps between DNA fragments from different domains and screening for the best combination. For example, in the case of three DNA fragments the overlapping regions may be as follows: the first end of the first fragment overlaps the first end of the linearized plasmid, the first end of the second fragment
10 overlaps the second end of the first fragment, and the second end of the second fragment overlaps the first end of the third fragment, the first end of the third fragment overlaps (as stated above) the second end of the second fragment, and the second end of the third fragment overlaps the second end of the linearized plasmid.

It is understood that when using two or more DNA fragments as the starting
15 material, it is preferred to have continuous overlaps between the ends of the plasmid and the DNA fragments.

Even though it is preferred to shuffle homologous nucleotide sequences in the form of DNA fragment(s) and linearized plasmid(s), it is also possible to shuffle two or more linearized plasmids comprising homologous nucleotide sequences encoding polypeptides.
20 However, in such a case it is important to linearize the plasmids at different sites.

In the present invention, two or more linearized plasmids and one or more homologous DNA fragments can be used as the starting material to be shuffled. The ratio between the linearized plasmid(s) and homologous DNA fragment(s) preferably lie in the range from 20:1 to 1:50, preferable from 2:1 to 1:10 (mol plasmid:mol fragments) with the
25 specific concentrations being from 1 pM to 10 M of the DNA.

The linearized plasmids may be gapped in such a way that the overlap between the fragments is deleted in the plasmid. The repair of the gap in the plasmid then requires that the fragments recombine with one another in addition to recombining with the ends of the gapped plasmid in order to reconstitute a circular, autonomously replicating plasmid. In a
30 preferred embodiment, the linearization of the plasmid or vector creates a sufficient gap in the coding sequence of the nucleotide sequence to force the homologous recombination of the DNA fragments with the corresponding regions of the nucleotide sequence, recreating a circular replicating plasmid.

35

Nucleotide Sequences

The present invention also relates to isolated nucleotide sequences which encode variants of beta-glucosidases, wherein the nucleotide sequence has been modified by a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of SEQ ID NO: 70, wherein the beta-glucosidase is (a) a polypeptide having an amino acid sequence which has at least about 70%, preferably at least about 75%, more preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70; (ii) a polypeptide encoded by a nucleotide sequence which hybridizes under low, preferably low-medium, more preferably medium, even more preferably medium-high, most preferably high, or even most preferably very high stringency conditions with (i) nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, (ii) the genomic nucleotide sequence comprising nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, or (iii) a complementary strand of (i) or (ii), wherein the variant has beta-glucosidase activity.

The isolated nucleotide sequences encoding beta-glucosidase variants of the present invention may further comprise one or more deletions and/or insertions of the sequence.

In a preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at two or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at three or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at least at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

In a preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser as a substitution at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitution G142S of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg as a substitution at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitution Q183R of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Gln as a substitution at a position corresponding to

position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitution H266Q of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

5 In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2. In another more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala,
10 Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Gly as a substitution at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant
15 comprising the substitution D703G of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising a substitution at
20 a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Gly as a substitution at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred
25 embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitution D705G of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In
30 a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-
35 glucosidase variant comprising Ser and Arg as substitutions at positions corresponding to

positions 142 and 183, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser and Gln as substitutions at positions corresponding to positions 142 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser and Gly as substitutions at positions corresponding to positions 142 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142 and 705 of amino acids 1 to 842 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser and Gly as substitutions at positions corresponding to positions 142 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183 and

266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val.

In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg and Gln as substitutions at positions corresponding to positions 183 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg and Gly as substitutions at positions corresponding to positions 183 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg and Gly as substitutions at positions corresponding to positions 183 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp,

Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Gln and Gly as substitutions at positions corresponding to positions 266 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

5 In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70
10 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Gln and Gly as substitutions at positions corresponding to positions 266 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

15 In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142,
20 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser, Arg, and Gln as substitutions at positions corresponding to positions 142, 183, and 266, respectively, of amino acids 1 to
25 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising
30 substitutions at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser, Gln, and Gly as substitutions at positions corresponding to positions 142, 266, and 703, respectively, of
35 amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising
5 substitutions at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser, Gln, and Gly as
10 substitutions at positions corresponding to positions 142, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising
15 substitutions at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg, Gln, and Gly as
20 substitutions at positions corresponding to positions 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising
25 substitutions at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg, Gln, and Gly as
30 substitutions at positions corresponding to positions 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising
35 substitutions at positions corresponding to positions 142, 183, and 703 of amino acids 1 to

842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser, Arg, and Gly as substitutions at positions corresponding to positions 142, 183, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser, Arg, and Gly as substitutions at positions corresponding to positions 142, 183, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Ser, Arg, Gln, and Gly as substitutions at positions corresponding to positions 142, 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising substitutions at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising Arg and Gly as substitutions at positions corresponding to positions 142, 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In a more preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising two or more substitutions selected from the group consisting of G142S, Q183R, H266Q, and D703G (or D705G) of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

5 In a most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + Q183R of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + H266Q of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated
10 nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions Q183R + H266Q of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant
15 comprising the substitutions Q183R + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2.

In another most preferred embodiment, the isolated nucleotide sequence encodes a
20 beta-glucosidase variant comprising the substitutions G142S + Q183R of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + H266Q of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the
25 substitutions G142S + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions Q183R + H266Q of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions Q183R + D705G of amino acids 1 to 844 of
30 SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions H266Q + D705G of amino acids 1 to 844 of SEQ ID NO: 70.

In another most preferred embodiment, the isolated nucleotide sequence encodes a
35 beta-glucosidase variant comprising the substitutions G142S + Q183R + H266Q of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated

nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions Q183R + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + Q183R + D703G of amino acids 1 to 842 of SEQ ID NO: 2.

In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + Q183R + H266Q of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + H266Q + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions Q183R + H266Q + D705G of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + Q183R + D705G of amino acids 1 to 844 of SEQ ID NO: 70.

In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + Q183R + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the isolated nucleotide sequence encodes a beta-glucosidase variant comprising the substitutions G142S + Q183R + H266Q + D705G of amino acids 1 to 842 of SEQ ID NO: 70.

In another most preferred embodiment, the isolated nucleotide sequence encoding a beta-glucosidase variant comprising the substitutions G142S + Q183R + H266Q + D703G of amino acids 1 to 842 of SEQ ID NO: 2 is encoded by the nucleotide sequence contained in pSATE111BG53 which is contained in *E. coli*/NRRL B-30652.

The term "isolated nucleotide sequence" as used herein refers to a nucleotide sequence which is essentially free of other nucleotide sequences, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleotide sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleotide sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleotide fragment comprising the nucleotide sequence encoding the polypeptide, insertion of the fragment into

a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleotide sequence will be replicated. The nucleotide sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

5

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a nucleotide sequence encoding a beta-glucosidase variant of the present invention operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid combined and juxtaposed in a manner that would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of a variant of the present invention. The term "coding sequence" is defined herein as a nucleotide sequence which directly specifies the amino acid sequence of its protein product. The boundaries of a genomic coding sequence are generally determined by the ATG start codon (eukaryotes), or alternative start codons such as GTG and TTG, located just upstream of the open reading frame at the 5'-end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3'-end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleotide sequences.

An isolated nucleotide sequence encoding a beta-glucosidase variant of the present invention may be manipulated in a variety of ways to provide for expression of the variant. Manipulation of the nucleotide sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleotide sequences utilizing recombinant DNA methods are well known in the art.

The term "control sequences" is defined herein to include all components which are necessary or advantageous for the expression of a beta-glucosidase variant of the present invention. Each control sequence may be native or foreign to the nucleotide sequence encoding the variant. Such control sequences include, but are not limited to, a leader,

polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleotide sequence encoding a variant beta-glucosidase of the present invention. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the nucleotide sequence such that the control sequence directs the expression of a variant beta-glucosidase.

The control sequence may be an appropriate promoter sequence, which is recognized by a host cell for expression of the nucleotide sequence. The promoter sequence contains transcriptional control sequences which mediate the expression of the variant beta-glucosidase. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleotide constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium venenatum* amyloglucosidase, *Fusarium oxysporum* trypsin-like protease (WO 96/00787), *Trichoderma reesei* beta-glucosidase, *Trichoderma reesei* cellobiohydrolase I, *Trichoderma reesei* endoglucanase I, *Trichoderma reesei* endoglucanase II, *Trichoderma reesei* endoglucanase III, *Trichoderma reesei* endoglucanase IV, *Trichoderma reesei* endoglucanase V, *Trichoderma reesei* xylanase I, *Trichoderma reesei* xylanase II, *Trichoderma reesei* beta-xylosidase, as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase); equivalents thereof; and mutant, truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP), *Saccharomyces cerevisiae* triose phosphate isomerase

(TPI), *Saccharomyces cerevisiae* metallothionine (CUP1), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos *et al.*, 1992, *Yeast* 8: 423-488.

5 The control sequence may also be a suitable transcription terminator sequence, which is recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3'-terminus of the nucleotide sequence encoding the variant beta-glucosidase. Any terminator which is functional in the host cell of choice may be used in the present invention.

10 Preferred terminators for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

15 Preferred terminators for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos *et al.*, 1992, *supra*.

20 The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5'-terminus of the nucleotide sequence encoding the variant beta-glucosidase. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

Preferred leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

25 Suitable leaders for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

30 The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3'-terminus of the polypeptide-encoding sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

35 Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Fusarium oxysporum* trypsin-like protease, and

Aspergillus niger alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15: 5983-5990.

The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a variant beta-glucosidase and directs the encoded polypeptide into the cell's secretory pathway. The 5'-end of the coding sequence of the nucleotide sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted variant beta-glucosidase. Alternatively, the 5'-end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the variant beta-glucosidase. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, *Aspergillus niger* glucoamylase, *Rhizomucor miehei* aspartic proteinase, *Humicola insolens* Cel45A cellulase, and *Humicola lanuginosa* lipase.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos *et al.*, 1992, *supra*.

The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a variant beta-glucosidase. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes for *Saccharomyces cerevisiae* alpha-factor, *Rhizomucor miehei* aspartic proteinase, and *Myceliophthora thermophila* laccase (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the variant beta-glucosidase relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleotide sequence encoding the variant beta-glucosidase would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleotide sequence encoding a variant beta-glucosidase of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleotide and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleotide sequence encoding the variant at such sites. Alternatively, the nucleotide sequence may be expressed by inserting the nucleotide sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleotide sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous

fungal host cell include, but are not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hph* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), and *trpC* (anthranilate synthase), as well as equivalents thereof. Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*.

The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is distinct from chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

The vectors of the present invention preferably contain an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.

For integration into the host cell genome, the vector may rely on the nucleotide sequence encoding the variant or any other element of the vector for integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, preferably 400 to 10,000 base pairs, and most preferably 800 to 10,000 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of

origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes functioning temperature-sensitive in the host cell (see, *e.g.*, Ehrlich, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1433). Examples of a plasmid replicator useful in a filamentous fungal cell are AMA1 and ANS1 (Gems *et al.*, 1991, *Gene* 98:61-67; Cullen *et al.*, 1987, *Nucleic Acids Research* 15: 9163-9175; WO 00/24883). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the gene can be accomplished according to the methods disclosed in WO 00/24883.

More than one copy of a nucleotide sequence of the present invention may be inserted into the host cell to increase production of a beta-glucosidase variant. An increase in the copy number of the nucleotide sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleotide sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleotide sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a nucleotide sequence encoding a variant beta-glucosidase, which are advantageously used in the recombinant production of the variant. A vector comprising a nucleotide sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be any eukaryote, such as a mammalian, insect, plant, or fungal cell.

The host cell may be any fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth *et al.*, *In, Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB

International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth *et al.*, 1995, *supra*, page 171) and all mitosporic fungi (Hawksworth *et al.*, 1995, *supra*).

5 In a preferred embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, *Soc. App. Bacteriol. Symposium Series No. 9*, 1980).

10 In a more preferred embodiment, the yeast host cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

In a most preferred embodiment, the yeast host cell is a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cell. In another most preferred embodiment, the yeast host cell is a *Kluyveromyces lactis* cell. In another most preferred embodiment, the yeast host cell is a *Yarrowia lipolytica* cell.

In another preferred embodiment, the fungal host cell is a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

25 In a more preferred embodiment, the filamentous fungal host cell is, but not limited to, an *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

In a most preferred embodiment, the filamentous fungal host cell is an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger* or *Aspergillus oryzae* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell. In an even

most preferred embodiment, the filamentous fungal host cell is a *Fusarium venenatum* (Nirenberg sp. nov.) cell. In another most preferred embodiment, the filamentous fungal host cell is a *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Thielavia terrestris*,
5 *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell. In another even most preferred embodiment, the filamentous fungal host cell is *Trichoderma reesei* RutC30.

Fungal cells may be transformed according to the procedures described herein.

10 **Methods of Production**

The present invention also relates to methods for producing a beta-glucosidase variant, comprising:

(a) cultivating a host cell under conditions suitable for the expression of the variant, wherein the host cell comprises a nucleotide sequence which has been modified by
15 a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of SEQ ID NO: 70, as described herein; and

(b) recovering the variant from the cultivation medium.

In the production methods of the present invention, the host cells are cultivated in a
20 nutrient medium suitable for production of the variant beta-glucosidase using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, or small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation
25 takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the
30 polypeptide is not secreted, it can be recovered from cell lysates.

In an alternative embodiment, the beta-glucosidase variant is not recovered, but rather a host cell of the present invention expressing a variant is used as a source of the variant.

The variant beta-glucosidases may be detected using methods known in the art that
35 are specific for the polypeptides. These detection methods may include use of specific

antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide as described herein in the Examples.

5 The resulting variant beta-glucosidase may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

10 A variant beta-glucosidase of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing), differential solubility (*e.g.*, ammonium sulfate precipitation), SDS-PAGE, or extraction (see, *e.g.*, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

15 **Other Polypeptides having Beta-Glucosidase Activity**

The present invention also relates to isolated polypeptides having beta-glucosidase activity, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at one or more positions corresponding to positions 142, 183, 266, and 703 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of SEQ ID NO: 70.

20 In a preferred embodiment, the amino acid sequence of the polypeptide differs from amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 SEQ ID NO: 70 by preferably 4 amino acids, more preferably 3 amino acids, even more preferably 2 amino acids, and most preferably 1 amino acid.

25 In a preferred embodiment, the polypeptide consists of 741 to 750, 751 to 760, 761 to 770, 771 to 780, 781 to 790, 791 to 800, 801 to 810, 811 to 820, 821 to 830, 831 to 840, 841 to 850, 851 to 860, 861 to 870, 871 to 880, 881 to 890, 891 to 900, 901 to 910, 911 to 920, 921 to 930, 931 to 940, or 941 to 950 amino acids.

30 In a preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at two or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the amino

35

acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at three or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at least at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

In a preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser at a position corresponding to position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser at position 142 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Arg at a position corresponding to position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Arg at position 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide

differs from SEQ ID NO: 2 or SEQ ID NO: 70 at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Gln at a position corresponding to position 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Gln at position 266 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2. In another more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Gly at a position corresponding to position 703 of amino acids 1 to 842 of SEQ ID NO: 2. In another most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Gly at position 703 of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In another even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Gly at a position corresponding to position 705 of amino acids 1 to 844 of SEQ ID NO: 70. In another most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Gly at position 705 of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In

a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser and Arg at positions corresponding to positions 142 and 183, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser and Arg at positions 142 and 183, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser and Gln at positions corresponding to positions 142 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser and Gln at positions 142 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser and Gly at positions corresponding to positions 142 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser and Gly at positions 142 and 703, respectively,

of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142 and 705 of amino acids 1 to 842 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142 and 705 of amino acids 1 to 842 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Ser and Gly at positions corresponding to positions 142 and 705, respectively, of amino acids 1 to 842 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Ser and Gly at positions 142 and 705, respectively, of amino acids 1 to 842 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Arg and Gln at positions corresponding to positions 183 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Arg and Gln at positions 183 and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Arg and Gly at positions corresponding to positions 183 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment, the amino acid sequence of the

polypeptide differs from SEQ ID NO: 2 by Arg and Gly at positions 183 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Arg and Gly at positions corresponding to positions 183 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Arg and Gly at positions corresponding to positions 183 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Gln and Gly at positions corresponding to positions 266 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Gln and Gly at positions 266 and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Gln and Gly at positions corresponding to positions 266 and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Gln and Gly at positions 266 and

705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser, Arg, and Gln at positions corresponding to positions 142, 183, and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by Ser, Arg, and Gln at positions 142, 183, and 266, respectively, of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser, Gln, and Gly at positions corresponding to positions 142, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser, Gln, and Gly at positions 142, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Ser, Gln, and Gly at positions corresponding to positions 142, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred

embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Ser, Gln, and Gly at positions 142, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

5 In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even
10 more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Arg, Gln, and Gly at positions corresponding to positions 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Arg, Gln, and Gly at positions 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

15 In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an
20 even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Arg, Gln, and Gly at positions corresponding to positions 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by
25 Arg, Gln, and Gly at positions 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid
30 sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser, Arg, and Gly at positions corresponding to positions 142, 183, and 703,
35 respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment,

the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser, Arg, and Gly at positions 142, 183, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Ser, Arg, and Gly at positions corresponding to positions 142, 183, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Ser, Arg, and Gly at positions 142, 183, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser, Arg, Gln, and Gly at positions corresponding to positions 142, 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2. In a most preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 by Ser, Arg, Gln, and Gly at positions 142, 183, 266, and 703, respectively, of amino acids 1 to 842 of SEQ ID NO: 2.

In another preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70. In a more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70 by Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val. In an even more preferred embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Arg and Gly at positions corresponding to positions 142, 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70. In a most preferred

embodiment, the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 by Arg and Gly at positions 142, 183, 266, and 705, respectively, of amino acids 1 to 844 of SEQ ID NO: 70.

5 The polypeptide consists of 741 to 750, 751 to 760, 761 to 770, 771 to 780, 781 to 790, 791 to 800, 801 to 810, 811 to 820, 821 to 830, 831 to 840, 841 to 850, 851 to 860, 861 to 870, 871 to 880, 881 to 890, 891 to 900, 901 to 910, 911 to 920, 921 to 930, 931 to 940, or 941 to 950 amino acids.

10 The isolated polypeptides have one or more improved properties compared to the polypeptide of SEQ ID NO: 2 or SEQ ID NO: 70, wherein the improved properties are selected from the group consisting of thermal activity, thermostability, pH activity, pH stability, substrate specificity, product specificity, and chemical stability, as described herein.

15 The present invention also relates to isolated nucleotide sequences encoding such polypeptides, nucleic acid constructs, expression vectors, and host cells comprising the nucleotide sequences, and methods of producing the polypeptides having beta-glucosidase acity, according to the same disclosure herein for variants of beta-glucosidases.

Degradation of biomass to monosaccharides, disaccharides, and polysaccharides

20 The beta-glucosidase variants and host cells of the present invention may be used in the production of monosaccharides, disaccharides, and polysaccharides as chemical or fermentation feedstocks from biomass for the production of ethanol, plastics, or other products or intermediates. The beta-glucosidase variants may be in the form of a crude fermentation broth with or without the cells removed or in the form of a semi-purified or purified enzyme preparation. Alternatively, a host cell of the present invention may be used as a source of the variant in a fermentation process with the biomass.

25 Biomass can include, but is not limited to, wood resources, municipal solid waste, wastepaper, and crop residues (see, for example, Wiselogle *et al.*, 1995, in *Handbook on Bioethanol* (Charles E. Wyman, editor), pp.105-118, Taylor & Francis, Washington D.C.; Wyman, 1994, *Bioresource Technology* 50: 3-16; Lynd, 1990, *Applied Biochemistry and Biotechnology* 24/25: 695-719; Mosier *et al.*, 1999, *Recent Progress in Bioconversion of Lignocellulosics*, in *Advances in Biochemical Engineering/Biotechnology*, T. Scheper, managing editor, Volume 65, pp.23-40, Springer-Verlag, New York).

35 The predominant polysaccharide in the primary cell wall of biomass is cellulose, the second most abundant is hemi-cellulose, and the third is pectin. The secondary cell wall, produced after the cell has stopped growing, also contains polysaccharides and is strengthened through polymeric lignin covalently cross-linked to hemicellulose. Cellulose is

a homopolymer of anhydrocellobiose and thus a linear beta-(1-4)-D-glucan, while hemicelluloses include a variety of compounds, such as xylans, xyloglucans, arabinoxylans, and mannans in complex branched structures with a spectrum of substituents. Although generally polymorphous, cellulose is found in plant tissue primarily as an insoluble crystalline matrix of parallel glucan chains. Hemicelluloses usually hydrogen bond to cellulose, as well as to other hemicelluloses, which helps stabilize the cell wall matrix.

Three major classes of glycohydrolases are used to breakdown cellulosic biomass:

- (1) The "endo-1,4-beta-glucanases" or 1,4-beta-D-glucan-4-glucanohydrolases (EC 3.2.1.4), which act randomly on soluble and insoluble 1,4-beta-glucan substrates.
- (2) The "exo-1,4-beta-D-glucanases" including both the 1,4-beta-D-glucan glucohydrolases (EC 3.2.1.74), which liberate D-glucose from 1,4-beta-D-glucans and hydrolyze D-cellobiose slowly, and cellobiohydrolases (1,4-beta-D-glucan cellobiohydrolases, EC 3.2.1.91), which liberate D-cellobiose from 1,4-beta-glucans.

- (3) The "beta-D-glucosidases" or beta-D-glucoside glucohydrolases (EC 3.2.1.21), which act to release D-glucose units from cellobiose and soluble cellodextrins, as well as an array of glycosides.

These three classes of enzymes work together synergistically resulting in efficient decrystallization and hydrolysis of native cellulose from biomass to yield reducing sugars.

The beta-glucosidase variants of the present invention may be used in conjunction with the above-noted enzymes to further degrade the cellulose component of the biomass substrate, (see, for example, Brigham *et al.*, 1995, in *Handbook on Bioethanol* (Charles E. Wyman, editor), pp.119-141, Taylor & Francis, Washington D.C.; Lee, 1997, *Journal of Biotechnology* 56: 1-24).

Ethanol can be produced by enzymatic degradation of biomass and conversion of the released saccharides to ethanol. This kind of ethanol is often referred to as bioethanol or biofuel. It can be used as a fuel additive or extender in blends of from less than 1% and up to 100% (a fuel substitute).

Detergent Compositions

The beta-glucosidase variants of the present invention may be added to and thus become a component of a detergent composition.

The detergent composition of the present invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning

operations, or be formulated for hand or machine dishwashing operations.

In a specific aspect, the present invention provides a detergent additive comprising the enzyme of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as a protease, lipase, cutinase, an amylase, 5 carbohydrase, cellulase, pectinase, mannanase, arabinase, galactanase, xylanase, oxidase, *e.g.*, a laccase, and/or peroxidase.

In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (*i.e.*, pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

10 Proteases: Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. The protease may be a serine protease or a metalloprotease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus*, *e.g.*, subtilisin Novo, subtilisin Carlsberg, 15 subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279). Examples of trypsin-like proteases are trypsin (*e.g.*, of porcine or bovine origin) and the *Fusarium* protease described in WO 89/06270 and WO 94/25583.

Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in 20 one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.

Preferred commercially available protease enzymes include AlcalaseTM, SavinaseTM, PrimaseTM, DuralaseTM, EsperaseTM, and KannaseTM (Novo Nordisk A/S), MaxataseTM, MaxacalTM, MaxapemTM, ProperaseTM, PurafectTM, Purafect OxPTM, FN2TM, and FN3TM 25 (Genencor International Inc.).

Lipases: Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from *Humicola* (synonym *Thermomyces*), *e.g.*, from *H. lanuginosa* (*T. lanuginosus*) as described in EP 258 068 and EP 305 216 or from *H. insolens* as described in WO 30 96/13580, a *Pseudomonas* lipase, *e.g.*, from *P. alcaligenes* or *P. pseudoalcaligenes* (EP 218 272), *P. cepacia* (EP 331 376), *P. stutzeri* (GB 1,372,034), *P. fluorescens*, *Pseudomonas sp.* strain SD 705 (WO 95/06720 and WO 96/27002), *P. wisconsinensis* (WO 96/12012), a *Bacillus* lipase, *e.g.*, from *B. subtilis* (Dartois *et al.*, 1993, *Biochemica et Biophysica Acta*, 1131: 253-360), *B. stearothermophilus* (JP 64/744992) or *B. pumilus* (WO 91/16422).

Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202.

Preferred commercially available lipase enzymes include Lipolase™ and Lipolase Ultra™ (Novo Nordisk A/S).

Amylases: Suitable amylases (α and/or β) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, α -amylases obtained from *Bacillus*, e.g., a special strain of *Bacillus licheniformis*, described in more detail in GB 1,296,839.

Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444.

Commercially available amylases are Duramyl™, Termamyl™, Fungamyl™ and BAN™ (Novo Nordisk A/S), Rapidase™ and Purastar™ (from Genencor International Inc.).

Cellulases: Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g., the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259.

Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and PCT/DK98/00299.

Commercially available cellulases include Celluzyme™, and Carezyme™ (Novo Nordisk A/S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation).

Peroxidases/Oxidases: Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g., from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.

Commercially available peroxidases include Guardzyme™ (Novo Nordisk A/S).

The detergent enzyme(s) may be included in a detergent composition by adding

separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, *i.e.*, a separate additive or a combined additive, can be formulated, for example, as a granulate, liquid, slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting
5 granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, *e.g.*, as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide
10 units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar
15 alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

The detergent composition of the invention may be in any convenient form, *e.g.*, a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.

20 The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl
25 sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid, or soap.

When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyltrimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty
30 acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine ("glucamides").

The detergent may contain 0-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic
35 acid, soluble silicates, or layered silicates (*e.g.*, SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose, poly(vinylpyrrolidone), poly (ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers, and lauryl methacrylate/acrylic acid copolymers.

5 The detergent may contain a bleaching system which may comprise a H₂O₂ source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetythylenediamine or nonanoyloxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of, for example, the amide, imide, or sulfone type.

10 The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, *e.g.*, a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, *e.g.*, an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in, for example, WO 92/19709 and WO 92/19708.

15 The detergent may also contain other conventional detergent ingredients such as, *e.g.*, fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

In the detergent compositions any enzyme, in particular the enzyme of the invention,
20 may be added in an amount corresponding to 0.01-100 mg of enzyme protein per liter of wash liquor, preferably 0.05-5 mg of enzyme protein per liter of wash liquor, in particular 0.1-1 mg of enzyme protein per liter of wash liquor.

The enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202, which is hereby incorporated as reference.

25

Plants

The present invention also relates to a transgenic plant, plant part, or plant cell which has been transformed with a nucleotide sequence encoding a variant beta-glucosidase of the present invention so as to express and produce the variant in recoverable
30 quantities. The variant may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the recombinant variant may be used as such for improving the quality of a food or feed, *e.g.*, improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a
35 monocot). Examples of monocot plants are grasses, such as meadow grass (blue grass,

Poa), forage grass such as Festuca, Lolium, temperate grass, such as Agrostis, and cereals, *e.g.*, wheat, oats, rye, barley, rice, sorghum, and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism *Arabidopsis thaliana*.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers as well as the individual tissues comprising these parts, *e.g.*, epidermis, mesophyll, parenchyme, vascular tissues, meristems. Specific plant cell compartments, such as chloroplasts, apoplasts, mitochondria, vacuoles, peroxisomes and cytoplasm are also considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part. Likewise, plant parts such as specific tissues and cells isolated to facilitate the utilisation of the invention are also considered plant parts, *e.g.*, embryos, endosperms, aleurone and seeds coats.

Also included within the scope of the present invention are the progeny of such plants, plant parts, and plant cells.

The transgenic plant or plant cell expressing a variant of the present invention may be constructed in accordance with methods known in the art. In short, the plant or plant cell is constructed by incorporating one or more expression constructs encoding a variant of the present invention into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

Conveniently, the expression construct is a nucleic acid construct which comprises a nucleic acid sequence encoding a variant of the present invention operably linked with appropriate regulatory sequences required for expression of the nucleic acid sequence in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences, is determined, for example, on the basis of when, where, and how the variant is desired to be expressed. For instance, the expression of the gene encoding a variant of the present invention may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example, described by Tague *et al.*, 1988, *Plant Physiology* 86: 506.

For constitutive expression, the 35S-CaMV, the maize ubiquitin 1, and the rice actin

1 promoter may be used (Franck *et al.*, 1980, *Cell* 21: 285-294, Christensen *et al.*, 1992, *Plant Mo. Biol.* 18: 675-689; Zhang *et al.*, 1991, *Plant Cell* 3: 1155-1165). Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990, *Ann. Rev. Genet.* 24: 275-303), or from
5 metabolic sink tissues such as meristems (Ito *et al.*, 1994, *Plant Mol. Biol.* 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu *et al.*, 1998, *Plant and Cell Physiology* 39: 885-889), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* (Conrad *et al.*, 1998, *Journal of Plant Physiology* 152: 708-711), a promoter from a seed oil body protein (Chen *et al.*, 1998, *Plant and Cell Physiology* 39: 935-941), the storage protein napA promoter from
10 *Brassica napus*, or any other seed specific promoter known in the art, *e.g.*, as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the *rbcs* promoter from rice or tomato (Kyoizuka *et al.*, 1993, *Plant Physiology* 102: 991-1000, the chlorella virus adenine methyltransferase gene promoter (Mitra and Higgins, 1994, *Plant*
15 *Molecular Biology* 26: 85-93), or the *aldP* gene promoter from rice (Kagaya *et al.*, 1995, *Molecular and General Genetics* 248: 668-674), or a wound inducible promoter such as the potato pin2 promoter (Xu *et al.*, 1993, *Plant Molecular Biology* 22: 573-588). Likewise, the promoter may inducible by abiotic treatments such as temperature, drought, or alterations in salinity or induced by exogenously applied substances that activate the promoter, *e.g.*,
20 ethanol, oestrogens, plant hormones such as ethylene, abscisic acid, and gibberellic acid, and heavy metals.

A promoter enhancer element may also be used to achieve higher expression of a polypeptide of the present invention in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide
25 sequence encoding a polypeptide of the present invention. For instance, Xu *et al.*, 1993, *supra*, disclose the use of the first intron of the rice actin 1 gene to enhance expression.

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genome according to
30 conventional techniques known in the art, including *Agrobacterium*-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation (Gasser *et al.*, 1990, *Science* 244: 1293; Potrykus, 1990, *Bio/Technology* 8: 535; Shimamoto *et al.*, 1989, *Nature* 338: 274).

Presently, *Agrobacterium tumefaciens*-mediated gene transfer is the method of
35 choice for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992,

Plant Molecular Biology 19: 15-38) and can also be used for transforming monocots, although other transformation methods are often used for these plants. Presently, the method of choice for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, *Plant Journal* 2: 275-281; Shimamoto, 1994, *Current Opinion Biotechnology* 5: 158-162; Vasil *et al.*, 1992, *Bio/Technology* 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh *et al.*, 1993, *Plant Molecular Biology* 21: 415-428.

Following transformation, the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well-known in the art. Often the transformation procedure is designed for the selective elimination of selection genes either during regeneration or in the following generations by using, for example, co-transformation with two separate T-DNA constructs or site specific excision of the selection gene by a specific recombinase.

The present invention also relates to methods for producing a variant of the present invention comprising (a) cultivating a transgenic plant or a plant cell comprising a nucleic acid sequence encoding a variant having beta-glucosidase activity of the present invention under conditions conducive for production of the variant; and (b) recovering the variant.

Other Uses

The beta-glucosidase variants of the present invention may also be used in the treatment of textiles as biopolishing agents and for reducing of fuzz, pilling, texture modification, and stonewashing (N.K. Lange, in P. Suominen, T. Reinikainen (Eds.), *Trichoderma reesei Cellulases and Other Hydrolases*, Foundation for Biotechnical and Industrial Fermentation Research, Helsinki, 1993, pp. 263-272). In addition, the described variants may also be used in wood processing for biopulping or debarking, paper manufacturing for fiber modification, bleaching, and reduction of refining energy costs, whitewater treatment, important to wastewater recycling, lignocellulosic fiber recycling such as deinking and secondary fiber processing, and wood residue utilization (S.D, Mansfield and A.R. Esteghlalian in S.D, Mansfield and J.N. Saddler (Eds.), *Applications of Enzymes to Lignocellulosics*, ACS Symposium Series 855, Washington, D.C., 2003, pp. 2-29).

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

Examples

Materials

Chemicals used as buffers and substrates were commercial products of at least reagent grade.

5

Strains

The yeast strain *Saccharomyces cerevisiae* YNG318 (MAT α , ura3-52, leu-2 Δ 2, pep4 Δ 1, his4-539, cir⁺) was used to express the *Aspergillus oryzae* and *Aspergillus fumigatus* beta-glucosidases and their variants. Bacterial strains used to generate plasmids were *Epicurian coli* XL-10 Gold ultracompetent cells, *Epicurian coli* XL1-Blue subcloning-competent cells, and *Epicurian coli* SURE electroporation-competent cells (Stratagene, La Jolla, CA). *Aspergillus oryzae* Jal250 strain (WO 99/61651) was used for expression of the *Aspergillus oryzae* beta-glucosidase. *Aspergillus fumigatus* PaHa34 was used as the source of the Family GH3A beta-glucosidase.

15

Media and Solutions

YPD medium was composed per liter of 10 g of yeast extract, 20 g of bacto tryptone, and 40 ml of 50% glucose.

Yeast selection medium was composed per liter of 6.7 g of yeast nitrogen base, 0.8 g of complete supplement mixture (CSM, Qbiogene, Inc., Carlsbad, CA; missing uracil and containing 40 mg/ml of adenine), 5 g of casamino acids (without amino acids), 100 ml of 0.5 M succinate pH 5.0, 40 ml of 50% glucose, 1 ml of 100 mM CuSO₄, 50 mg of ampicillin, and 25 mg of chloramphenicol.

Yeast selection plate medium was composed per liter of yeast selection medium supplemented with 20 g of bacto agar and 150 mg of 5-bromo-4-chloro-3-indolyl-beta-D-glucopyranoside (X-Glc, INALCO SPA, Milano, Italy) but lacking both ampicillin and chloramphenicol.

M400 medium is composed per liter of 50 g of maltodextrin, 2 g of MgSO₄·7H₂O, 2 g of KH₂PO₄, 4 g of citric acid, 8 g of yeast extract, 2 g of urea, 0.5 ml of AMG trace metals solution, and 0.5 g CaCl₂.

AMG trace metals solution was composed per liter of 14.3 g of ZnSO₄·7H₂O, 2.5 g of CuSO₄·5H₂O, 0.5 g of NiCl₂·6H₂O, 13.8 g of FeSO₄·7H₂O, 8.5 g of MnSO₄·H₂O, and 3 g of citric acid.

1X BS was composed per liter of 2 g of MgSO₄·7H₂O, 2 g of K₂SO₄, and 10 g of KH₂PO₄.

Minimal medium *Aspergillus oryzae* selection plates were composed per liter of 6 g of NaNO₃, 0.52 g of KCl, 1.52 g of KH₂PO₄, 1 ml of COVE trace elements solution, 20 g of agar Noble, 20 ml of 50% glucose, 2.5 ml of 20% MgSO₄·7H₂O.

COVE trace elements solution was composed per liter of 0.04 g of NaB₄O₇·10H₂O, 0.4 g of CuSO₄·5H₂O, 1.2 g of FeSO₄·7H₂O, 0.7 g of MnSO₄·H₂O, 0.8 g of Na₂MoO₄·2H₂O, and 10 g of ZnSO₄·7H₂O.

Yeast lysis buffer was composed of 1% sodium dodecyl sulfate (SDS), 10 mM Tris-HCl, and 1 mM EDTA, pH 8.0.

Potato dextrose medium was composed per liter of 39 grams of potato dextrose (Difco).

PDA plates were composed per liter of 39 grams of potato dextrose agar (Difco).

MDU2BP medium was composed per liter of 45 g of maltose, 1 g of MgSO₄·7H₂O, 1 g of NaCl, 2 g of K₂SO₄, 12 g of KH₂PO₄, 7 g of yeast extract, 2 g of urea, and 0.5 ml of AMG trace metals solution, pH to 5.0.

Plasmid DNA Preparation and DNA Sequencing

Plasmid DNA from *E. coli* strains was prepared using a BioRobot 9600 (QIAGEN, Inc., Chatsworth, CA).

DNA sequencing was performed on an ABI3700 (Applied Biosystems, Foster City, CA) using dye terminator chemistry (Giesecke *et al.*, 1992, *Journal of Virol. Methods* 38: 47-60). Sequences were assembled using phred/phrap/consed (University of Washington, Seattle WA) with sequence specific primers.

Example 1: Construction of pSATE111 *Saccharomyces cerevisiae* expression vector

A 2,605 bp DNA fragment comprising the region from the ATG start codon to the TAA stop codon of the *Aspergillus oryzae* beta-glucosidase coding sequence (SEQ ID NO: 1 for cDNA sequence and SEQ ID NO: 2 for the deduced amino acid sequence) was amplified by PCR from pJaL660 (WO 2002/095014) as template with primers 992127 (sense) and 992328 (antisense) shown below.

992127: 5'-GCAGATCTACCATGAAGCTTGGTTGGATCGAG-3' (SEQ ID NO: 3)

992328: 5'-GCCTCGAGTTACTGGGCCTTAGGCAGCGAG-3' (SEQ ID NO: 4)

Primer 992127 has an upstream *Bgl*/II site and the primer 992328 has a downstream *Xho*I site.

The amplification reactions (50 µl) were composed of 1X PCR buffer containing MgCl₂

(Roche Applied Science, Mannheim, Germany), 0.25 mM dNTPs, 50 μ M primer 992127, 50 μ M primer 992328, 80 ng of pJaL660, and 2.5 units of *Pwo* DNA Polymerase (Roche Applied Science, Mannheim, Germany). The reactions were incubated in an Eppendorf Mastercycler 5333 (Eppendorf Scientific, Inc., Westbury, NY) programmed for 1 cycle at 94°C for 5 minutes followed by 25 cycles each at 94°C for 60 seconds, 55°C for 60 seconds, and 72°C for 120 seconds (10 minute final extension). The PCR product was then subcloned into the PCR-Blunt II-TOPO vector using the PCR-Blunt II-TOPO Cloning Kit (Invitrogen, Carlsbad, CA) following the manufacturer's instructions to generate plasmid pSATE101 (Figure 1). Plasmid pSATE101 was digested with *Bgl*/II and *Xho*I to liberate the beta-glucosidase gene.

The reaction products were isolated on a 1.0% agarose gel using 40 mM Tris-acetate-1 mM EDTA (TAE) buffer where a 2.6 kb product band was excised from the gel and purified using a QIAquick Gel Extraction Kit (QIAGEN Inc., Valencia, CA) according to the manufacturer's instructions.

The 2.6 kb PCR product was digested and cloned into the *Bam* HI and *Xho*I sites of the copper inducible 2 μ m yeast expression vector pCu426 (Labbe and Thiele, 1999, *Methods Enzymol.* 306: 145-53) to generate pSATE111 (Figure 2).

Example 2: Construction of pMJ04 expression vector

Expression vector pMJ04 was constructed by PCR amplifying the *Trichoderma reesei* exocellobiohydrolase 1 gene (*cbh1*) terminator from *Trichoderma reesei* RutC30 (Montenecourt and Eveleigh, 1979, *Adv. Chem. Ser.* 181: 289-301) genomic DNA using primers 993429 (antisense) and 993428 (sense) shown below. The antisense primer was engineered to have a *Pac*I site at the 5'-end and a *Spe*I site at the 3'-end of the sense primer.

Primer 993429 (antisense):

5'-AACGTTAATTAAGGAATCGTTTTGTGTTT-3' (SEQ ID NO: 5)

Primer 993428 (sense):

5'-AGTACTAGTAGCTCCGTGGCGAAAGCCTG-3' (SEQ ID NO: 6)

Trichoderma reesei RutC30 genomic DNA was isolated using a DNeasy Plant Maxi Kit (Qiagen, Chatsworth, CA).

The amplification reactions (50 μ l) were composed of 1X ThermoPol Reaction Buffer (New England Biolabs, Beverly, MA), 0.3 mM dNTPs, 100 ng of *Trichoderma reesei* RutC30 genomic DNA, 0.3 μ M primer 993429, 0.3 μ M primer 993428, and 2 units of Vent DNA polymerase (New England Biolabs, Beverly, MA). The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 5 cycles each for 30 seconds at 94°C,

30 seconds at 50°C, and 60 seconds at 72°C, followed by 25 cycles each for 30 seconds at 94°C, 30 seconds at 65°C, and 120 seconds at 72°C (5 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 229 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit.

5 The resulting PCR fragment was digested with *Pac*I and *Spe*I and ligated into pAILo01 digested with the same restriction enzymes using a Rapid Ligation Kit (Roche, Indianapolis, IN), to generate pMJ04 (Figure 3).

Example 3: Construction of pCaHj568 expression vector

10 Expression plasmid pCaHj568 was constructed from pCaHj170 (U.S. Patent 5,763,254) and pMT2188. Plasmid pCaHj170 comprises the *Humicola insolens* endoglucanase V (EGV) coding region. Plasmid pMT2188 was constructed as follows: The pUC19 origin of replication was PCR amplified from pCaHj483 (WO 98/00529) with primers 142779 and 142780 shown below. Primer 142780 introduced a *Bbu* I site in the PCR
15 fragment.

142779: 5'-TTGAATTGAAAATAGATTGATTTAAACTTC-3' (SEQ ID NO: 7)

142780: 5'-TTGCATGCGTAATCATGGTCATAGC-3' (SEQ ID NO: 8)

20 The Expand PCR system (Roche Molecular Biochemicals, Basel, Switzerland) was used for the amplification following the manufacturer's instructions and the subsequent PCR amplifications. PCR products were separated on a 1% agarose gel using TAE buffer and an 1160 bp fragment was isolated and purified using a Jetquick gel extraction spin kit (Genomed, Wielandstr, Germany).

25 The URA3 gene was amplified from the *Saccharomyces cerevisiae* cloning vector pYES2 (Invitrogen, Carlsbad, CA) using primers 140288 and 142778 below. Primer 140288 introduced an *Eco* RI site in the PCR fragment.

140288: 5'-TTGAATTCATGGGTAATAACTGATAT-3' (SEQ ID NO: 9)

142778: 5'-AAATCAATCTATTTTCAATTCAATTCATCATT-3' (SEQ ID NO: 10)

PCR products were separated on a 1% agarose gel using TAE buffer and an 1126 bp fragment was isolated and purified using a Jetquick gel extraction spin kit.

30 The two PCR fragments were fused by mixing and amplification using primers 142780 and 140288 shown above by overlap method splicing (Horton *et al.*, 1989, *Gene* 77: 61-68). PCR products were separated on a 1% agarose gel using TAE buffer and a 2263 bp fragment was isolated and purified using a Jetquick gel extraction spin kit.

35 The resulting fragment was digested with *Eco* RI and *Bbu* I and ligated to the largest fragment of pCaHj483 digested with the same enzymes. The ligation mixture was used to

transform *pyrF*-negative *E. coli* strain DB6507 (ATCC 35673) made competent by the method of Mandel and Higa, 1970, *J. Mol. Biol.* 45: 154. Transformants were selected on solid M9 medium (Sambrook *et al.*, 1989, *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press) supplemented per liter with 1 g of casaminoacids, 500 µg of thiamine, and 10 mg of kanamycin. A plasmid from one transformant was isolated and designated pCaHj527 (Figure 4).

The NA2-tpi promoter present on pCaHj527 was subjected to site directed mutagenesis by a simple PCR approach. Nucleotides 134–144 were converted from GTACTAAAACC to CCGTTAAATTT using mutagenic primer 141223:

10 Primer 141223: 5'-GGATGCTGTTGACTCCGGAATTTAACGGTTTGGTCTTGCATCCC-3' (SEQ ID NO: 11)

Nucleotides 423–436 were converted from ATGCAATTTAACT to CGGCAATTTAACGG using mutagenic primer 141222:

15 Primer 141222: 5'-GGTATTGTCCTGCAGACGGCAATTTAACGGCTTCTGCGAATCGC-3' (SEQ ID NO: 12)

The resulting plasmid was designated pMT2188 (Figure 5).

The *Humicola insolens* endoglucanase V coding region was transferred from pCaHj170 as a *Bam* HI-*Sal* I fragment into pMT2188 digested with *Bam* HI and *Xho* I to generate pCaHj568 (Figure 6).

20

Example 4: Construction of pMJ05 expression vector

Expression vector pMJ05 was constructed by PCR amplifying the 915 bp *Humicola insolens* endoglucanase V coding region from pCaHj568 using primers HiEGV-F and HiEGV-R shown below.

25 HiEGV-F (sense): 5'-AAGCTTAAGCATGCGTTCTCCCCCTCC-3' (SEQ ID NO: 13)

HiEGV-R (antisense): 5'-CTGCAGAATTCTACAGGCACTGATGGTACCAG-3' (SEQ ID NO: 14)

The amplification reactions (50 µl) were composed of 1X ThermoPol Reaction Buffer, 0.3 mM dNTPs, 10 ng of pCaHj568 plasmid, 0.3 µM HiEGV-F primer, 0.3 µM HiEGV-R primer, and 2 units of Vent DNA polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 5 cycles each for 30 seconds at 94°C, 30 seconds at 50°C, and 60 seconds at 72°C, followed by 25 cycles each for 30 seconds at 94°C, 30 seconds at 65°C, and 120 seconds at 72°C (5 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 937 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

35

This 937 bp purified fragment was used as template DNA for subsequent amplifications using the following primers:

HiEGV-R (antisense): 5'-CTGCAGAATTCTACAGGCACTGATGGTACCAG-3' (SEQ ID NO: 15)

HiEGV-F-overlap (sense): 5'-*ACCGCGGACTGCGCATCATGCGTTCCTCCCCCTCC*-3' (SEQ ID NO: 16)

Primer sequences in italics are homologous to 17 bp of the *Trichoderma reesei cbh1* promoter and underlined primer sequences are homologous to 29 bp of the *Humicola insolens* endoglucanase V coding region. The 36 bp overlap between the promoter and the coding sequence allowed precise fusion of the 994 bp fragment comprising the *Trichoderma reesei cbh1* promoter to the 918 bp fragment comprising the *Humicola insolens* endoglucanase V open reading frame.

The amplification reactions (50 µl) were composed of 1X ThermoPol Reaction Buffer, 0.3 mM dNTPs, 1 µl of 937 bp purified PCR fragment, 0.3 µM HiEGV-F-overlap primer, 0.3 µM HiEGV-R primer, and 2 units of Vent DNA polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 5 cycles each for 30 seconds at 94°C, 30 seconds at 50°C, and 60 seconds at 72°C, followed by 25 cycles each for 30 seconds at 94°C, 30 seconds at 65°C, and 120 seconds at 72°C (5 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 945 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

A separate PCR was performed to amplify the *Trichoderma reesei cbh1* promoter sequence extending from 994 bp upstream of the ATG start codon of the gene from *Trichoderma reesei* RutC30 genomic DNA using the following primers (sense primer was engineered to have a *Sa*/I restriction site at the 5'-end):

TrCBHIpro-F (sense): 5'-AAACGTCGACCGAATGTAGGATTGTTATC-3' (SEQ ID NO: 17)

TrCBHIpro-R (antisense): 5'-GATGCGCAGTCCGCGGT-3' (SEQ ID NO: 18)

The amplification reactions (50 µl) were composed of 1X ThermoPol Reaction Buffer, 0.3 mM dNTPs, 100 ng of *Trichoderma reesei* RutC30 genomic DNA, 0.3 µM TrCBHIpro-F primer, 0.3 µM TrCBHIpro-R primer, and 2 units of Vent DNA polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 30 seconds at 94°C, 30 seconds at 55°C, and 120 seconds at 72°C (5 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 998 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

The 998 bp purified PCR fragment was used as template DNA for subsequent

amplifications using the following primers:

TrCBH1pro-F: 5'-AAACGTCGACCGAATGTAGGATTGTTATC-3' (SEQ ID NO: 19)

TrCBH1pro-R-overlap: 5'-GGAGGGGGGAGGAACGCAT*GATGCGCAGTCCGCGGT*-3' (SEQ ID NO: 20)

5 Sequences in italics are homologous to 17 bp of the *Trichoderma reesei cbh1* promoter and underlined sequences are homologous to 29 bp of the *Humicola insolens* endoglucanase V coding region. The 36 bp overlap between the promoter and the coding sequence allowed precise fusion of the 994 bp fragment comprising the *Trichoderma reesei cbh1* promoter to the 918 bp fragment comprising the *Humicola insolens* endoglucanase V open reading frame.

10 The amplification reactions (50 µl) were composed of 1X ThermoPol Reaction Buffer, 0.3 mM dNTPs, 1 µl of 998 bp purified PCR fragment, 0.3 µM TrCBH1pro-F primer, 0.3 µM TrCBH1pro-R-overlap primer, and 2 units of Vent DNA polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 5 cycles each for 30 seconds at 94°C, 30 seconds at 50°C, and 60 seconds at 72°C, followed by 25 cycles each for 30 seconds at 94°C, 30 seconds at 65°C, and 120 seconds at 72°C (5 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 1017 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

20 The 1017 bp *Trichoderma reesei cbh1* promoter PCR fragment and the 945 bp *Humicola insolens* endoglucanase V PCR fragments were used as template DNA for subsequent amplification using the following primers to precisely fuse the 994 bp *Trichoderma reesei cbh1* promoter to the 918 bp *Humicola insolens* endoglucanase V coding region using overlapping PCR.

25 TrCBH1pro-F: 5'-AAACGTCGACCGAATGTAGGATTGTTATC-3' (SEQ ID NO: 21)

HiEGV-R: 5'-CTGCAGAATTCTACAGGCACTGATGGTACCAG-3' (SEQ ID NO: 22)

30 The amplification reactions (50 µl) were composed of 1X ThermoPol Reaction Buffer, 0.3 mM dNTPs, 0.3 µM TrCBH1pro-F primer, 0.3 µM HiEGV-R primer, and 2 units of Vent DNA polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 5 cycles each for 30 seconds at 94°C, 30 seconds at 50°C, and 60 seconds at 72°C, followed by 25 cycles each for 30 seconds at 94°C, 30 seconds at 65°C, and 120 seconds at 72°C (5 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 1926 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

35

The resulting 1926 bp fragment was cloned into pCR-Blunt-II-TOPO vector (Invitrogen, Carlsbad, CA) using the ZeroBlunt TOPO PCR Cloning Kit following the manufacturer's protocol. The resulting plasmid was digested with *Not*I and *Sa*I and the 1926 bp fragment purified and ligated into pMJ04 expression vector, which was also
 5 digested with the same two restriction enzymes, to generate pMJ05 (Figure 7).

Example 5: Construction of pSMai130 expression vector

A 2586 bp DNA fragment spanning from the ATG start codon to the TAA stop codon of the *Aspergillus oryzae* beta-glucosidase coding sequence (SEQ ID NO: 1 for cDNA
 10 sequence and SEQ ID NO: 2 for the deduced amino acid sequence; *E. coli* DSM 14240) was amplified by PCR from pJaL660 (WO 2002/095014) as template with primers 993467 (sense) and 993456 (antisense) shown below. A *Spe*I site was engineered at the 5' end of the antisense primer to facilitate ligation. Primer sequences in italics are homologous to 24 bp of the *Trichoderma reesei cbh1* promoter and underlined sequences are homologous to
 15 22 bp of the *Aspergillus oryzae* beta-glucosidase coding region.

Primer 993467: 5'-*ATAGTCAACCGCGGACTGCGCATCATGAAGCTTGGTTGGATCGAGG*-3' (SEQ ID NO: 23)

Primer 993456: 5'-*ACTAGTTTACTGGGCCTTAGGCAGCG*-3' (SEQ ID NO: 24)

The amplification reactions (50 µl) were composed of *Pfx* Amplification Buffer
 20 (Invitrogen, Carlsbad, CA), 0.25 mM dNTPs, 10 n of pJaL660, 6.4 µM primer 993467, 3.2 µM primer 993456, 1 mM MgCl₂, and 2.5 units of *Pfx* polymerase (Invitrogen, Carlsbad, California). The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 60 seconds at 94°C, 60 seconds at 55°C, and 180 seconds at 72°C (15 minute final extension). The reaction products were isolated on a 1.0% agarose
 25 gel using TAE buffer where a 2586 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

A separate PCR was performed to amplify the *Trichoderma reesei cbh1* promoter sequence extending from 1000 bp upstream of the ATG start codon of the gene, using primer 993453 (sense) and primer 993463 (antisense) shown below to generate a 1000 bp
 30 PCR fragment. Primer sequences in italics are homologous to 24 bp of the *Trichoderma reesei cbh1* promoter and underlined primer sequences are homologous to 22 bp of the *Aspergillus oryzae* beta-glucosidase coding region. The 46 bp overlap between the promoter and the coding sequence allowed precise fusion of the 1000 bp fragment comprising the *Trichoderma reesei cbh1* promoter to the 2586 bp fragment comprising the
 35 *Aspergillus oryzae* beta-glucosidase open reading frame.

Primer 993453: 5'-GTCGACTCGAAGCCCGAATGTAGGAT-3' (SEQ ID NO: 25)

Primer 993463: 5'-CCTCGATCCAACCAAGCTTCAT *GATGCGCAGTCCGCGGTTGACTA*-3' (SEQ ID NO: 26)

The amplification reactions (50 µl) were composed of *Pfx* Amplification Buffer, 0.25 mM dNTPs, 100 ng of *Trichoderma reesei* RutC30 genomic DNA, 6.4 µM primer 993453, 3.2 µM primer 993463, 1 mM MgCl₂, and 2.5 units of *Pfx* polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 60 seconds at 94°C, 60 seconds at 55°C, and 180 seconds at 72°C (15 minute final extension).

The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 1000 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

The purified fragments were used as template DNA for subsequent amplification using primer 993453 (sense) and primer 993456 (antisense) shown above to precisely fuse the 1000 bp *Trichoderma reesei cbh1* promoter to the 2586 bp *Aspergillus oryzae* beta-glucosidase by overlapping PCR.

The amplification reactions (50 µl) were composed of *Pfx* Amplification Buffer, 0.25 mM dNTPs, 6.4 µM primer 99353, 3.2 µM primer 993456, 1 mM MgCl₂, and 2.5 units of *Pfx* polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 60 seconds at 94°C, 60 seconds at 60°C, and 240 seconds at 72°C (15 minute final extension).

The resulting 3586 bp fragment was digested with *Sal*I and *Spe*I and ligated into pMJ04, digested with the same two restriction enzymes, to generate pSMai130 (Figure 8).

Example 6: Construction of pSMai135

The *Aspergillus oryzae* beta-glucosidase coding region (minus the putative native signal sequence, see Figure 9) from Lys-20 to the TAA stop codon was PCR amplified from pJaL660 (WO 2002/095014) as template with primer 993728 (sense) and primer 993727 (antisense) shown below. Sequences in italics are homologous to 20 bp of the *Humicola insolens* endoglucanase V signal sequence and sequences underlined are homologous to 22 bp of the *Aspergillus oryzae* beta-glucosidase coding region. A *Spe*I site was engineered into the 5' end of the antisense primer.

Primer 993728: 5'-TGCCGGTGTGGCCCTTGCCAAGGATGATCTCGCGTACTCCC-3' (SEQ ID NO: 27)

Primer 993727: 5'-GACTAGTCTTACTGGGCCTTAGGCAGCG-3' (SEQ ID NO: 28)

The amplification reactions (50 µl) were composed of *Pfx* Amplification Buffer, 0.25

mM dNTPs, 10 ng of pJaL660, 6.4 μ M primer 993728, 3.2 μ M primer 993727, 1 mM MgCl₂, and 2.5 units of *Pfx* polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 60 seconds at 94°C, 60 seconds at 55°C, and 180 seconds at 72°C (15 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 2523 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

A separate PCR amplification was performed to amplify 1000 bp of the *Trichoderma reesei cbh1* promoter and 63 bp of the putative *Humicola insolens* endoglucanase V signal sequence (ATG start codon to Ala-21, Figure 10, SEQ ID NO: 29), using primer 993724 (sense) and primer 993729 (antisense) shown below. Primer sequences in italics are homologous to 20 bp of the *Humicola insolens* endoglucanase V signal sequence and underlined primer sequences are homologous to 22 bp of the *Aspergillus oryzae* beta-glucosidase coding region. Plasmid pMJ05, which comprises the *Humicola insolens* endoglucanase V coding region under the control of the *cbh1* promoter, was used as a template to generate a 1063 bp fragment comprising the *Trichoderma reesei cbh1* promoter/*Humicola insolens* endoglucanase V signal sequence fragment. A 42 bp of overlap was shared between the *Trichoderma reesei cbh1* promoter/*Humicola insolens* endoglucanase V signal sequence and the *Aspergillus oryzae* coding sequence to provide a perfect linkage between the promoter and the ATG start codon of the 2523 bp *Aspergillus oryzae* beta-glucosidase.

Primer 993724: 5'-ACGCGTCGACCGAATGTAGGATTGTTATCC-3' (SEQ ID NO: 30)

Primer 993729: 5'-GGGAGTACGCGAGATCATCCTT*GGCAAGGGCCAACACCGGCA*-3' (SEQ ID NO: 31)

The amplification reactions (50 μ l) were composed of *Pfx* Amplification Buffer, 0.25 mM dNTPs, 10 ng/ μ l pMJ05, 6.4 μ M primer 993728, 3.2 μ M primer 993727, 1 mM MgCl₂, and 2.5 units of *Pfx* polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 60 seconds at 94°C, 60 seconds at 60°C, and 240 seconds at 72°C (15 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 1063 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

The purified overlapping fragments were used as a template for amplification using primer 993724 (sense) and primer 993727 (antisense) described above to precisely fuse the 1063 bp fragment comprising the *Trichoderma reesei cbh1* promoter/*Humicola insolens*

endoglucanase V signal sequence to the 2523 bp fragment comprising the *Aspergillus oryzae* beta-glucosidase open reading frame by overlapping PCR.

The amplification reactions (50 µl) were composed of Pfx Amplification Buffer, 0.25 mM dNTPs, 6.4 µM primer 993724, 3.2 µM primer 993727, 1 mM MgCl₂, and 2.5 units of Pfx polymerase. The reactions were incubated in an Eppendorf Mastercycler 5333 programmed as follows: 30 cycles each for 60 seconds at 94°C, 60 seconds at 60°C, and 240 seconds at 72°C (15 minute final extension). The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a 3591 bp product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

The resulting 3591 bp fragment was digested with *Sa*/I and *Spe* I and ligated into pMJ04 digested with the same restriction enzymes to generate pSMai135 (Figure 11).

Example 7: Construction of pALFd1 *Saccharomyces cerevisiae* expression vector

Plasmid pALFd1 was generated from pSATE111 to swap the native *Aspergillus oryzae* beta-glucosidase secretion signal with the secretion signal of the *Humicola insolens* endoglucanase V to enhance *Aspergillus oryzae* beta-glucosidase production and secretion in *Saccharomyces cerevisiae*. Plasmid pSATE111 was digested with *Xho* I and *Spe* I to release a 2.6 kb fragment (*Aspergillus oryzae* beta-glucosidase) and a 6 kb (rest of the vector) fragment. The digestion was run in a 0.7% agarose gel using TAE buffer and the 6 kb fragment was isolated by gel purification using a QIAquick Gel Extraction Kit (QIAGEN Inc., Valencia, CA) following the manufacturer's protocol and ligated to the 2.6 kb PCR fragment, containing the *Aspergillus oryzae* beta-glucosidase coding region (minus the secretion signal sequence) and the *Humicola insolens* endoglucanase V signal sequence, which was amplified from pSMai135 using primers 993950 and 993951 shown below. The primers contain *Spe* I and *Xho* I restriction sites at their ends for subsequent subcloning into the *Spe* I and *Xho* I restriction sites of pSATE111.

Primer 993950: 5'-AATCCGACTAGTGGATCTACCATGCGTTCCTCCCCCTCC-3' (SEQ ID NO: 32)

Primer 993951: 5'-GCGGGCCTCGAGTTACTGGGCCTTAGGCAGCG-3' (SEQ ID NO: 33)

The amplification reactions (100 µl) were composed of PCR Thermo Pol Buffer, 0.20 mM dNTPs, 0.14 µg of pSMai135 plasmid DNA, 50 µM primer 993950, 50 µM primer 993951, and 2 units of Vent DNA polymerase. The reactions were incubated in a RoboCycler Gradient 40 Thermal Cycler (Stratagene, La Jolla, CA) programmed as follows: one cycle of 1 minute at 95°C, and 25 cycles each for 1 minute at 95°C, 1 minute at 60 or 64°C, and 3 minutes at 72°C (10 minute final extension). The reaction products were

visualized on a 0.7% agarose gel using TAE buffer. The resulting 2.6 kb fragments were purified using a PCR MinElute PCR Purification (QIAGEN, Chatsworth, CA) according to the manufacturer's instructions. The purified fragments were combined and digested with *Spe* I and *Xho* I and ligated into pSATE111 digested with the same two restriction enzymes to generate pALFd1 (Figure 12).

Example 8: Generation of primary libraries of mutagenized beta-glucosidase in *Saccharomyces cerevisiae*

In an effort to identify regions on the *Aspergillus oryzae* beta-glucosidase that are critical for protein thermostability, the entire wild-type *Aspergillus oryzae* beta-glucosidase gene was mutagenized using error-prone PCR with homologous sequences to the yeast expression vector pSATE111, which can undergo *in vivo* recombination between homologous domains of distinct fragments. This process generated circular, replicating plasmids from a combination of linearized vector and PCR products.

Primer 992328 (from Example 1) and primer AoJal660.2, shown below, were used in the error-prone PCR amplification of the beta-glucosidase gene from pSATE101 to generate mutagenized sequences that could be cloned into pSATE111 for expression of the beta-glucosidase enzyme in yeast.

Primer AoJal660.2: 5'-AGGGTGAATGGGCGGAA-3' (SEQ ID NO: 34)

The error-prone PCR amplifications (50 μ l) were composed of 1X *Taq* buffer containing 1.5 mM MgCl₂ (Promega Corporation, Madison, WI), 60 ng of pSATE101, 0.16 mM dATP, 0.07 mM each of dCTP, dGTP, and dTTP, 50 μ M of primer AoJal660.2, 50 μ M of primer 992328, 0.1 mM MnCl₂, and 5 units of *Taq* DNA polymerase (Promega Corporation, Madison, WI). The amplification reactions were incubated as described in Example 1.

Plasmid pSATE111 was gapped by digestion with *Eco* RI and *Sma* I, and then gel purified using QiaexII resin (QIAGEN Inc., Valencia, CA). The digestion was verified by fractionating an aliquot of the digestion on a 0.7% agarose gel using TAE buffer and staining with ethidium bromide where expected fragments of 8,054 bp (gapped vector containing part of the beta-glucosidase coding sequence) and 672 bp (from the beta-glucosidase gene) were obtained. The digestion was purified using QiaexII resin.

Three μ l aliquots of the above PCR reactions were mixed with 0.5 μ l of the gapped pSATE111 vector for cotransformation into *Saccharomyces cerevisiae* YNG318 competent cells. The co-transformed fragments contained at least 250 bp of homologous DNA sequence at the ends to facilitate gap repair of the expressed plasmid. Competent cells of *Saccharomyces cerevisiae* YNG 318 were prepared prior to each transformation following

the YEASTMAKER Yeast Transformation Protocol (CLONTECH Laboratories, Inc., Palo Alto, CA) with the following modifications: (1) The volume of yeast culture used to inoculate the overnight incubation (16–20 hours) was between 100–1,000 µl; (2) recovery of cells upon transformation was performed in YPD medium for 45 minutes at 30°C; and (3) the transformation mixture was aliquoted for plating onto yeast selection plate medium while the remainder of the transformants were frozen at -80°C in a controlled rate freezer (Nalge Nunc International, Rochester, NY).

Plates were incubated at 30°C for approximately 4 days. Colonies producing active beta-glucosidase turned blue after incubation due to beta-glucosidase hydrolysis of X-Glc. Activity of the library was estimated by the percentage of blue colonies obtained. The library was 67% active.

Example 9: Screening of beta-glucosidase libraries

The primary beta-glucosidase library was spread on Genetix QTray's (22 x 22 cm Petri dishes, Genetics Ltd., Hampshire, United Kingdom) and incubated for 5 days at 30°C. Using a Genetix QPix (Genetix Ltd., Hampshire, United Kingdom), active colonies were picked using X-Glc selection into 96-well plates containing yeast selection medium. Plates were incubated for 7 days at 30°C. Screening buffer (0.1 M succinate pH 5) was added to the growth plates prior to the start of the screen. Using an ORCA robot (Beckman Coulter, Fullerton, CA), the growth plates were transported to a Multimek (Beckman Coulter, Fullerton, CA) and samples were taken from the growth plate and mixed into 96-well polycarbonate v-bottom plates. Samples were then taken from the v-bottom plates and dispensed into empty 96-well flat bottom plates for an initial plate assay with p-nitrophenyl-beta-D-glucopyranoside as substrate in 0.1 M succinate pH 5 at ambient temperature. The v-bottom plate was transported to a custom 96-well heating block and incubated at 65°C for a total of 10 minutes. Samples were then taken from the v-bottom plates subjected to the heating block and dispensed into empty 96-well flat bottom plates for a final plate assay with p-nitrophenyl-beta-D-glucopyranoside as substrate in 0.1 M succinate pH 5 at ambient temperature. The initial and final assay plates were then transported to a Multidrop (LabSystems, Vantaa, Finland) where the p-nitrophenyl-beta-D-glucopyranoside substrate was added. After the predetermined assay incubation time had expired, between 30-120 minutes, the initial and final assay plates were quenched with 2 M Tris pH 8 buffer. Both plates were read using a Spectramax plate reader (Molecular Devices, Sunnyvale, CA) at 405 nm. The ratio of the final read to the initial read was calculated using Microsoft Excel (Microsoft Corporation, Redmond, WA) to determine the percent residual activity (%RA).

Based on %RA measurements, screening of the libraries constructed in Example 8 generated two variants: BG13 and BG14. The residual activity produced by these variants was 13% and 17% for BG13 and BG14, respectively.

5 **Example 10: Shuffled library of beta-glucosidase variants BG13 and BG14**

To shuffle the DNA of beta-glucosidase variants BG13 and BG14 of Example 9, plasmid DNA was isolated from the variants. Each variant was grown at 30°C overnight in 3 ml of yeast selection medium containing 75 µg of chloramphenicol to prevent contamination.

10 Samples of 100 µl from the overnight cultures were centrifuged for 3 minutes at 13,200 x g. The supernatant was removed and DNA was isolated from the remaining pellet according to the protocol described by Kaiser and Auer, 1993, *BioTechniques* 14 (4): 552, except 20 µl of yeast lysis buffer was used.

The *Aspergillus oryzae* beta-glucosidase genes from variants BG13 and BG14 were amplified by PCR using the following primers:

15 pSAt1115' nested primer: 5'-GACATTTTTTGCTGTCAGTCA-3' (SEQ ID NO: 35)

pSAt1113' nested primer: 5'-AATGTTACATGCGTACACGC-3' (SEQ ID NO: 36)

Three PCR reactions using DNA rescued from variant BG13 as a template and 5 reactions using DNA rescued from variant BG14 were conducted. The amplification reactions (100 µl) were composed of 0.5 µl of yeast plasmid DNA, 1X AmpliTaq buffer not containing MgCl₂, 125 µM each of dATP, dCTP, dGTP, and dTTP, 50 pmole of each primer, 20 1.5 mM MgCl₂, and 1 unit of AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA). The reactions were incubated in an Eppendorf Mastercycler 5333 programmed for 1 cycle at 95°C for 5 minutes; 25 cycles each at 95°C for 1 minute, 50°C for 1 minute; and 72°C for 3 minutes; and a final extension cycle at 72°C for 10 minutes. The three PCR 25 reactions for BG13 and five PCR reactions for BG14 were combined and purified using a QIAquick PCR Purification Kit (QIAGEN Inc., Valencia, CA). DNA was eluted into 30 µl of EB buffer (QIAGEN Inc., Valencia, CA). The concentration of the purified PCR products obtained after amplification of each variant was verified by visualization in a 0.7% agarose gel run in TAE buffer and stained with ethidium bromide. Each variant yielded 125 ng of 30 DNA per microliter.

For shuffling of the DNA of BG13 and BG14 variants, 3.2 µl (400 ng) of the BG13 PCR product and 3.2 µl (400 ng) of the BG14 PCR product were combined with 2 µl (400 ng) of gapped pSAt111 prepared as described in Example 8, except *Spe*I and *Xho*I were used to gap the vector and then transformed into freshly made competent *Saccharomyces* 35 *cerevisiae* YNG 318 cells as described in Example 8. The generated library was 78% active

based on the percentage of blue colonies generated.

Totally, 6,336 active colonies from this library were picked and screened as described in Example 9, which resulted in the isolation of 6 improved thermostable variants, four of which were designated BG40, BG41, BG42, and BG43. For sequencing of the DNA of variants BG40, BG41, BG42, and BG43, DNA was isolated from a 100 µl sample of yeast selection broth according to the procedure of Kaiser and Auer, 1993, *supra*. The isolated DNA was transformed into *E. coli* SURE electroporation-competent cells according to the manufacturer's instructions. Plasmid DNA was isolated as described previously and then sequenced.

The entire coding region of each *Aspergillus oryzae* beta-glucosidase variant gene was sequenced using 0.5 µl of plasmid DNA and 3.2 pmol of the following primers:

- AoJal660.1: 5'-GTTTCGGCTCAGGACTG-3' Position: 2492 Forward (SEQ ID NO: 37)
- AoJal660.1a: 5'-ACTTCCGCCCATTCACC-3' Position: 141 Reverse (SEQ ID NO: 38)
- AoJal660.2: 5'-AGGGTGAATGGGCGGAA-3' Position: 123 Forward (SEQ ID NO: 39)
- AoJal660.2a: 5'-GGCGGAAATGCTCTTGT-3' Position: 614 Reverse (SEQ ID NO: 40)
- AoJal660.3: 5'-GGATGGCGGTAGAACT-3' Position: 469 Forward (SEQ ID NO: 41)
- AoJal660.3a: 5'-GCGGTCCAATCACTCAT-3' Position: 861 Reverse (SEQ ID NO: 42)
- AoJal660.4: 5'-GCTACGGTTGCGAGAAT-3' Position: 774 Forward (SEQ ID NO: 43)
- AoJal660.4a: 5'-CTCAAGGGCAAGGCACC-3' Position: 1232 Reverse (SEQ ID NO: 44)
- AoJal660.5: 5'-GGTGCCTTGCCCTTGAG-3' Position: 1232 Forward (SEQ ID NO: 45)
- AoJal660.5a: 5'-TTCGCTGCGGTCTTGAC-3' Position: 1629 Reverse (SEQ ID NO: 46)
- AoJal660.6: 5'-GTGGAAGAACGGCGACA-3' Position: 1591 For (SEQ ID NO: 47)
- AoJal660.6a: 5'-CCCAGCCGTAGTTAGAA-3' Position: 2195 Rev (SEQ ID NO: 48)
- AoJal660.7: 5'-CGTCCC GATACACTCCC-3' Position: 2019 For (SEQ ID NO: 49)
- AoJal660.7a: 5'-CCTGGAGCGGCAGTTTC-3' Position: 2573 Rev (SEQ ID NO: 50)
- AoJal660.8: 5'-GGTCGGTGTCTTAACGG-3' Position 964 For (SEQ ID NO: 51)
- AoJal.660.8a: 5'-ACTATCCTGCAAACACAAGC-3' Position: 292 Rev (SEQ ID NO: 52)
- AoJa1660.9: 5'-CCTTTCACCTTGGGGCA-3' Position 1802 For (SEQ ID NO: 53)
- AoJal660.9a: 5'-GGAGTTACCAGACTCCTGGC-3' Position 1756 Rev (SEQ ID NO: 54)
- AoJa1660.10a: 5'-ACCTTCCGAAACATGGTTAT-3' Position 1132 Rev (SEQ ID NO: 55)

Sequencing indicated there were consistent mutations in the mutants isolated that led to amino acid substitutions. Variant BG40 possessed 5 mutations, in which 3 of them led to amino acid substitutions. The first mutation, which led to the substitution G4S, was found in the predicted signal peptide sequence of beta-glucosidase. Three mutations were found in the active site of the protein, but only 1 of the mutations led to an amino acid

substitution: H266Q. A final mutation was found in the X-domain of the protein: D365N. The X-domain is the region outside of the active site region.

Variant BG41 possessed three mutations with two of them leading to amino acid substitutions: G142S and H266Q. All substitutions were found in the active site of the protein.

Variant BG42 possessed three mutations with two being silent. The only actual amino acid substitution was H266Q.

Variant BG43 possessed three mutations, one being silent. The E-13V amino acid substitution was located in the predicted signal sequence and the H266Q amino acid substitution was found in the active site of the protein.

The only common amino acid substitution found in all of the isolated variants was H266Q.

Example 11: Second round of shuffling of beta-glucosidase improved variants

To generate a shuffled library with several of the mutants previously isolated, the beta-glucosidase coding regions of the BG41 and BG43 variants were amplified using plasmid DNA isolated as described previously. A 100 µl PCR reaction was performed as described in Example 10 except 200 µM of each dATP, dCTP, dGTP, and dTTP and 1X AmpliTaq buffer containing 1.5 mM MgCl₂ were used. The amplified beta-glucosidase inserts (BG41 and BG43) were purified as described in Example 10 each yielding an estimated DNA concentration of 125 ng per microliter. The coding regions of BG13 and BG14 variants were also further amplified and purified for shuffling by using 1 µl of plasmid DNA in a PCR reaction as described in Example 10. The yield of each purified product was 1,250 ng per microliter for BG13 and 125 ng per microliter for BG14.

A fifth variant designated BG2 was generated as described in Example 8 using the primers described in Example 10, and isolated by screening as described in Example 9. DNA of variant BG2 was also added to the shuffle with the DNA of BG13, BG14, BG41, BG43, but later analysis showed that BG2 was a false-positive. The purified PCR product for each mutant was combined (125 ng each, except for BG14 where 12.5 ng was used) with 400 ng of pSATE111 gapped with *Spe* I/*Xho* I for transformation by gap repair into 50 µl of *Saccharomyces cerevisiae* YNG318 competent cells as described in Example 8. The resulting library was 93.9% active based on the percentage of blue colonies.

Screening of the library was performed as described in Example 9, except plates were incubated at 68°C. Totally, 15,439 active clones were picked from the library and screened, which resulted in the isolation of variants BG47, BG48, and BG 49, which had

53%, 87%, and 21% residual activity after incubation for 10 minutes at 68°C using p-nitrophenyl-beta-D-glucopyranoside as substrate as described in Example 9.

For sequencing of the DNA of variants BG47, BG48, and BG 49, DNA was isolated as described in Example 10, except DNA was isolated from a 500 µl sample of yeast selection
5 broth and transformed into *E. coli* XL-10 Gold ultracompetent cells.

Sequencing of these mutants revealed that variant BG47 contained an E-13V amino acid substitution in the signal sequence, a silent mutation, and two amino acid substitutions at G142S and H266Q in the active site. Variant BG48 contained the same mutations as found in variant BG41 plus amino acid substitutions at A16T in the active site and at D703G
10 in the X domain. Variant BG49 was identical to BG43.

Example 12: Generation of a site-specific randomized library at positions G142 and H266

In an effort to identify the best substitutions at positions 142 and 266, which were
15 present in the BG41 variant, the nucleotides that encode the amino acids at these positions, G166S and H266Q, in BG41, were randomized by replacing them with NN(G/C). Therefore, the region that encodes these amino acids in the *Aspergillus oryzae* beta-glucosidase gene was amplified by PCR and transformed with the pSATE111BG41 which was digested with *B/p* I, so that the amplified PCR fragments which are homologous to the linearized yeast
20 expression vector pSATE111BG41, with the exception of the degenerated nucleotides, could undergo *in vivo* recombination when transformed into *Saccharomyces cerevisiae*. This process generated circular, replicating plasmids from a combination of linearized vector and PCR products.

Primer BG41SDMUpper (which contains degenerated nucleotides at the position
25 which encodes the amino acid 143, in bold) and primer BG41SDMLower (which contains degenerated nucleotides at the position which encodes the amino acid 266, in bold), shown below, were used in the PCR amplification of the beta-glucosidase gene from pSATE111BG41 to generate a partial sequence of the beta-glucosidase gene that contains these randomized positions and could be cloned into pSATE111BG41 for expression of the
30 beta-glucosidase enzyme in yeast.

Primer BG41SDMUpper:

5'-GGTAGAAACTGGGA**NN**STTCTCACCAGATCCAGCCCTC-3' (SEQ ID NO: 56)

Primer BG41LowerLower:

5'-GCCTACGCCGCTGTG**NN**SAGCGGTCCAATCACT-3' (SEQ ID NO: 57)

35 The PCR amplifications (100 µl) were composed of 1X Pfx Amplification Buffer, 150

ng of pSATE111BG41, 2 µl of 10 mM blend of dATP, dTTP, dGTP, and dCTP, 3 µl of 50 mM MgSO₄ 50 µM of primer BG41SDMUpper, 50 µM of primer BG41LowerLower, 2.5 units of Platinum Pfx DNA Polymerase (Invitrogen, Carlsbad, CA). The amplification conditions were one cycle at 95°C for 5 minutes; 25 cycles each at 95°C for 1 minute, 52, 55, 58, or 61°C
5 for 1 minute, and 72°C for 30 seconds; and a final cycle of 72°C for 10 minutes. The heat block then went to a 4°C soak cycle.

Plasmid pSATE111BG41 was linearized by digestion with *B/p* I, and then cleaned up using the QIAquick Nucleotide Removal Kit (QIAGEN Inc., Valencia, CA) following the manufacturer's instructions. The four above PCR reactions were combined and cleaned up
10 using a QIAquick PCR Purification Kit and eluted in 10 µl of EB buffer following manufacturer's instructions. An aliquot of 7 µl of the cleaned PCR product (3.5 µg) was combined with 560 ng of the linearized pSATE111BG41 vector for cotransformation into *Saccharomyces cerevisiae* YNG318 competent cells as described as in Example 8. The library was 82.8% active. The high activity of this library suggested the randomization of
15 the G142 and H266 positions was not successful. However, this library was still screened as described in Example 9.

Example 13: Third round of shuffling of beta-glucosidase improved variants

To obtain a further improved variant, a shuffled library with the DNA of the
20 previously described variants BG2, BG13, BG14, and BG48 was constructed as well as with variant BG50, which arose from generation of a site-specific randomized library as described in Example 12 and was isolated by screening as described in Example 9. The DNA of this variant was partially sequenced and had the same mutations as present in its parental sequence, BG41, but with an extra mutation: Q183R. Therefore, this variant was a product
25 of mutagenesis in the amplification reaction of the pSATE111BG41 vector. Generation of the library was performed as described in Example 10. Screening of the library was performed as described in Example 9, except plates were incubated at 70°C. The library led to the isolation of variants BG52, BG53, and BG54, which had a %RA of 60%, 65%, 50%, respectively, at 70°C. Sequencing of the DNA of these variants was performed as described
30 in Example 10. Variant BG52 had the same substitutions as BG48 with a S-5P substitution in the predicted signal sequence. Variant BG53 had the same substitutions as BG41 with the addition of a Q183R substitution and the same D703G amino acid substitution present in BG48. BG54 contained the following substitutions: S-5P, G142S, Q183R, and H266Q.

Table 1 summarizes the variants obtained from screening of either the primary or
35 shuffled libraries and their amino acid substitutions. Table 2 shows the thermostability of

the variants at 65°C, 68°C, and 70°C for 10 minutes. Mutations in the DNA sequence that led to amino acid substitutions are in bold. Mutations in the DNA sequence that did not lead to amino acid substitutions are in plain text.

5

Table 1. Thermostable Beta-Glucosidase Variants

Mutant	Amino acid substitutions	Library origin
BG13	N/A	Primary of WT BG
BG14	N/A	Primary of WT BG
BG40	G-16S ; V226V; H266Q ; P335P; D365N	Shuffling BG13 and BG14
BG41	G142S ; V226V; H266Q	Shuffling BG13 and BG14
BG42	V226V; H266Q ; N514N	Shuffling BG13 and BG14
BG43	E-13V ; V226V; H266Q	Shuffling BG13 and BG14
BG47	E-13V ; C55C; G142S ; H266Q	Shuffling "BG2", BG13, BG14, BG 43
BG48	A16T ; A132A; G142S ; V226V; H266Q ; D703G	Shuffling "BG2", BG13, BG14, BG 43
BG49	E-13V , V226V; H266Q	Shuffling "BG2", BG13, BG14, BG 43
BG50	Partial seq. G142S ; Q183R ; V226V; H266Q	Primary of BG41
BG52	S-5P ; A16T ; G142S ; H266Q ; D703G	Shuffling "BG2", BG13, BG14, BG48, BG50
BG53	G142S ; Q183R ; H266Q ; D703G	Shuffling "BG2", BG13, BG14, BG48, BG50
BG54	S-5P ; G142S ; Q183R ; H266Q	Shuffling "BG2", BG13, BG14, BG48, BG50

Table 2. Thermostability of Beta-Glucosidase Variants

Mutant	Amino acid substitutions	%RA at 65°C	%RA at 68°C	%RA at 70°C
BG13	N/A	13%	N/A	N/A
BG14	N/A	17%	N/A	N/A
BG40	G-16S ; V226V; H266Q ; P335P; D365N	54%	N/A	N/A
BG41	G142S ; V226V; H266Q	79%	45%	N/A
BG42	V226V; H266Q ; N514N	45%	N/A	N/A
BG43	E-13V ; V226V; H266Q	45%	31%	N/A
BG47	E-13V ; C55C; G142S ; H266Q	85%	53%	N/A
BG48	A16T ; A132A; G142S ; V226V; H266Q ; D703G	100%	87%	44%
BG49	E-13V ; V226V; H266Q	N/A	69% (at 69°C)	N/A
BG50	Partial seq. G142S ; Q183R ; H266Q	N/A	21%	N/A
BG52	S-5P ; A16T ; G142S ; H266Q ; D703G	N/A	N/A	60%

BG53	G142S; Q183R; H266Q; D703G	N/A	N/A	65%
BG54	S-5P; G142S; Q183R; H266Q	N/A	N/A	50%

Samples of beta-glucosidase were diluted in the same buffer as used in Example 9 to the same activity relative to each other. The sample was divided into two polypropylene test tubes, one part of the sample was incubated submerged in a temperature controlled water bath, and the other part was incubated at ambient temperature, both for a period of up to 42 hours. At the end of the incubation period, samples of both were placed into a 96-well plate. Methylumbelliferyl-beta-D-glucopyranoside (MUG) substrate (200 μ l of 0.5 μ M solution of MUG) was added to the 96-well plate of samples and incubated at ambient temperature for 15 minutes. The reaction was stopped with the addition of 2M Tris pH 9.0 buffer, and the plate was read on a fluorometer to obtain Relative Fluorescent Units (RFU) at excitation 365, emission 454. The percent residual activity was determined using the same method as described in Example 9. The results are shown in Table 3. Overall, the results correlated with the results shown in Table 2.

Table 3. Thermostability of beta-glucosidase variants at longer incubation times

Mutations as appropriate	Other ID as appropriate	%RA at 55°C for 42 hr	%RA at 60°C for 15 hr	%RA at 60°C for 23.5 hr	%RA at 65°C for 1 hr
A. niger WT	ANBG	12%	0%	0%	5%
A. oryzae WT	AOBG	69%	2%	0%	0%
H266Q	BG43	Not Done	9%	Not Done	1%
G142S; H266Q	BG41	88%	40%	35%	40%
A16T; G142S; H266Q; D703G	BG48	87%	41%	37%	48%

Example 14: Construction of pAlLo2 expression vector

Expression vector pAlLo1 was constructed by modifying pBANe6 (U.S. Patent 6,461,837), which comprises the NA2-tpi promoter, *Aspergillus niger* amyloglucosidase terminator sequence (AMG terminator), and *Aspergillus nidulans* acetamidase gene (*amdS*). Modification of pBANe6 was performed by first eliminating three *Nco* I restriction sites at positions 2051, 2722, and 3397 bp from the *amdS* selection marker by site directed mutagenesis. All changes were designed to be "silent" leaving the actual protein sequence of the *amdS* gene product unchanged. Removal of these three sites was performed simultaneously with a GeneEditor Site-Directed Mutagenesis Kit (Promega, Madison, WI)

according to the manufacturer's instructions using the following primers (underlined nucleotide represents the changed base):

AMDS3NcoMut (2050): 5'-GTGCCCCATGATACGCCTCCGG-3' (SEQ ID NO: 58)

AMDS2NcoMut (2721): 5'-GAGTCGTATTTCCAAGGCTCCTGACC-3' (SEQ ID NO: 59)

5 AMDS1NcoMut (3396): 5'-GGAGGCCATGAAGTGGACCAACGG-3' (SEQ ID NO: 60)

A plasmid comprising all three expected sequence changes was then submitted to site-directed mutagenesis, using a QuickChange Mutagenesis Kit (Stratagene, La Jolla, CA), to eliminate the *Nco* I restriction site at the end of the AMG terminator at position 1643. The following primers (underlined nucleotide represents the changed base) were used for mutagenesis:

Upper Primer to mutagenize the *Aspergillus niger* amyloglucosidase (AMG) terminator sequence:

5'-CACCGTGAAAGCCATGCTCTTTCTTCGTGTAGAAGACCAGACAG-3' (SEQ ID NO: 61)

Lower Primer to mutagenize the *Aspergillus niger* amyloglucosidase (AMG) terminator sequence:

5'-CTGGTCTTCTACACGAAGGAAAGAGCATGGCTTTCACGGTGTCTG-3' (SEQ ID NO: 62)

The last step in the modification of pBANE6 was the addition of a new *Nco* I restriction site at the beginning of the polylinker using a QuickChange mutagenesis kit and the following primers (underlined nucleotides represent the changed bases) to yield pAllo1 (Figure 13).

Upper Primer to mutagenize the *Aspergillus niger* amylase promoter (NA2-tpi):

5'-CTATATACACAACCTGGATTTACCATGGGCCCCGCGGCCGAGATC-3' (SEQ ID NO: 63)

Lower Primer to mutagenize the *Aspergillus niger* amylase promoter (NA2-tpi):

5'-GATCTGCGGCCGCGGGCCCATGGTAATCCAGTTGTGTATATAG-3' (SEQ ID NO: 64)

The *amdS* gene of pAllo1 was swapped with the *Aspergillus nidulans pyrG* gene. Plasmid pBANE10 (Figure 14) was used as a source for the *pyrG* gene as a selection marker. Analysis of the sequence of pBANE10 showed that the *pyrG* marker was contained within an *Nsi* I restriction fragment and does not contain either *Nco* I or *Pac* I restriction sites. Since the *amdS* is also flanked by *Nsi* I restriction sites the strategy to switch the selection marker was a simple swap of *Nsi* I restriction fragments. Plasmid DNA from pAllo1 and pBANE10 were digested with the restriction enzyme *Nsi* I and the products purified by agarose gel electrophoresis. The *Nsi* I fragment from pBANE10 containing the *pyrG* gene was ligated to the backbone of pAllo1 to replace the original *Nsi* I DNA fragment containing the *amdS* gene. Recombinant clones were analyzed by restriction digest to determine that they had the correct insert and also its orientation. A clone with the *pyrG* gene transcribed

in the counterclockwise direction was selected. The new plasmid was designated pAILo2 (Figure 15).

Example 15: Subcloning of the improved thermostable beta-glucosidase BG41 and BG48 variants into *Aspergillus oryzae* for protein characterization

The coding regions of beta-glucosidase variants BG41 and BG48 were subcloned into the *Aspergillus oryzae* vector pAILo02 digested with *Nco* I and *Pac* I to form a perfect junction with the ATG of the gene and the *Aspergillus niger* amylase promoter (NA2-tpi) and the *Aspergillus niger* amyloglucosidase terminator sequence. Since the beta-glucosidase coding region possessed two *Nco* I sites, subcloning of the beta-glucosidase gene into pAILo2 was accomplished by designing two primers, shown below, that expand the beta-glucosidase gene in pSATE111 and also anneal to pAILo2 close to the *Nco* I and *Pac* I sites.

Aoryzaebeta-glucosidaseUpper:

5'-**ACTGGATTACCATGAAGCTTGGTTGGATC**-3' (SEQ ID NO: 65)

ACTGGATTACCATG anneals to pAILo2 and AAGCTTGGTTGGATC anneals to pSATE111.

Aoryzaebeta-glucosidaseLower:

5'-**AGTCACCTCTAGTTATTACTGGGCCTTAGG**-3' (SEQ ID NO: 66)

AGTCACCTCTAGTTA anneals to pAILo2 and TTAGTGGGCCTTAGG anneals to pSATE111.

To amplify the DNA of variants BG41 and BG48, 0.5 µl of each plasmid DNA template was used in a 100 µl reaction containing 1X ThermoPol Reaction buffer containing 2 mM MgSO₄, 0.05 mM of each dATP, dGTP, dCTP, and dTTP, 50 pmole of each primer (Aoryzaebeta-glucosidaseUpper and Aoryzaebeta-glucosidaseLower primers), and 1 unit of Vent DNA polymerase. Two amplification reactions were performed where the first reaction was subjected to 1 cycle at 95°C for 5 minutes; 25 cycles each at 95°C for 1 minute, 50°C for 1 minute, 72°C for 3 minutes; and a final extension cycle at 72°C for 10 minutes, and the second reaction was performed under the same conditions but at an annealing temperature of 56°C. An aliquot of each PCR product was run on a 0.7% agarose gel using TAE buffer, as previously described, generating expected bands of approximately 3 kb. Both PCR reactions were combined and were purified using a MinElute PCR Purification Kit and DNA and eluting the DNA into 10 µl of EB buffer. The yield of each purified PCR product was estimated to be 250 ng per microliter by visualization on a 0.7% agarose gel using TAE buffer.

Plasmid pAILo2 digested with *Pac* I and blunted at the *Nco* I site was concentrated by precipitation with 0.1 volume of 3 M sodium acetate pH 5.0 and 2 volumes of 95% ethanol overnight at -20°C. The precipitated plasmid was centrifuged at 13,200 x *g* using a

microcentrifuge for 15 minutes. The supernatant was removed, and the pellet was washed with 1 ml of 70% ethanol. The precipitated pellet was centrifuged again at 13,200 x *g* for 15 minutes, followed by removal of the supernatant, drying of the pellet under vacuum, and resuspension in 20 µl of water. The plasmid had a concentration of 80 ng per microliter.

5 The concentration was verified by visualization on a 0.7% agarose gel using TAE buffer. Cloning of the beta-glucosidase PCR product described above and the digested pALLo2 vector was accomplished by using a BD In-Fusion PCR Cloning Kit (Stratagene, La Jolla, CA).

The resulting expression vectors containing the coding regions of variant BG41 or BG48 were designated pALFd3BG41 (Figure 16) and pALFd3BG48 (Figure 17), respectively.

10

Example 16: Expression of beta-glucosidase variants BG41 and BG48 in *Aspergillus oryzae*

Approximately 4.5 µg of pALFd3BG41 and 6.25 µg of pALFd3BG48 plasmid DNA were used to independently transform *Aspergillus oryzae* Jal250 protoplasts. *Aspergillus oryzae* Jal250 protoplasts were prepared according to the method of Christensen *et al.*, *Bio/Technology* 6: 1419-1422.

15

The transformation of *Aspergillus oryzae* Jal250 with pALFd3BG41 yielded 5 independent transformants, while transformation with pALFd3BG48 yielded 15 independent transformants, where 9 of them were further subcultured. Four days after each independent transformant had been transferred to 100 mm minimal medium selection plates, spores were transferred from the selection plates to 24-well plates containing M400 medium diluted 1 to 5 with 1X BS and incubated at 34°C. Seven days after incubation, 10 µl of each supernatant were analyzed using 8-16% SDS-PAGE gels (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. SDS-PAGE profiles of the cultures of the four pALFd3BG41 transformants showed a major band of approximately 120 kDa which corresponded to the molecular weight of *Aspergillus oryzae* beta-glucosidase. SDS-PAGE profiles of the cultures of the six pALFd3BG48 transformants also showed a major band of approximately 120 kDa.

20

25

Example 17: Thermostability determinations of beta-glucosidase variants BG41 and BG48 with cellobiose

30

The thermostability of beta-glucosidase variants BG41 and BG48 (unpurified fermentation broths) was determined by incubating the broth with 10 mM cellobiose in 100 mM sodium citrate buffer with 0.01% Tween-20 at pH 5.0 up to 21 hours at 65°C.

35 Results of the thermostability determination of beta-glucosidase variants BG41 and

BG48, as shown in Figure 18, demonstrated that the variants were significantly more stable over time than either *Aspergillus niger* beta-glucosidase (Novozym 188) or *Aspergillus oryzae* beta-glucosidase.

5 **Example 18: Construction of a beta-glucosidase variant with the G142S substitution**

 The nucleotide region containing the G to A mutation to produce the G142S substitution was subcloned into the coding sequence of pSATE111 for further characterization of the effects of this single amino acid substitution. The G to A mutation
10 was located between the *Spe* I and *Bpu* 1102 I unique sites of the pSATE111 vector. Plasmids pSATE111 (approximately 50 µg) and pSATE111BG41 (approximately 300 µg) were digested with *Spe* I and *B/p* I, an isoschizomer of *Bpu* 1102 I. The reactions yielded two fragments: one containing most of pSATE111 (8146 bp) and a smaller fragment of 580 bp from the beta-glucosidase coding sequence containing the G to A mutation. Digested
15 pSATE111 was treated with shrimp alkaline phosphatase for dephosphorylation of the digested DNA products by adding 1X SAP buffer and 2 µl of SAP (Roche Applied Science, Mannheim, Germany) and incubating the reaction for 10 minutes at 37°C followed by incubation at 85°C for 10 minutes for enzyme inactivation. Both digestions were run on 0.7% agarose gel and purified using a QIAGEN Gel purification kit according to the
20 manufacturer's instructions.

 Digested pSATE111 was ligated to the 580 bp fragment from the pATE111BG41 digestion containing the position that encoded amino acid 142 with the nucleotide mutation that led to the G142S amino acid substitution. Ligation was accomplished by using the Rapid DNA Ligation Kit (Roche Applied Science, Mannheim, Germany) following the
25 manufacturer's instructions.

 The ligation reaction was transformed into XL1-Blue *E. coli* subcloning-competent cells according to the manufacturer's instructions (Stratagene, La Jolla, CA). Upon transformation, plasmid DNA from an isolated colony was isolated as described in Example 10 and sequenced, confirming the presence of the unique G to A mutation in the entire
30 coding region of the gene. Subsequently, the plasmid DNA was transformed into yeast competent cells as described in Example 8, which resulted in isolation of a beta-glucosidase variant containing the G142S substitution. This beta-glucosidase variant was designated the G142S mutant. Since BG43 contained only the H266Q substitution and the G142S mutant contained only the G142S substitution, the effects of each substitution, G142S and H266Q,
35 could be individually characterized.

Example 19: Assay of the effects of G142S and H266Q mutations

A thermal stability test was performed at 60°C for 23 hours demonstrating the synergistic effect of the mutations. Samples of the beta-glucosidase variants were diluted in the same buffer as used in Example 9 to the same enzyme activities relative to each other. Each sample was divided into two polypropylene test tubes, one tube of the samples was incubated submerged in a temperature controlled water bath at 60°C and the other part was incubated at ambient temperature, both for a period of up to 42 hours. At the end of the incubation period, samples of both were placed into a 96-well plate. Methylumbelliferyl-beta-D-glucopyranoside (MUG) substrate (200 µl of 0.5 µM solution of MUG) was added to the 96-well plate of samples and incubated at ambient temperature for 15 minutes. The reaction was stopped with the addition of 2 M Tris buffer, pH 9.0 and the plate was read on a fluorometer to obtain the Relative Fluorescent Units (RFU) at excitation 365, emission 454. The percent residual activity was determined using the same method described in Example 9.

The effects of mutations G142S and H266Q individually and combined into one molecule are shown in Figure 19. Individual testing of these mutations showed that the combination of them in one molecule had a greater effect on thermal stability of beta-glucosidase activity in buffer than either of them individually as shown in Figure 19. The bar is the mathematical composite of these two amino acid substitutions.

Example 20: Identification of a glycosyl hydrolase Family GH3A gene in the genomic sequence of *Aspergillus fumigatus*

A tblastn search (Altschul *et al.*, 1997, *Nucleic Acids Res.* 25: 3389-3402) of the *Aspergillus fumigatus* partial genome sequence (The Institute for Genomic Research, Rockville, MD) was carried out using as query a beta-glucosidase protein sequence from *Aspergillus aculeatus* (Accession No. P48825). Several genes were identified as putative Family GH3A homologs based upon a high degree of similarity to the query sequence at the amino acid level. One genomic region of approximately 3000 bp with greater than 70% identity to the query sequence at the amino acid level was chosen for further study.

Example 21: *Aspergillus fumigatus* genomic DNA extraction

Aspergillus fumigatus was grown in 250 ml of potato dextrose medium in a baffled shake flask at 37°C and 240 rpm. Mycelia were harvested by filtration, washed twice in TE buffer (10 mM Tris-1 mM EDTA), and frozen under liquid nitrogen. Frozen mycelia were

ground by mortar and pestle to a fine powder, which was resuspended in pH 8.0 buffer containing 10 mM Tris, 100 mM EDTA, 1% Triton X-100, 0.5 M guanidine-HCl, and 200 mM NaCl. DNase free RNase A was added at a concentration of 20 mg/liter and the lysate was incubated at 37°C for 30 minutes. Cellular debris was removed by centrifugation, and DNA
5 was isolated by using a Qiagen Maxi 500 column (QIAGEN Inc., Chatsworth, CA). The columns were equilibrated in 10 ml of QBT washed with 30 ml of QC, and eluted with 15 ml of QF (all buffers from QIAGEN Inc., Chatsworth, CA). DNA was precipitated in isopropanol, washed in 70% ethanol, and recovered by centrifugation. The DNA was resuspended in TE buffer.

10

Example 22: Cloning of the Family GH3A beta-glucosidase gene and construction of an *Aspergillus oryzae* expression vector

Two synthetic oligonucleotide primers shown below were designed to PCR amplify a *Aspergillus fumigatus* gene encoding a putative Family GH3A beta-glucosidase from the
15 genomic DNA prepared in Example 21. An InFusion Cloning Kit (BD Biosciences, Palo Alto, CA) was used to clone the fragment directly into the expression vector, pAILo2, without the need for restriction digests and ligation.

Forward primer: 5'-ACTGGATTTACCATGAGATTCGGTTGGCTCG-3' (SEQ ID NO: 67)

Reverse primer: 5'-AGTCACCTCTAGTTACTAGTAGACACGGGGC-3' (SEQ ID NO: 68)

20 Bold letters represent coding sequence. The remaining sequence is homologous to the insertion sites of pAILo2.

Fifty picomoles of each of the primers above were used in a PCR reaction containing 100 ng of *Aspergillus fumigatus* genomic DNA, 1X Pfx Amplification Buffer, 1.5 µl of 10 mM blend of dATP, dTTP, dGTP, and dCTP, 2.5 units of Platinum Pfx DNA Polymerase, 1 µl of 50
25 mM MgSO₄ and 2.5 µl of 10X pCRx Enhancer solution (Invitrogen, Carlsbad, CA) in a final volume of 50 µl. The amplification conditions were one cycle at 94°C for 2 minutes; and 30 cycles each at 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 3 minutes. The heat block then went to a 4°C soak cycle.

The reaction products were isolated on a 1.0% agarose gel using TAE buffer where a
30 3 kb product band was excised from the gel and purified using a QIAquick Gel Extraction Kit according to the manufacturer's instructions.

The fragment was then cloned into the pAILo2 expression vector using an Infusion Cloning Kit. The vector was digested with *Nco* I and *Pac* I. The fragment was purified by gel electrophoresis and Qiaquick gel purification. The gene fragment and the digested
35 vector were ligated together in a reaction resulting in the expression plasmid pEJG97 (Figure

20) in which transcription of the Family GH3A beta-glucosidase gene was under the control of the NA2-tpi promoter. The ligation reaction (50 μ l) was composed of 1X InFusion Buffer (BD Biosciences, Palo Alto, CA), 1X BSA (BD Biosciences, Palo Alto, CA), 1 μ l of Infusion enzyme (diluted 1:10) (BD Biosciences, Palo Alto, CA), 150 ng of pAllo2 digested with *Nco*I and *Pac*I, and 50 ng of the *Aspergillus fumigatus* beta-glucosidase purified PCR product. The reaction was incubated at room temperature for 30 minutes. One μ l of the reaction was used to transform *E. coli* XL10 Solopac Gold cells (Stratagene, La Jolla, CA). An *E. coli* transformant containing the pEJG97 plasmid was detected by restriction digestion of the plasmid DNA.

Example 23: Characterization of the *Aspergillus fumigatus* genomic sequence encoding a Family GH3A beta-glucosidase

DNA sequencing of the *Aspergillus fumigatus* beta-glucosidase gene from pEJG97 was performed as described previously using a primer walking strategy. A gene model for the *Aspergillus fumigatus* sequence was constructed based on similarity to homologous genes from *Aspergillus aculeatus*, *Aspergillus niger*, and *Aspergillus kawachii*. The nucleotide sequence (SEQ ID NO: 69) and deduced amino acid sequence (SEQ ID NO: 70) of the *Aspergillus fumigatus* beta-glucosidase gene are shown in Figure 21. The genomic fragment encoded a polypeptide of 863 amino acids, interrupted by 8 introns of 62, 55, 58, 63, 58, 58, 63 and 51 bp. The %G+C content of the gene is 54.3%. Using the SignalP software program (Nielsen *et al.*, 1997, *Protein Engineering* 10: 1-6), a signal peptide of 19 residues was predicted. The predicted mature protein contains 844 amino acids with a molecular mass of 91.7 kDa.

A comparative alignment of beta-glucosidase sequences was determined using the Clustal W method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5. The alignment showed that the deduced amino acid sequence of the *Aspergillus fumigatus* beta-glucosidase gene shared 78%, 76%, and 76% identity to the deduced amino acid sequences of the *Aspergillus aculeatus* (accession number P48825), *Aspergillus niger* (accession number O00089), and *Aspergillus kawachii* (accession number P87076) beta-glucosidases.

Example 24: Expression of the *Aspergillus fumigatus* Family GH3A beta-

glucosidase gene in *Aspergillus oryzae* JAL250

Aspergillus oryzae JAL250 protoplasts were prepared according to the method of Christensen *et al.*, 1988, *Bio/Technology* 6: 1419-1422. Five µg of pEJG97 (as well as pALLo2 as a vector control) was used to transform *Aspergillus oryzae* JAL250.

5 The transformation of *Aspergillus oryzae* JAL250 with pEJG97 yielded about 100 transformants. Ten transformants were isolated to individual PDA plates.

 Confluent PDA plates of five of the ten transformants were washed with 5 ml of 0.01% Tween 20 and inoculated separately into 25 ml of MDU2BP medium in 125 ml glass shake flasks and incubated at 34°C, 250 rpm. Five days after incubation, 0.5 µl of
10 supernatant from each culture was analyzed using 8-16% Tris-Glycine SDS-PAGE gels (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. SDS-PAGE profiles of the cultures showed that one of the transformants (designated transformant 1) had a major band of approximately 130 kDa.

15 **Example 25: Extraction of total RNA from *Aspergillus oryzae***

 The *Aspergillus oryzae* transformant described in Example 22 was frozen with liquid nitrogen and stored at -80°C. Subsequently, the frozen tissue was ground in an electric coffee grinder with a few chips of dry ice added to keep the powdered mycelia frozen. Then, the ground material was transferred with a spatula to a 50 ml sterile conical tube
20 which had been previously filled with 20 ml of Fenzol (Active Motif, Inc., Carlsbad, CA). This mixture was mixed rapidly to dissolve the frozen material to a thick solution, and placed in a 50°C water bath for 15 minutes. Five ml of RNase free chloroform was added to the mixture and vortexed vigorously. Then, the mixture was allowed to stand at room temperature for 10 minutes. Next the mixture was centrifuged at 2700 rpm in a Sorvall RT7
25 centrifuge (Sorvall, Inc, Newtown, CT) at room temperature for 20 minutes. The top phase was transferred to a new conical tube and an equal volume of phenol-chloroform-isoamylalcohol (25:24:1) was added. The mixture was vortexed and centrifuged for 10 minutes. This procedure was repeated twice so that three phenol-chloroform isoamylalcohol extractions were done. Then, the top phase was transferred to a new tube and an equal
30 volume of chloroform:isoamylalcohol (24:1), was added. The mixture was vortexed once again and centrifuged for 10 minutes. After centrifugation, the aqueous phase, approximately 5 ml at this point, was transferred to a new Oak Ridge tube and 0.5 ml of 3 M sodium acetate pH 5.2 and 6.25 ml of isopropanol were added. The mixture was mixed and incubated at room temperature for 15 minutes. Subsequently, the mixture was centrifuged
35 at 12,000 x g for 30 minutes, at 4°C in a Sorvall RC5B (Sorvall, Inc, Newtown, CT).

Following centrifugation, the supernatant was removed and 18 ml of 70% ethanol was carefully added to the pellet. Another centrifugation step was done for 10 minutes at 4°C at 12,000 x g. The supernatant was carefully removed and the pellet was air dried. The RNA pellet was resuspended in 500 µl diethyl pyrocarbonate (DEPC) treated water. At this point heating at 65°C for 10 minutes aided in resuspension. The total RNA was stored at -80°C. Quantitation and assessing RNA quality was done on an Agilent Bioanalyzer 2100 (Englewood, CO) using RNA chips. All the materials and reagents used in this protocol were RNase free.

10 **Example 26: Cloning of the *Aspergillus fumigatus* beta-glucosidase cDNA sequence**

The total RNA extracted from the *Aspergillus oryzae* transformant containing pEJG97 was used to clone the *Aspergillus fumigatus* beta-glucosidase cDNA sequence (SEQ ID NO: 71 for cDNA sequence and SEQ ID NO: 70 for the deduced amino acid sequence). The mRNA from the total RNA was purified using the Poly(A)Purist Mag kit (Ambion, Inc., Austin, TX) following the manufacturer's instructions. The *Aspergillus fumigatus* beta-glucosidase cDNA sequence, was then amplified in two fragments: a 1,337 bp DNA fragment spanning from the ATG start codon to the 1,332 position (labeled as 5' fragment) and a second 1,300 bp DNA fragment (labeled 3' fragment) spanning from the 1,303 position until the stop codon using the ProStar UltraHF RT-PCR System (Stratagene), following the manufacturer's protocol for a 50 µl reaction using 200 ng of poly-A mRNA, the primers Afuma (sense) and Afumc (antisense) for the 5' fragment, and primers Afumd (sense) and Afumb (antisense) for the 3' fragment as shown below:

Afuma: 5'- GGCTCATGAGATTCGGTTGGCTCGAGGTC -3' (SEQ ID NO: 72)

25 Afumc: 5'- GCCGTTATCACAGCCGCGGTCGGGGCAGCC-3' (SEQ ID NO: 73)

Afumd: 5'- GGCTGCCCCGACCGCGGCTGTGATAACGGC-3' (SEQ ID NO: 74)

Afumb: 5'- GCTTAATTAATCTAGTAGACACGGGGCAGAGGCGC -3' (SEQ ID NO: 75)

Primer Afuma has an upstream *Bsp* HI site and the primer Afumb has a downstream *Pac* I site. Twenty nine nucleotides at the 3'-end of the 1,337 fragment overlapped with the 5'-end of the 1,303 fragment. In the overlap region there was a unique *Sac* II site.

Both fragments were subcloned individually into the pCR4Blunt-TOPO vector (Invitrogen, Carlsbad, CA) using the Zero Blunt TOPO PCR Cloning Kit for sequencing (Invitrogen, Carlsbad, CA), following the manufacturer's protocol, generating plasmids pCR4Blunt-TOPOAfcDNA5' and pCR4Blunt-TOPOAfcDNA3', containing the 5' and 3' fragments respectively (Figures 22 and 23).

The entire coding region of both *Aspergillus fumigatus* beta-glucosidase fragments was confirmed by sequencing using 0.5 µl of each plasmid DNA and 3.2 pmol of the following primers:

- BGLU1.for: 5'-ACACTGGCGGAGAAGG-3' (SEQ ID NO: 76)
 5 BGLU2.for: 5'-GCCCAGGGATATGGTTAC-3' (SEQ ID NO: 77)
 BGLU3.for: 5'-CGACTCTGGAGAGGGTTTC-3' (SEQ ID NO: 78)
 BGLU4.rev: 5'-GGACTGGGTCATCACAAAG -3' (SEQ ID NO: 79)
 BGLU5.rev: 5'-GCGAGAGGTCATCAGCA -3' (SEQ ID NO: 80)
 M13 forward: 5'-GTAAAACGACGGCCAGT-3' (SEQ ID NO: 81)
 10 M13 reverse: 5'-CAGGAAACAGCTATGA-3' (SEQ ID NO: 82)

Sequencing results indicated the presence of several nucleotide changes when comparing the *Aspergillus fumigatus* beta-glucosidase cDNA sequence obtained to the *Aspergillus fumigatus* beta-glucosidase cDNA sequence deduced from genome data of The Institute for Genomic Research (Rockville, MD). At position 500, T was replaced by C, so
 15 that the coding sequence GTT was changed to GCT, so that valine was replaced by alanine. At position 903, T was replaced by C, so that the coding sequence CCC was changed to CCT, however, this change was silent. At position 2,191, G was replaced by C, so that the coding sequence CAG was changed to GAG, so that glutamic acid was replaced by glutamine. Finally, at position 2,368, C was replaced by T, so that the coding sequence CTG
 20 was changed to TTG, however, this change was also silent.

Once the two fragments had been sequenced, both clones containing each fragment were digested with *Sac* II and *Pme* I using approximately 9 µg of each plasmid DNA. Digestion of pCR4Blunt-TOPOAfcDNA5' with the above enzymes generated a fragment of 3,956 bp (containing most of the vector) and a second fragment of 1,339 bp (containing the
 25 *Aspergillus fumigatus* beta-glucosidase cDNA 5' fragment). Digestion of the pCR4Blunt-TOPOAfcDNA3' vector with the same enzymes generated a 5,227 bp fragment (containing most of the pCR4Blunt-TOPO vector and the *Aspergillus fumigatus* beta-glucosidase cDNA 3' fragment) and a second fragment of 31 bp. Digested pCR4Blunt-TOPOAfcDNA3' was treated with shrimp alkaline phosphatase for dephosphorylation of the digested DNA
 30 products by adding 1X SAP buffer and 1 µl of shrimp alkaline phosphatase (Roche Applied Science, Mannheim, Germany) and incubating the reaction for 10 minutes at 37°C followed by incubation at 85°C for 10 minutes for enzyme inactivation. Both digestions were run on 0.7% agarose gel using TAE buffer and purified using a QIAGEN Gel purification kit according to the manufacturer's instructions.

35 The 1,339 bp band generated from the pCR4Blunt-TOPOAfcDNA5' digestion and the

5,527 bp fragment generated from the pCR4Blunt-TOPOAfcDNA3' digestion were ligated by using the Rapid DNA Ligation Kit following the manufacturer's instructions. The ligation reaction was transformed into XL1-Blue *E. coli* subcloning-competent cells according to the manufacturer's instructions. Upon transformation, plasmid DNA from an isolated colony was sequenced to confirm that both the 5' and 3' fragments of the *Aspergillus fumigatus* beta-glucosidase cDNA were subcloned in tandem generating a 6,566 bp pCR4Blunt-TOPOAfcDNA vector (Figure 24).

Example 27: Construction of the pALFd6 and pALFd7 *Sacharomyces cerevisiae* expression vectors

The *Aspergillus fumigatus* beta-glucosidase full length cDNA was amplified by PCR using the following primers that have homology to the pCU426 vector and the 5' and 3' sequences of the *Aspergillus fumigatus* beta-glucosidase cDNA as indicated:

AfumigatusBGUpper:
 5'-CTTCTTGTTAGTGCAATATCATATAGAAGTCATCGACTAGTGGATCTACCATGAGATTGGTTGGCTCG-3' (SEQ ID NO: 83)
ATGAGATTGGTTGGCTCG has homology to the 5' end of the *Aspergillus fumigatus* cDNA
 AfumigatusBGLower:
 5'-GCGTGAATGTAAGCGTGACATAACTAATTACATGACTCGAGCTAGTAGACACGGGGCAGAG-3' (SEQ ID NO: 84)
CTAGTAGACACGGGGCAGAG has homology to the 3' end of the *Aspergillus fumigatus* cDNA

The amplification reaction (100 µl) was composed of 0.5 µl of the pCR4Blunt-TOPOAfcDNA plasmid containing the *Aspergillus fumigatus* cDNA sequence, 1X Pfx Amplification Buffer, 50 µM each of dATP, dCTP, dGTP, and dTTP, 50 pmole of each of the above primers, 1.5 mM MgSO₄, and 2.5 units of Platinum Pfx DNA polymerase. The reactions were incubated in an RoboCycler Gradient 40 programmed for 1 cycle at 95°C for 5 minutes; 25 cycles each at 95°C for 1 minute, 50°C for 1 minute; and 72°C for 3 minutes; and a final extension cycle at 72°C for 10 minutes. The PCR reaction was purified using a QIAquick PCR Purification Kit. DNA was eluted into 30 µl of EB buffer. The PCR product had 37 bp of homologous DNA sequence which was mixed with 1 µl of the pCU426 vector gapped with *Spe* I and *Xho* I for cotransformation into *Saccharomyces cerevisiae* YNG318 competent cells as described as in Example 8. These colonies did not turn blue as expected, suggesting some sequencing error in the *Aspergillus fumigatus* beta-glucosidase cDNA sequence. Further sequencing of the *Aspergillus fumigatus* cDNA sequence indicated an

insertion of an extra nucleotide in the cDNA sequence, which disrupted the open-reading frame of the enzyme.

Simultaneously to expressing the *Aspergillus fumigatus* beta-glucosidase cDNA in *Saccharomyces cerevisiae*, the *Humicola insolens* endoglucanase V signal sequence was swapped with the native signal sequence of the *Aspergillus fumigatus* cDNA sequence also for expression in *Saccharomyces cerevisiae* to compare the expression of the *Aspergillus fumigatus* beta-glucosidase with each signal sequence. The *Aspergillus fumigatus* cDNA sequence was amplified by PCR with a primer that has homology to the *Humicola insolens* endoglucanase V signal sequence in the vector pALFd1 and homology to the 5' end of the mature *Aspergillus fumigatus* beta-glucosidase cDNA sequence. The primers used for amplification of the *Aspergillus fumigatus* beta-glucosidase cDNA sequence are the AfumigatusBGLower primer described before and the HiEGVafumigatus primer described below:

HiEGVafumigatus:

5'-CCGCTCCGCCGTTGTGGCCGCCCTGCCGGTGTGGCCCTTGCC**GAATTGGCTTTCTCTCC**-3'
(SEQ ID NO: 85)

GAATTGGCTTTCTCTCC has homology to the 5' end of the *Aspergillus fumigatus* mature sequence.

The amplification reaction (100 µl) was composed of 0.5 µl of pCR4Blunt-TOPOAfcDNA, 1 X *Pfx* Amplification Buffer, 50 µM each of dATP, dCTP, dGTP, and dTTP, 50 pmole of each above primer, 1.5 mM MgSO₄, and 2.5 unit of Platinum *Pfx* DNA polymerase.

The reactions were incubated in an RoboCycler Gradient 40 programmed for 1 cycle at 95°C for 5 minutes; 25 cycles each at 95°C for 1 minute, 50°C for 1 minute; and 72°C for 3 minutes; and a final extension cycle at 72°C for 10 minutes. The PCR reaction was purified using a QIAquick PCR Purification Kit. DNA was eluted into 10 µl of EB buffer. Three µl of the purified PCR product was mixed with 1.8 µl of the gapped pALFd1 vector with *Eco* RI and *Xho* I for cotransformation into *Saccharomyces cerevisiae* YNG318 competent cells as described as in Example 8. These colonies turned light blue. However, one colony stood out as very blue. DNA rescue from this colony was done as described in Example 10 and the plasmid was transformed into *E. coli*/SURE electroporation-competent cells (Stratagene, La Jolla, CA) for sequencing. Full-length sequencing indicated the *Aspergillus fumigatus* beta-glucosidase cDNA sequence was correct. This plasmid was designated pALFd7 (Figure 25), which contained the *Aspergillus fumigatus* beta-glucosidase cDNA sequence with the *Humicola insolens* endoglucanase V signal sequence for yeast expression.

To produce a yeast expression vector containing the correct *Aspergillus fumigatus*

cDNA sequence with its native signal sequence, the region containing the correct nucleotide sequence from the yeast expression vector containing the *Aspergillus fumigatus* cDNA sequence with the *Humicola insolens* endoglucanase V signal sequence (pALFd7) was amplified by PCR using the above BGLU.5rev primer and the following primer:

5 BGL.7for:

5'-CTGGCGTTGGCGCTGTC-3' (SEQ ID NO: 86)

The amplification reaction (100 µl) was composed of 0.5 µl of pALFd7, 1X *Pfx* Amplification Buffer, 50 µM each of dATP, dCTP, dGTP, and dTTP, 50 pmole of each above primer, 1.5 mM MgSO₄, and 2.5 units of Platinum *Pfx* DNA polymerase. The reactions were incubated in an RoboCycler Gradient 40 programmed for 1 cycle at 95°C for 5 minutes; 25 cycles each at 95°C for 1 minute, 50°C for 1 minute; and 72°C for 1 minutes; and a final extension cycle at 72°C for 10 minutes.

The 701 bp PCR fragment was purified using a QIAquick PCR Purification Kit. DNA was eluted into 10 µl of EB buffer. Three µl of the purified PCR product was mixed with 3 µl of the yeast expression vector containing the *Aspergillus fumigatus* cDNA sequence with the native signal sequence and the extra nucleotide gapped with the *Sac* II and *Xma* I vector for cotransformation into *Saccharomyces cerevisiae* YNG318 competent cells as described as in Example 8. These colonies turned blue. Plasmid DNA was rescued from one randomly picked blue colony as described in Example 10, and transformed into *E. coli* SURE electroporation-competent cells (Stratagene, La Jolla, CA) for sequencing. Full-length sequencing indicated the *Aspergillus fumigatus* beta-glucosidase cDNA sequence was correct. This yeast expression vector was designated pALFd6 (Figure 26), which contained the *Aspergillus fumigatus* cDNA sequence with its native signal sequence.

25 **Example 28: Construction of an *Aspergillus fumigatus* beta-glucosidase variant with G142S substitution**

The nucleotide region that encoded the G142 amino acid in the *Aspergillus fumigatus* coding sequence of pEJG97AfumFAM3A was mutagenized to produce a G to A mutation that encoded a G142S substitution present in the *Aspergillus oryzae* beta-glucosidase sequence variant BG53. The mutagenesis was performed using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and the following primers (underlined nucleotides represents the codon with the changed base that encoded the new amino acid substitution):

SDMG142SUpper:

5'-GCGGCAGAATCTGGGAAAGCTTCTCTCCTG-3' (SEQ ID NO: 87)

35 SDMG142SLower:

5'-CAGGAGAGAAGCTTTCCCAGATTCTGCCGC-3' (SEQ ID NO: 88)

The presence of the G to A mutation was confirmed by sequencing. The new vector was designated pEJG97AfumFAM3AG142S (Figure 27). The G to A mutation was located between the 231 bp fragment obtained by digestion of the pEJG97AfumFAM3AG142S vector with *Eco* RI and *Bst* XI. These sites were unique in the pALFd7 vector.

Both pEJG97AfumFAM3AG142S and pALFd7 (approximately 6 µg each) were digested with *Eco* RI and *Bst* XI. The reaction with pALFd7 yielded two fragments, one containing most of vector (8504 bp) and a smaller fragment of 231 bp from the beta-glucosidase coding sequence containing the wild-type location where the G to A mutation was created in the pEJG97AfumFAM3AG142S vector. The reaction with pEJG97AfumFAM3AG142S yielded three fragments, one containing most of vector (7351 bp), a second smaller fragment of 1254 bp, and a smaller fragment of 231 bp from the beta-glucosidase coding sequence containing the G to A mutation. Digested pALFd7 was treated with shrimp alkaline phosphatase for dephosphorylation of the digested DNA products by adding 1X SAP buffer and 1 µl of SAP from Roche (Roche Applied Science, Mannheim, Germany) and incubating the reaction for 10 minutes at 37°C followed by incubation at 85°C for 10 minutes for enzyme inactivation. Both digestions were run on 0.7% agarose gel and purified using a QIAGEN Gel purification kit according to the manufacturer's instructions.

Digested pALFd7 was ligated to the 231 bp fragment from the pEJG97AfumFAM3AG142S digestion containing the position that encoded amino acid 142 with the nucleotide mutation that led to the G142S amino acid substitution. Ligation was accomplished by using the Rapid DNA Ligation Kit following the manufacturer's instructions.

The ligation reaction was transformed into XL1-Blue *E. coli* subcloning-competent cells according to the manufacturer's instructions. Upon transformation, plasmid DNA from an isolated colony was sequenced as described in Example 10 and the presence of the unique G to A mutation in the entire coding region of the gene was confirmed. Subsequently, the plasmid DNA was transformed into yeast competent cells as described in Example 8, which resulted in isolation of an *Aspergillus fumigatus* beta-glucosidase variant containing the G142S substitution. The yeast expression vector containing the *Aspergillus fumigatus* beta-glucosidase variant with the G142S substitution was designated pALFd7G142S (Figure 28).

Example 29: Construction of an *Aspergillus fumigatus* beta-glucosidase variant with H266Q substitution

The nucleotide region that encoded the H266 amino acid in the *Aspergillus fumigatus* coding sequence of the pEJG97AfumFAM3A vector was mutagenized to produce a C to A mutation that encoded a H266Q substitution present in the *Aspergillus oryzae* beta-glucosidase variant BG53. The mutagenesis was performed using the QuickChange Site-Directed Mutagenesis Kit with the following primers (underlined nucleotides represents the codon with the changed base that encoded the new amino acid substitution):

SDMH266QUpper:

5'-TGA CTGGAGCGCT CAACACAGCGGTGTCG-3' (SEQ ID NO: 89)

SDMH266QLower:

10 5'-CGACACCGCTGTG TTGAGCGCTCCAGTCA -3' (SEQ ID NO: 90)

The presence of the C to A mutation was confirmed by sequencing. The new vector was designated pEJG97AfumFAM3AH266Q (Figure 29). The C to A mutation was located between the 270 bp fragment obtained by digestion of pEJG97AfumFAM3AH266Q with *B/p* I, an isoschizomer of *Bpu* 1102 I, and *Xma* I. These sites were unique in the pALFd7 vector. Both pEJG97AfumFAM3AH266Q and pALFd7 (approximately 6 µg each) were digested with *B/p* I and *Xma* I. The reaction with pALFd7 yielded two fragments, one containing most of vector (8465 bp) and a smaller fragment of 270 bp from the beta-glucosidase coding sequence containing the wild-type location where the C to A mutation was created in the pEJG97AfumFAM3AH266Q vector. The reaction with pEJG97AfumFAM3AH266Q yielded three fragments, one containing most of vector (6,331 bp), a second smaller fragment of 2,235 bp, and a smaller fragment of 270 bp from the beta-glucosidase coding sequence containing the C to A mutation. Digested pALFd7 was treated with shrimp alkaline phosphatase for dephosphorylation of the digested DNA products by adding 1X SAP buffer and 2 ul of SAP from Roche (Roche Applied Science, Mannheim, Germany) and incubating the reaction for 10 minutes at 37°C followed by incubation at 85°C for 10 minutes for enzyme inactivation. Both digestions were run on 0.7% agarose gel and purified using a QIAGEN Gel purification kit according to the manufacturer's instructions.

Digested pALFd7 was ligated to the 270 bp fragment from the pEJG97AfumFAM3AH266Q digestion containing the position that encoded amino acid 142 with the nucleotide mutation that led to the H266Q amino acid substitution. Ligation was accomplished by using the Rapid DNA Ligation Kit following the manufacturer's instructions.

The ligation reaction was transformed into XL1-Blue *E. coli* subcloning-competent cells according to the manufacturer's instructions. Upon transformation, plasmid DNA from an isolated colony was sequenced as described in Example 10 and the presence of the unique C to A mutation in the entire coding region of the gene was confirmed.

Subsequently, the plasmid DNA was transformed into yeast competent cells as described in Example 8, which resulted in isolation of an *Aspergillus fumigatus* beta-glucosidase variant containing the H266Q substitution. The yeast expression vector containing the *Aspergillus fumigatus* beta-glucosidase variant with the G142S substitution was designated pALFd7H266Q.

Example 30: Construction of an *Aspergillus fumigatus* beta-glucosidase variant with G142S and H266Q substitutions

Plasmid pEJG97AfumFAM3AH266Q contained the C to A mutation located in the 270 bp fragment obtained by digestion of pEJG97AfumFAM3AH266Q with *Blp*I and *Xma*I. The pALFd7G142S vector contained the G to A mutation that produced the G142S substitution in the *Aspergillus fumigatus* beta-glucosidase sequence. Both pEJG97AfumFAM3AH266Q and pALFd7G142S (approximately 6 µg each) were digested with *Blp*I and *Xma*I. The reaction with pALFd7 yielded two fragments, one containing most of vector (8,465 bp) and a smaller fragment of 270 bp from the beta-glucosidase coding sequence containing the wild-type location where the C to A mutation was created in the pEJG97AfumFAM3AH266Q vector. The reaction with pEJG97AfumFAM3AH266Q yielded three fragments, one containing most of vector (6,331 bp), a second smaller fragment of 2,235 bp, and a smaller fragment of 270 bp from the beta-glucosidase coding sequence containing the C to A mutation. Digested pALFd7G142S was treated with shrimp alkaline phosphatase for dephosphorylation of the digested DNA products by adding 1X SAP buffer and 2 ul of SAP from Roche (Roche Applied Science, Mannheim, Germany) and incubating the reaction for 10 minutes at 37°C followed by incubation at 85°C for 10 minutes for enzyme inactivation. Both digestions were run on 0.7% agarose gel using TAE buffer and purified using a QIAGEN Gel purification kit according to the manufacturer's instructions.

Digested pALFd7G142S was ligated to the 270 bp fragment from the pEJG97AfumFAM3AH266Q digestion containing the nucleotide mutation that led to the H266Q amino acid substitution. Ligation was accomplished by using the Rapid DNA Ligation Kit following the manufacturer's instructions.

The ligation reaction was transformed into XL1-Blue *E. coli* subcloning-competent cells according to the manufacturer's instructions. Upon transformation, plasmid DNA from an isolated colony was sequenced as described in Example 10 and the presence of the G to A mutation that encoded the G142S substitution and the C to A mutation which encoded the H266Q substitution in the entire coding region of the gene was confirmed. Subsequently, the plasmid DNA was transformed into yeast competent cells as described in Example 8,

which resulted in isolation of an *Aspergillus fumigatus* beta-glucosidase variant containing the G142S and H266Q substitutions. The yeast expression vector containing the *Aspergillus fumigatus* beta-glucosidase variant with both the G142S and H266Q substitutions was designated pALFd7G142SH266Q.

5

Example 31: Construction of an *Aspergillus fumigatus* beta-glucosidase variant with H266Q and D705G substitutions

The nucleotide region that encoded the D705 amino acid in the *Aspergillus fumigatus* coding sequence of pEJG97AfumFAM3A was mutagenized to produce a A to G mutation that encoded a homologous D703G substitution present in the *Aspergillus oryzae* beta-glucosidase variant BG53. The mutagenesis was performed using the QuickChange Site-Directed Mutagenesis Kit according to the manufacturer's instructions and the following primers (underlined nucleotides represents the codon with the changed base that encoded the new amino acid substitution):

15 SDMD705GUpper:

5'-GAGGATTCTTCTGGCGACCCGAACCTACGGC-3' (SEQ ID NO: 91)

SDMD705GLower:

5'-GCCGTAGTTCGGGTCGCCAGAAGAATCCTC-3' (SEQ ID NO: 92)

The presence of the A to G mutation was confirmed by sequencing. The new vector was designated pEJG97AfumFAM3AD705G. The A to G mutation was located in the 711 bp fragment obtained by digestion of the pEJG97AfumFAM3AD705G vector with *Bst*EII which has 2 sites in the pEJG97AfumFAM3AD705G. To clone the 711 bp fragment containing the mutation in the pALFd7H266Q vector, both pEJG97AfumFAM3AD705G and pALFd7H266Q vectors (approximately 6 µg each) were digested with *Bst* EII. The digestion with pALFd7H266Q yielded two fragments, one containing most of vector (8,024 bp) and a smaller fragment of 711 bp from the beta-glucosidase coding sequence containing the wild-type location encoding the D705 amino acid. The digestion with pEJG97AfumFAM3AD705G yielded two fragments, one containing most of vector (8,125 bp), and a smaller fragment of 711 bp from the beta-glucosidase coding sequence containing the A to G mutation. Digested pALFd7H266Q was treated with shrimp alkaline phosphatase for dephosphorylation of the digested DNA products by adding 1X SAP buffer and 2 ul of SAP and incubating the reaction for 10 minutes at 37°C followed by incubation at 85°C for 10 minutes for enzyme inactivation. Both digestions were run on 0.7% agarose gel and purified using a QIAGEN Gel purification kit according to the manufacturer's instructions.

35 Digested pALFd7H266Q was ligated to the 711 bp fragment from the

pEJG97AfumFAM3AD705G digestion containing the nucleotide mutation that led to the D705G amino acid substitution. Ligation was accomplished by using the Rapid DNA Ligation Kit following the manufacturer's instructions. The ligation reaction was transformed into XL1-Blue *E. coli* subcloning-competent cells according to the manufacturer's instructions.

5 Upon transformation, plasmid DNA from an isolated colony was sequenced as described in Example 10 and the presence of the unique C to A and A to G mutations that encode the G166S and H266Q amino acid substitutions, respectively, in the entire coding region of the gene was confirmed. Subsequently, the plasmid DNA was transformed into yeast competent cells as described in Example 8, which resulted in isolation of an *Aspergillus fumigatus* beta-glucosidase variant containing the H266Q and D705G substitutions. The yeast expression

10 vector containing the *Aspergillus fumigatus* beta-glucosidase variant with the H266Q and D705G substitutions was designated pALFd7H266QD705G.

Example 32: Assay of the effects of the G142S, H266Q, G142S and H266Q, and H266Q and D705G mutations in *Aspergillus fumigatus* beta-glucosidase

Residual activity measurements of the *Aspergillus fumigatus* beta-glucosidases encoded by the following vectors was carried out as described in Example 9 at 80°C after 10 minutes: pALFd7, which contains the wild-type *Aspergillus fumigatus* beta-glucosidase cDNA core sequence with the *Humicola insolens* endoglucanase V signal sequence, and the same

20 constructs with the following mutations, labeled respectively, pALFd7G142S, with the G142S amino acid substitution; pALFd7H266Q, with the H266Q amino acid substitution; pALFd7G142SH266Q, with the G142S and H266Q amino acid substitutions; and pALFd7H266QD705G, with the H266Q and D705G amino acid substitutions. Table 4 below shows the relative residual activity of the beta-glucosidases at 80°C. The results showed

25 that the amino acid substitutions improved the residual activity of *Aspergillus fumigatus* beta-glucosidase enzyme at 80°C. The G61S and H266Q amino acid substitution combination had the highest impact in improving the thermostability of the *Aspergillus fumigatus* beta-glucosidase enzyme.

30 Table 4. Relative Residual Activity of *Aspergillus fumigatus* Beta-Glucosidase Variants

Amino acid substitutions	Relative residual activity at 80°C
A. fumigatus WT	1.00
A. fumigatus G142S	1.37
A. fumigatus H266Q	1.08

A. fumigatus G142S; H266Q	1.73
A. fumigatus H266Q; D705G	1.57

Deposit of Biological Material

The following biological material has been deposited under the terms of the
 5 Budapest Treaty with the Agricultural Research Service Patent Culture Collection, Northern
 Regional Research Center, 1815 University Street, Peoria, Illinois, 61604, and given the
 following accession numbers:

	Deposit	Accession Number	Date of Deposit
10	<i>E. coli</i> /TOP10 (pEJG113)	NRRL B-30695	October 17, 2003
	<i>E. coli</i> (pSATE111BG53)	NRRL B-30652	May 2, 2003

The strains have been deposited under conditions that assure that access to the
 cultures will be available during the pendency of this patent application to one determined
 15 by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R.
 §1.14 and 35 U.S.C. §122. The deposits represent substantially pure cultures of the
 deposited strains. The deposits are available as required by foreign patent laws in countries
 wherein counterparts of the subject application, or its progeny are filed. However, it should
 be understood that the availability of a deposit does not constitute a license to practice the
 20 subject invention in derogation of patent rights granted by governmental action.

The invention described and claimed herein is not to be limited in scope by the
 specific embodiments herein disclosed, since these embodiments are intended as
 illustrations of several aspects of the invention. Any equivalent embodiments are intended
 25 to be within the scope of this invention. Indeed, various modifications of the invention in
 addition to those shown and described herein will become apparent to those skilled in the
 art from the foregoing description. Such modifications are also intended to fall within the
 scope of the appended claims. In the case of conflict, the present disclosure including
 definitions will control.

30 Various references are cited herein, the disclosures of which are incorporated by
 reference in their entireties.

Applicant's or agent's file
reference number **WO 2004/099228**

International application No.
To be assigned **PCT/US2004/013401**

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 *bis*)

A. The indications made below relate to the microorganism referred to in the description
on page 108, line 10.

B. IDENTIFICATION OF

Further deposits are identified on an additional sheet ☐

Name of depository institution

Agricultural Research Service Patent Culture Collection (NRRL)

Address of depository institution (including postal code and country)

**Northern Regional Research Center
1815 University Street
Peoria, IL 61604, US**

Date of deposit
October 17, 2003

Accession Number
B-30695

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐

In respect of those designations in which a European and/or Australia Patent is sought, during the pendency of the patent application, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (Rule 28(4) EPC/Regulation 3.25 of Australia Statutory Rule 1991 No. 71).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications
e.g. "Accession Number of Deposit")

For receiving Office use only

☒ This sheet was received with the international
application

Authorized officer

Marlene Younger

For International Bureau use only

☐ This sheet was received with the International Bureau
on:

Authorized officer

Claims

What is claimed is:

- 5 1. An isolated variant of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity.
- 10 2. The variant of claim 1, wherein the parent beta-glucosidase is (a) a polypeptide comprising an amino acid sequence which has at least 70% identity to amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70; or (b) a polypeptide encoded by a nucleotide sequence which hybridizes under low stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, or their
15 complementary strands.
3. The variant of claim 2, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 70% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.
- 20 4. The variant of claim 2, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 75% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.
- 25 5. The variant of claim 2, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 80% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.
6. The variant of claim 2, wherein the parent beta-glucosidase comprises an amino acid
30 sequence which has at least 85% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.
7. The variant of claim 2, wherein the parent beta-glucosidase comprises an amino acid
35 amino acids 1 to 844 of SEQ ID NO: 70.

8. The variant of claim 2, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 95% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

5

9. The variant of claim 1, wherein the parent beta-glucosidase comprises the amino acid sequence of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

10. The variant of claim 1, wherein the parent beta-glucosidase consists of the amino acid sequence of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

11. The variant of claim 2, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under low stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71.

12. The variant of claim 2, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under medium stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71.

13. The variant of claim 2, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under medium-high stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71.

25

14. The variant of claim 2, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under high stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71.

15. The variant of any of claims 1-14, wherein the parent beta-glucosidase is a wild-type beta-glucosidase.

16. The variant of any of claims 1-15, wherein the parent beta-glucosidase is an *Acremonium*, *Agaricus*, *Alternaria*, *Aspergillus*, *Botryosphaeria*, *Chaetomidium*, *Claviceps*, *Cochliobolus*, *Coprinopsis*, *Coptotermes*, *Cryphonectria*, *Exidia*, *Fusarium*, *Gibberella*,

35

Holomastigotoides, Humicola, Irpex, Lentinula, Leptosphaeria, Melanocarpus, Neurospora, Penicillium, Phanerochaete, Poitrasia, Pseudotrichonympha, Scytalidium, Talaromyces, Thermoascus, Thielavia, Trichoderma, Trichophaea, Verticillium, Volvariella, or Xylaria beta-glucosidase.

5

17. The variant of claim 16, wherein the *Trichoderma* beta-glucosidase is a *Trichoderma reesei* beta-glucosidase.

18. The variant of claim 1, which comprises a substitution at a position corresponding to position 142 of SEQ ID NO: 2 or SEQ ID NO: 70.

10

19. The variant of claim 18, wherein the substitution is Ser.

20. The variant of claim 1, which comprises a substitution at a position corresponding to position 183 of SEQ ID NO: 2 or SEQ ID NO: 70.

15

21. The variant of claim 20, wherein the substitution is Arg.

22. The variant of claim 1, which comprises a substitution at a position corresponding to position 266 of SEQ ID NO: 2 or SEQ ID NO: 70.

20

23. The variant of claim 22, wherein the substitution is Gln.

24. The variant of claim 1, which comprises a substitution at a position corresponding to position 703 of SEQ ID NO: 2 or position 705 of SEQ ID NO: 70.

25

25. The variant of claim 24, wherein the substitution is Gly.

26. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

30

27. The variant of claim 1, which substitutions at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

35

28. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
- 5 29. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
30. The variant of claim 1, which comprises substitutions at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of
10 SEQ ID NO: 70.
31. The variant of claim 1, which comprises substitutions at positions corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
- 15 32. The variant of claim 1, which comprises substitutions at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
33. The variant of claim 1, which comprises substitutions at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
20
34. The variant of claim 1, which comprises substitutions at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
35. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to
25 844 of SEQ ID NO: 70.
36. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
30
37. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
38. The variant of claim 1, which comprises substitutions at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
35

39. The variant of claim 1, which comprises substitutions at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 5 40. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
41. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 10 42. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
43. The variant of claim 1, which comprises substitutions at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 15 44. The variant of claim 1, which comprises one or more substitutions selected from the group consisting of G142S, Q183R, H266Q, and D703G (or D705G).
- 20 45. The variant of claim 1, which comprises the substitutions G142S + Q183R + H266Q + D703G (or D705G):
46. The variant of claim 1, which comprises the substitutions G142S + Q183R + H266Q.
- 25 47. The variant of claim 1, which comprises the substitutions G142S + H266Q + D703G (or D705G).
48. The variant of claim 1, which comprises the substitutions Q183R + H266Q + D703G (or D705G).
- 30 49. The variant of claim 1, which comprises the substitutions G142S + Q183R + D703G (or D705G).
50. The variant of claim 1, which comprises the substitutions G142S + Q183R.
- 35

51. The variant of claim 1, which comprises the substitutions G142S + H266Q.
52. The variant of claim 1, which comprises the substitutions G142S + D703G (or D705G).
53. The variant of claim 1, which comprises the substitutions Q183R + H266Q.
54. The variant of claim 1, which comprises the substitutions Q183R + D703G (or D705G).
55. The variant of claim 1, which comprises the substitutions H266Q + D703G (or D705G).
56. The variant of any of claims 1-55, wherein the number of substitutions is 4, 3, 2, or 1.
57. The variant of any of claims 1-56, which comprises an amino acid sequence with at least 70% identity to the amino acid sequence of the parent beta-glucosidase.
58. The variant of claim 57, which comprises an amino acid sequence with at least 75% identity to the amino acid sequence of the parent beta-glucosidase.
59. The variant of claim 58, which comprises an amino acid sequence with at least 80% identity to the amino acid sequence of the parent beta-glucosidase.
60. The variant of claim 59, which comprises an amino acid sequence with at least 85% identity to the amino acid sequence of the parent beta-glucosidase.
61. The variant of claim 60, which comprises an amino acid sequence with at least 90% identity to the amino acid sequence of the parent beta-glucosidase.
62. The variant of claim 61, which comprises an amino acid sequence with at least 95% identity to the amino acid sequence of the parent beta-glucosidase.
63. The variant of any of claims 1-62, which has one or more improved properties

compared to the parent beta-glucosidase, wherein the improved properties are selected from the group consisting of thermal activity, thermostability, pH activity, pH stability, substrate specificity, product specificity, and chemical stability.

- 5 64. The variant of claim 63, wherein the thermal activity of the variant beta-glucosidase is at least 1.5-fold, preferably at least 2-fold, more preferably at least 5-fold, most preferably at least 7-fold, and even most preferably at least 20-fold more thermally active than the parent beta-glucosidase of the variant.
- 10 65. The variant of claim 1, wherein the variant consists of 741 to 750, 751 to 760, 761 to 770, 771 to 780, 781 to 790, 791 to 800, 801 to 810, 811 to 820, 821 to 830, 831 to 840, 841 to 850, 851 to 860, 861 to 870, 871 to 880, 881 to 890, 891 to 900, 901 to 910, 911 to 920, 921 to 930, 931 to 940, or 941 to 950 amino acids.
- 15 66. The variant of claim 1, which is encoded by a nucleotide sequence which is contained in *E. coli* NRRL B-30652.
67. An isolated nucleotide sequence encoding the variant of any of claims 1-66.
- 20 68. A nucleic acid construct comprising the nucleotide sequence of claim 67.
69. An expression vector comprising the nucleic acid construct of claim 68.
70. A host cell comprising the nucleic acid construct of claim 68.
- 25 71. The host cell of claim 70, which is a bacterium, fungus, insect, mammalian, or plant cell.
72. The host cell of claim 71, wherein the fungus is a yeast.
- 30 73. The host cell of claim 71, wherein the fungus is a filamentous fungus.
74. A method for producing a variant of a parent beta-glucosidase, comprising:
(a) cultivating the host cell of claim 70 under conditions suitable for the
35 expression of the variant; and

(b) recovering the variant from the cultivation medium.

75. A detergent composition comprising a beta-glucosidase variant of any of claims 1-66 and a surfactant.

5

76. A method for degrading or converting cellulose- and hemicellulose-containing biomass, comprising treating the biomass with an effective amount of a beta-glucosidase variant of any of claims 1-66 and recovering the degraded biomass.

10 77. The method of claim 76, further comprising treating the biomass with an effective amount of endo-1,4-beta-glucanase and exo-1,4-beta-D-glucanase.

78. A method for degrading or converting a cellulose- and hemicellulose-containing biomass, comprising treating the biomass with a host cell of any of claims 70-73 and
15 recovering the degraded biomass.

79. The method of claim 78, further comprising treating the biomass with an effective amount of endo-1,4-beta-glucanase and exo-1,4-beta-D-glucanase.

20 80. A plant comprising the nucleotide sequence of claim 67.

81. A method for obtaining a variant of a parent beta-glucosidase, comprising:

(a) introducing a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to
25 positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity; and

(b) recovering the variant.

82. The method of claim 81, wherein the parent beta-glucosidase is (i) a polypeptide
30 comprising an amino acid sequence which has at least 70% identity to amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70; or (ii) a polypeptide encoded by a nucleotide sequence which hybridizes under low stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or nucleotides 58 to 2589 of SEQ ID NO: 71, or their complementary strands.

35

83. The method of claim 82, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 70% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

5 84. The method of claim 82, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 75% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

10 85. The method of claim 82, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 80% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

15 86. The method of claim 82, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 85% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

20 87. The method of claim 82, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 90% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

88. The method of claim 82, wherein the parent beta-glucosidase comprises an amino acid sequence which has at least 95% identity with amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

25 89. The method of claim 81, wherein the parent beta-glucosidase comprises the amino acid sequence of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

30 90. The method of claim 81, wherein the parent beta-glucosidase consists the amino acid sequence of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

35 91. The method of claim 82, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under low stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or the nucleotide sequence of nucleotides 58 to 2583 of SEQ ID NO:

1.

92. The method of claim 82, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under medium stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or the nucleotide sequence of nucleotides 58 to 2583 of SEQ ID NO: 1.

93. The method of claim 82, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under medium-high stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or the nucleotide sequence of nucleotides 58 to 2583 of SEQ ID NO: 1.

94. The method of claim 82, wherein the parent beta-glucosidase is encoded by a nucleotide sequence which hybridizes under high stringency conditions with nucleotides 58 to 2583 of SEQ ID NO: 1 or the nucleotide sequence of nucleotides 58 to 2583 of SEQ ID NO: 1.

95. The method of any of claims 81-94, wherein the parent beta-glucosidase is a wild-type beta-glucosidase.

96. The method of any of claims 81-95, wherein the parent beta-glucosidase is an *Acremonium*, *Agaricus*, *Alternaria*, *Aspergillus*, *Botryosphaeria*, *Chaetomidium*, *Claviceps*, *Cochliobolus*, *Coprinopsis*, *Coptotermes*, *Cryphonectria*, *Exidia*, *Fusarium*, *Gibberella*, *Holomastigotoides*, *Humicola*, *Irpex*, *Lentinula*, *Leptosphaeria*, *Melanocarpus*, *Neurospora*, *Penicillium*, *Phanerochaete*, *Poitrasia*, *Pseudotriconympha*, *Scytalidium*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Trichoderma*, *Trichophaea*, *Verticillium*, *Volvariella*, or *Xylaria* beta-glucosidase.

97. The method of claim 96, wherein the *Trichoderma* beta-glucosidase is a *Trichoderma reesei* beta-glucosidase.

98. The method of claim 81, wherein the variant comprises a substitution at a position corresponding to position 142 of SEQ ID NO: 2 or SEQ ID NO: 70.

99. The method of claim 98, wherein the substitution is Ser.

100. The method of claim 81, wherein the variant comprises a substitution at a position corresponding to position 183 of SEQ ID NO: 2 or SEQ ID NO: 70.

5 101. The method of claim 100, wherein the substitution is Arg.

102. The method of claim 81, wherein the variant comprises a substitution at a position corresponding to position 266 of SEQ ID NO: 2 or SEQ ID NO: 70.

10 103. The method of claim 102, wherein the substitution is Gln.

104. The method of claim 81, wherein the variant comprises a substitution at a position corresponding to position 703 of SEQ ID NO: 2 or position 705 of SEQ ID NO: 70.

15 105. The method of claim 104, wherein the substitution is Gly.

106. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142 and 183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

20

107. The method of claim 81, wherein the variant substitutions at positions corresponding to positions 142 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

25 108. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142 and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

109. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

30

110. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 183 and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

35 111. The method of claim 81, wherein the variant comprises substitutions at positions

corresponding to positions 183 and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

112. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 183 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

5

113. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 266 and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

114. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

10

115. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

15

116. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

117. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

20

118. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

119. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

25

120. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

30

121. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

122. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.

35

123. The method of claim 81, wherein the variant comprises substitutions at positions corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.

5

124. The method of claim 81, wherein the variant comprises one or more substitutions selected from the group consisting of G142S, Q183R, H266Q, and D703G (or D705G).

125. The method of claim 81, wherein the variant comprises the substitutions G142S +
10 Q183R + H266Q + D703G (or D705G).

126. The method of claim 81, wherein the variant comprises the substitutions G142S + Q183R + H266Q.

127. The method of claim 81, wherein the variant comprises the substitutions G142S +
15 H266Q + D703G (or D705G).

128. The method of claim 81, wherein the variant comprises the substitutions Q183R + H266Q + D703G (or D705G).

20

129. The method of claim 81, wherein the variant comprises the substitutions G142S + Q183R + D703G (or D705G).

130. The method of claim 81, wherein the variant comprises the substitutions G142S +
25 Q183R.

131. The method of claim 81, wherein the variant comprises the substitutions G142S + H266Q.

132. The method of claim 81, wherein the variant comprises the substitutions G142S +
30 D703G (or D705G).

133. The method of claim 81, wherein the variant comprises the substitutions Q183R + H266Q.

35

134. The method of claim 81, wherein the variant comprises the substitutions Q183R + D703G (or D705G).

135. The method of claim 81, wherein the variant comprises the substitutions H266Q +
5 D703G (or D705G).

136. The method of any of claims 81-135, wherein the number of substitutions is 4, 3, 2, or 1.

10 137. The method of any of claims 81-136, wherein the variant comprises an amino acid sequence with at least 70% identity to the amino acid sequence of the parent beta-glucosidase.

138. The method of claim 137, wherein the variant comprises an amino acid sequence
15 with at least 75% identity to the amino acid sequence of the parent beta-glucosidase.

139. The method of claim 138, wherein the variant comprises an amino acid sequence with at least 80% identity to the amino acid sequence of the parent beta-glucosidase.

20 140. The method of claim 139, wherein the variant comprises an amino acid sequence with at least 85% identity to the amino acid sequence of the parent beta-glucosidase.

141. The method of claims 140, wherein the variant comprises an amino acid sequence with at least 90% identity to the amino acid sequence of the parent beta-glucosidase.
25

142. The method of claim 141, wherein the variant comprises an amino acid sequence with at least 95% identity to the amino acid sequence of the parent beta-glucosidase.

143. The method of any of claims 81-142, wherein the variant has one or more improved
30 properties compared to the parent beta-glucosidase, wherein the improved properties are selected from the group consisting of thermal activity, thermostability, pH activity, pH stability, substrate specificity, product specificity, and chemical stability.

144. The method of claim 143, wherein the thermal activity of the variant is at least 1.5-
35 fold, preferably at least 2-fold, more preferably at least 5-fold, most preferably at least 7-

fold, and even most preferably at least 20-fold more thermally active than the parent beta-glucosidase of the variant.

145. The method of claim 81, wherein the variant consists of 741 to 750, 751 to 760, 761
5 to 770, 771 to 780, 781 to 790, 791 to 800, 801 to 810, 811 to 820, 821 to 830, 831 to 840,
841 to 850, 851 to 860, 861 to 870, 871 to 880, 881 to 890, 891 to 900, 901 to 910, 911 to
920, 921 to 930, 931 to 940, or 941 to 950 amino acids.

146. An isolated polypeptide having beta-glucosidase activity, wherein the amino acid
10 sequence of the polypeptide differs from SEQ ID NO:2 or SEQ ID NO: 70 at one or more
positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ
ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of
SEQ ID NO: 70.

147. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
15 differs from SEQ ID NO:2 or SEQ ID NO: 70 at a position corresponding to position 142 of
SEQ ID NO: 2 or SEQ ID NO: 70.

148. The polypeptide of claim 147, wherein the difference is Ser.
20

149. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 or SEQ ID NO: 70 at a position corresponding to position 183 of
SEQ ID NO: 2 or SEQ ID NO: 70.

150. The polypeptide of claim 149, wherein the difference is Arg.
25

151. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 or SEQ ID NO: 70 at a position corresponding to position 266 of
SEQ ID NO: 2 or SEQ ID NO: 70.
30

152. The polypeptide of claim 151, wherein the difference is Gln.

153. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 or SEQ ID NO: 70 at a position corresponding to position 703 of
35 SEQ ID NO: 2 or position 705 of SEQ ID NO: 70.

154. The polypeptide of claim 153, wherein the difference is Gly.

155. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
5 differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 142 and
183 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

156. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 142 and
10 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

157. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 at positions corresponding to positions 142 and 703 of amino
acids 1 to 842 of SEQ ID NO: 2.

15

158. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 142 and
705 of amino acids 1 to 844 of SEQ ID NO: 70.

20 159. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 183 and
266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.

160. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
25 differs from SEQ ID NO:2 at positions corresponding to positions 183 and 703 of amino
acids 1 to 842 of SEQ ID NO: 2.

161. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO: 70 at positions corresponding to positions 183 and 705 of amino
30 acids 1 to 844 of SEQ ID NO: 70.

162. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide
differs from SEQ ID NO:2 at positions corresponding to positions 266 and 703 of amino
acids 1 to 842 of SEQ ID NO: 2.

35

163. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 266 and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 5 164. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 142, 183, and 266 of amino acids 1 to 842 of SEQ ID NO: 2 or amino acids 1 to 844 of SEQ ID NO: 70.
- 10 165. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 at positions corresponding to positions 142, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
- 15 166. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 20 167. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 at positions corresponding to positions 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
- 25 168. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 30 169. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 at positions corresponding to positions 142, 183, and 703 of amino acids 1 to 842 of SEQ ID NO: 2.
- 30 170. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 or SEQ ID NO: 70 at positions corresponding to positions 142, 183, and 705 of amino acids 1 to 844 of SEQ ID NO: 70.
- 35 171. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO:2 at positions corresponding to positions 142, 183, 266, and 703 of

amino acids 1 to 842 of SEQ ID NO: 2.

172. The polypeptide of claim 146, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO: 70 at positions corresponding to positions 142, 183, 266, and 705
5 of amino acids 1 to 844 of SEQ ID NO: 70.

173. The polypeptide of any of claims 146-154, wherein the amino acid sequence of the polypeptide differs from SEQ ID NO: 2 or SEQ ID NO: 70 by 4, 3, 2, or 1 amino acids.

10 174. The polypeptide of any of claims 110-119, which has one or more improved properties compared to the polypeptide of SEQ ID NO: 2 or SEQ ID NO: 70, wherein the improved properties are selected from the group consisting of thermal activity, thermostability, pH activity, pH stability, substrate specificity, product specificity, and chemical stability.

15 175. The polypeptide of claim 120, wherein the thermal activity of the polypeptide is at least 1.5-fold, preferably at least 2-fold, more preferably at least 5-fold, most preferably at least 7-fold, and even most preferably at least 20-fold more thermally active compared to the polypeptide of SEQ ID NO: 2 or SEQ ID NO: 70.

20 176. The polypeptide of claim 110, wherein the polypeptide consists of 741 to 750, 751 to 760, 761 to 770, 771 to 780, 781 to 790, 791 to 800, 801 to 810, 811 to 820, 821 to 830, 831 to 840, 841 to 850, 851 to 860, 861 to 870, 871 to 880, 881 to 890, 891 to 900, 901 to 910, 911 to 920, 921 to 930, 931 to 940, or 941 to 950 amino acids.

25 177. An isolated nucleotide sequence encoding the polypeptide of any of claims 146-176.

178. A nucleic acid construct comprising the nucleotide sequence of claim 177.

30 179. An expression vector comprising the nucleic acid construct of claim 178.

180. A host cell comprising the nucleic acid construct of claim 178.

35 181. The host cell of claim 180, which is a bacterium, fungus, insect, mammalian, or plant cell.

182. The host cell of claim 181, wherein the fungus is a yeast.
183. The host cell of claim 181, wherein the fungus is a filamentous fungus.
- 5 184. A method for producing a polypeptide having beta-glucosidase activity, comprising:
(a) cultivating the host cell of claim 180 under conditions suitable for the expression of the polypeptide; and
(b) recovering the polypeptide from the cultivation medium.
- 10 185. A detergent composition comprising a polypeptide having beta-glucosidase activity of any of claims 146-176 and a surfactant.
186. A method for degrading or converting cellulose- and hemicellulose-containing
15 biomass, comprising treating the biomass with an effective amount of a polypeptide having beta-glucosidase activity of any of claims 146-176 and recovering the degraded biomass.
187. The method of claim 186, further comprising treating the biomass with an effective amount of endo-1,4-beta-glucanase and exo-1,4-beta-D-glucanase.
- 20 188. A method for degrading or converting a cellulose- and hemicellulose-containing biomass, comprising treating the biomass with a host cell of any of claims 180-183 and recovering the degraded biomass.
- 25 189. The method of claim 188, further comprising treating the biomass with an effective amount of endo-1,4-beta-glucanase and exo-1,4-beta-D-glucanase.
190. A plant comprising the nucleotide sequence of claim 177.

1/38




Fig. 1

2/38




Fig. 2

3/38




Fig. 3

4/38




Fig. 4

5/38




Fig. 5

6/38




Fig. 6

7/38




Fig. 7

8/38




Fig. 8

9/38

```

atg aag ctt ggt tgg atc gag gtg gcc gca ttg gcg gct gcc tca gta      48
Met Lys Leu Gly Trp Ile Glu Val Ala Ala Leu Ala Ala Ser Val
1      5      10      15

gtc agt gcc aag gat gat ctc gcg tac tcc cct cct ttc tac cct tcc      96
Val Ser Ala Lys Asp Asp Leu Ala Tyr Ser Pro Pro Phe Tyr Pro Ser
20      25      30

cca tgg gca gat ggt cag ggt gaa tgg gcg gaa gta tac aaa cgc gct      144
Pro Trp Ala Asp Gly Gln Gly Glu Trp Ala Glu Val Tyr Lys Arg Ala
35      40      45

gta gac ata gtt tcc cag atg acg ttg aca gag aaa gtc aac tta acg      192
Val Asp Ile Val Ser Gln Met Thr Leu Thr Glu Lys Val Asn Leu Thr
50      55      60

act gga aca gga tgg caa cta gag agg tgt gtt gga caa act ggc agt      240
Thr Gly Thr Gly Trp Trp Gln Leu Glu Glu Arg Cys Val Gly Gln Thr Gly Ser
65      70      75      80

gtt ccc aga ctc aac atc ccc agc ttg tgt ttg cag gat agt cct ctt      288
Val Pro Arg Leu Asn Ile Pro Ser Leu Cys Leu Gln Asp Ser Pro Leu
85      90      95

```

Fig. 9A

10/38

```

336      ggt att cgt ttc tcg gac tac aat tca gct ttc cct gcg ggt gtt aat
      Gly ile Arg Phe 100      Tyr Asp Tyr Asn Ser Ala Phe Pro Ala Gly Val Asn
                                     105
384      gtc gct gcc acc tgg gac aag acg ctc gcc tac ctt cgt ggt cag gca
      Val Ala Ala Thr Trp Asp Lys Thr Leu Ala Tyr Leu Arg Gly Gln Ala
      115      120      125
432      atg ggt gag gag ttc agt gat aag ggt att gac gtt cag ctg ggt cct
      Met Gly Glu Glu Phe Ser Asp Lys Gly Ile Asp Val Gln Leu Gly Pro
      130      135      140
480      gct gct ggc cct ctc ggt gct cat ccg gat ggc ggt aga aac tgg gaa
      Ala Ala Gly Pro Leu Gly Ala His Pro Asp Gly Gly Arg Asn Trp Glu
      145      150      155      160
528      ggt ttc tca cca gat cca gcc ctc acc ggt gta ctt ttt gcg gag acg
      Gly Phe Ser Pro Asp Pro Ala Leu Thr Gly Val Leu Phe Ala Glu Thr
      165      170      175
576      att aag ggt att caa gat gct ggt gtc att gcg aca gct aag cat tat
      Ile Lys Gly ile Gln Asp Ala Gly Val ile Ala Thr Ala Lys His Tyr
      180      185      190

```

Fig. 9B

11/38

atc atg aac gaa caa gag cat ttc cgc caa caa ccc gag gct gcg ggt Ile Met Asn Glu Gln Glu His Phe Arg Gln Pro Glu Ala Ala Gly	195 200 205	624
tac gga ttc aac gta agc gac agt ttg agt tcc aac gtt gat gac aag Tyr Gly Phe Asn Val Ser Asp Ser Leu Ser Ser Asn Val Asp Asp Lys	210 215	672
act atg cat gaa ttg tac ctg tgg ccc ttc gcg gat gca gta cgc gct Thr Met His Glu Leu Tyr Leu Trp Pro Phe Ala Asp Ala Val Arg Ala	225 230 235	720
gga gtc ggt gct gtc atg tgc tct tac aac caa atc aac aac agc tac Gly Val Gly Ala Val Met Cys Ser Tyr Asn Gln Ile Asn Asn Ser Tyr	245 250	768
ggt tgc gag aat agc gaa act ctg aac aag aag ctt ttg aag gcg gag ctt Gly Cys Glu Asn Ser Glu Thr Leu Asn Lys Leu Lys Ala Glu Leu	260 265 270	816
ggt ttc caa ggc ttc gtc atg agt gat tgg acc gct cat cac agc ggc Gly Phe Gln Gly Phe Val Met Ser Asp Trp Thr Ala His His Ser Gly	275 280 285	864

Fig. 9C

12/38

gta ggc gct gct tta gca ggt ctg gat atg tcg atg ccc ggt gat gtt Val Gly Ala Ala Leu Ala Gly Leu Asp Met Ser Met Pro Gly Asp Val	290 295 300 310 315 320	912
acc ttc gat agt ggt acg tct ttc tgg ggt gca aac ttg acg gtc ggt Thr Phe Asp Ser Gly Thr Ser Phe Trp Gly Ala Asn Leu Thr Val Gly	305 310 315 320	960
gtc ctt aac ggt aca atc ccc caa tgg cgt gtt gat gac atg gct gtc Val Leu Asn Gly Thr Ile Pro Gln Trp Arg Val Asp Met Ala Val	325 330 335	1008
cgt atc atg ggc gct tat tac aag gtt ggc cgc gac acc aaa tac acc Arg Ile Met Ala Ala Tyr Tyr Lys Val Gly Arg Asp Thr Lys Tyr Thr	340 345	1056
cct ccc aac ttc agc tcg tgg acc agg gac gaa tat ggt ttc gcg cat Pro Pro Asn Phe Ser Ser Trp Thr Arg Asp Glu Tyr Gly Phe Ala His	355 360 365	1104
aac cat gtt tcg gaa ggt gct tac gag agg gtc aac gaa ttc gtg gac Asn His Val Ser Glu Gly Ala Tyr Glu Arg Val Asn Glu Phe Val Asp	370 375 380	1152

Fig. 9D

13/38

gtg	caa	cgc	gat	cat	gcc	gac	cta	atc	cgt	cgc	atc	ggc	gcg	cag	agc	1200
Val	Gln	Arg	Asp	His	Ala	Asp	Leu	Ile	Arg	Arg	Ile	Gly	Ala	Gln	Ser	
385					390					395					400	
act	gtt	ctg	ctg	aag	aac	aag	ggt	gcc	ttg	ccc	ttg	agc	cgc	aag	gaa	1248
Thr	Val	Leu	Leu	Lys	Asn	Lys	Gly	Ala	Leu	Pro	Leu	Ser	Arg	Lys	Glu	
					405				410					415		
aag	ctg	gtc	gcc	ctt	ctg	gga	gag	gat	gcg	ggt	tcc	aac	tcc	tgg	ggc	1296
Lys	Leu	Val	Ala	Leu	Leu	Gly	Glu	Asp	Ala	Gly	Ser	Asn	Ser	Trp	Gly	
					420				425				430			
gct	aac	ggc	tgt	gat	gac	cgt	ggt	tgc	gat	aac	ggt	acc	ctt	gcc	atg	1344
Ala	Asn	Gly	Cys	Asp	Asp	Arg	Arg	Gly	Cys	Asp	Asn	Gly	Thr	Leu	Met	
					435				440			445				
gcc	tgg	ggt	agc	ggt	act	gcg	aat	ttc	cca	tac	ctc	gtg	aca	cca	gag	1392
Ala	Trp	Gly	Ser	Gly	Thr	Ala	Asn	Phe	Pro	Tyr	Leu	Val	Thr	Pro	Glu	
					450				455			460				
cag	gcg	att	cag	aac	gaa	gtt	ctt	cag	ggc	cgt	ggt	aat	gtc	ttc	gcc	1440
Gln	Ala	Ile	Gln	Asn	Glu	Val	Leu	Gln	Gly	Arg	Gly	Asn	Val	Phe	Ala	
465					470					475					480	

Fig. 9E

14/38

gtg acc gac agt tgg gcg ctc gac aag atc gct gcg gct gcc cgc cag	1488
Val Thr Asp Ser Trp Ala Leu Asp Lys Ile Ala Ala Ala Arg Gln	485 490 495
gcc agc gta tct ctc gtc ttc gtc aac tcc gac tca gga gaa ggc tat	1536
Ala Ser Val Ser Leu Val Phe Val Asn Ser Asp Ser Gly Glu Gly Tyr	500 505 510
ctt agt gtg gat gga aat gag ggc gat cgt aac aac atc act ctg tgg	1584
Leu Ser Val Asp Gly Asn Glu Gly Asp Arg Asn Asn Ile Thr Leu Trp	515 520 525
aag aac ggc gac aat gtg gtc aag acc gca gcg aat aac tgt aac aac	1632
Lys Asn Gly Asp Asn Val Val Lys Thr Ala Ala Asn Asn Cys Asn Asn	530 535 540
acc gtt gtc atc atc cac gtc tcc gtc gga cca gtt ttg atc gat gaa tgg	1680
Thr Val Val Ile Ile His Ser Val Gly Pro Val Leu Ile Asp Glu Trp	545 550 555 560
tat gac cac ccc aat gtc act ggt att ctc tgg gct ggt ctg cca ggc	1728
Tyr Asp His Pro Asn Val Thr Gly Ile Leu Trp Ala Gly Leu Pro Gly	565 570 575

Fig. 9F

15/38

cag gag tct ggt aac tcc att gcc gat gtg ctg tac ggt cgt gtc aac Gln Glu Ser Gly Asn Ser Ile Ala Asp Val Leu Tyr Gly Arg Val Asn 580 585 590	1776
cct ggc gcc aag tct cct ttc act tgg ggc aag acc cgg gag tcg tat Pro Gly Ala Lys Ser Pro Phe Thr Trp Gly Lys Thr Arg Glu Ser Tyr 595 600 605	1824
ggt tct ccc ttg gtc aag gat gcc aac aat ggc aac gga gcg ccc cag Gly Ser Pro Leu Val Lys Asp Ala Asn Asn Gly Ala Pro Gln 610 615 620	1872
tct gat ttc acc cag ggt gtt ttc atc gat tac cgc cat ttc gat aag Ser Asp Phe Thr Gln Gly Val Phe Ile Asp Tyr Arg His Phe Asp Lys 625 630 635 640	1920
ttc aat gag acc cct atc tac gag ttt ggc tac ggc ttg agc tac acc Phe Asn Glu Thr Pro Ile Tyr Glu Phe Gly Tyr Gly Leu Ser Tyr Thr 645 650 655	1968
acc ttc gag ctc tcc gac ctc cat gtt cag ccc ctg aac gcg tcc cga Thr Phe Glu Leu Ser Asp Leu His Val Gln Pro Leu Asn Ala Ser Arg 660 665 670	2016

Fig. 9G

16/38

tac act ccc acc agt ggc atg act gaa gct gca aag aac ttt ggt gaa	2064
Tyr Thr Pro Thr Ser Gly Met Thr Glu Ala Ala Lys Asn Phe Gly Glu	675 680 685
att ggc gat gcg tcg gag tac gtg tat ccg gag ggg ctg gaa agg atc	2112
Ile Gly Asp Ala Ser Glu Tyr Val Tyr Pro Glu Gly Leu Glu Arg Ile	690 695 700
cat gag ttt atc tat ccc tgg atc aac tct acc gac ctg aag gca tcg	2160
His Glu Phe Ile Tyr Pro Trp Ile Asn Ser Thr Asp Leu Lys Ala Ser	705 710 715 720
tct gac gat tct aac tac ggc tgg gaa gac tcc aag tat att ccc gaa	2208
Ser Asp Asp Ser Asn Tyr Gly Trp Glu Asp Ser Lys Tyr Ile Pro Glu	725 730 735
ggc gcc acg gat ggc tct gcc cag ccc cgt ttg ccc gct agt ggt ggt	2256
Gly Ala Thr Asp Gly Ser Ala Gln Pro Arg Leu Pro Ala Ser Gly Gly	740 745 750
ggc gga gga aac ccc ggt ctg tac gag gat ctt ttc cgc gtc tct gtg	2304
Ala Gly Gly Asn Pro Gly Leu Tyr Glu Asp Leu Phe Arg Val Ser Val	755 760 765

Fig. 9H

17/38

aag gtc aag aac acg ggc aat gtc gcc ggt gat gaa gtt cct cag ctg	2352
Lys Val Lys Asn Thr Gly Thr Gly Asn Val Ala Gly Asp Glu Val Pro Gln Leu	
770 775 780	
tac gtt tcc cta ggc ggc ccg aat gag ccc aag gtg gta ctg cgc aag	2400
Tyr Val Ser Leu Gly Gly Thr Asn Glu Pro Lys Val Val Leu Arg Lys	
785 790 795 800	
ttt gag cgt att cac ttg gcc cct tcg cag gag gcc gtg tgg aca acg	2448
Phe Glu Arg Ile His Leu Ala Pro Ser Gln Glu Ala Val Trp Thr Thr	
805 810 815	
acc ctt acc cgt cgt gac ctt gca aac tgg gac gtt tcg gct cag gac	2496
Thr Leu Thr Arg Arg Asp Leu Ala Asn Trp Asp Val Ser Ala Gln Asp	
820 825 830	
tgg acc gtc act cct tac ccc aag acg atc tac gtt gga aac tcc tca	2544
Trp Thr Val Thr Pro Tyr Pro Lys Thr Thr Ile Tyr Val Gly Asn Ser Ser	
835 840 845	
cgg aaa ctg ccg ctc cag gcc tcg ctg cct aag gcc cag taa	2586
Arg Lys Leu Pro Leu Gln Ala Ser Leu Pro Lys Ala Gln	
850 855 860	

Fig. 9I

ATG CGT TCC TCC CCC CTC CTC CGC TCC GCC GTT GTG GCC GCC CTG CCG GTG TTG GCC CTT GCC
M R S S P L L R S A V V A A L P V L A L A

Fig. 10

19/38




Fig. 11

20/38




Fig. 12

21/38




Fig. 13

22/38




Fig. 14

23/38




Fig. 15

24/38




Fig. 16

25/38




Fig. 17

26/38




Fig. 18

27/38




Fig. 19

28/38




Fig. 20

[illegible]

30/38

GATAACGGGGCTCTCAGCCAGATGGCAGATGTTGTCATCTCAATCCAGGTGAGTGGGGGCTCTTAGAAAAAGAACGTTCTCTGAATGAAAGTTTTTTAACCA 1900
D N G A L S Q M A D V A S Q S S
TTGCGAACAGCGTGTCTTTTGGTTTGTCAACGCCGACTCTGGAGAGGGTTTCATCAGTTCGACGGCAACGAGGTGACCGCAAAAAATCTCACTCTGTG 2000
V S L V F V N A D S G E G F I S V D G N E G D R K N L T L W
GAAGAACGGCGAGGCGGTCAATTGACACTGTTGTGACCCACTGCAACAACACGATTTGTGTTATTTCACAGTGTGGGCCCGTCTTGATCGACCGGTGGTAT 2100
K N G E A V I D T V V S H C N N T I V I H S V G P V L I D R W Y
GATAACCCCAACGTCACTGCCATCATCTGGCCCGGCTTGCCCGGTGAGAGTGGCACTCCCTGGTCCGACGTGCTCTATGGCCGCGTCAACCCCCAGCG 2200
D N P N V T A I I W A G L P G Q E S G N S L V D V L Y G R V N P S
CCAAGACCCCGTTCACTGGGGCAAGACTCGGGAGTCTTACGGGGCTCCCTTGCTCAACGAGCTAAATGGCAATGGTGTCTCCCGAGGATGATTCAA 2300
A K T P F T W G K T R E S Y G A P L L T E P N N G N G A P Q D D F N
CGAGGGCGTCTTCATTGACTACCGTCACITTTGACAAGCGCAATGAGACCCCAATTTATGAGTTTGGCCATGGCTTGAGCTACACCACCTTTGGTTACTCT 2400
E G V F I D Y R H F D K R N E T P I Y E F G H G L S Y T T F G Y S
CACCTTCGGGTTTCAGGCCCTCAATAGTTCGAGTTCGGCATATGTCGCCACTAGCGGAGAGACCAAGCCTGCGCCAACTATGGTGAGATCGGTAGTGCCG 2500
H L R V Q A L N S S S A Y V P T S G E T K P A P T Y G E I G S A
CCGACTACCTGTATCCCGAGGGTCTCAAAAGAAATTACCAAGTTTATTACCTTGGCTCAACTCGACCGACCTCGAGGATTTCTTGACGACCCGAACTA 2600
A D Y L Y P E G L K R I T K F I Y P W L N S T D L E D S S D D P N Y
CGGCTGGGAGGACTCGGAGTACATTCGCCAAGGCGGTAGGATGGGTCTCCTCAACCCCTCTCTGAAGGCTGGCGCGCTCCTGGTGGTAAACCTACCCCTT 2700
G W E D S E Y I P E G A R D G S P Q P L L K A G G A P G G N P T L
TATCAGGATCTTGTAGGTGTGGCCACCATAAACCAACTGTTAAGTCCCTCAATTTGGTGAGTGACCCGCAATGTTCTCTTGGC 2800
Y Q D L V R V S A T I T N T G N V A G Y E V P Q L
TTGCAATTGGCTAACTCGCTTCTAGTATGTTTCACTGGGCGGACCGAACGAGCCTCGGGTCTGTTCTGCGCAAGTTGACCGAATCTTCTGGCTCCTGG 2900
Y V S L G G P N E P R V V L R K F D R I F L A P G
GGAGCAAAAGGTTTGGACCAACGACTCTTAACCGTCTGATCTCGCCAATTGGCAATTTGGATGTGGAGGCTCAGGACTGGGTCAACAAAGTACCCCAAGAAAGTG 3000
E Q K V W T T T L N R R D L A N W D V E A Q D W V I T K Y P K K V
CACGTGGGCAGCTCCTCGCGTAAGTGCCTCTGAGAGCGGCTCTGCCCCGTGTCTACTAG 3060
H V G S S S R K L P L R A P L P R V Y .

Fig. 21B

31/38




Fig. 22

32/38




Fig. 23

33/38




Fig. 24

34/38




Fig. 25

35/38




Fig. 26

36/38




Fig. 27

37/38




Fig. 28

38/38




Fig. 29

SEQUENCE LISTING

<110> NOVOZYMES BIOTECH, INC.

<120> Variants of Beta-Glucosidases

<130> 10371.204-WO

<150> 60/467,767

<151> 2003-05-02

<150> 60/528,342

<151> 2003-12-09

<160> 92

<170> PatentIn version 3.2

<210> 1

<211> 2586

<212> DNA

<213> *Aspergillus oryzae*

<220>

<221> CDS

<222> (1)..(2583)

<400> 1

atg aag ctt ggt tgg atc gag gtg gcc gca ttg gcg gct gcc tca gta	48
Met Lys Leu Gly Trp Ile Glu Val Ala Ala Leu Ala Ala Ala Ser Val	
1 5 10 15	

gtc agt gcc aag gat gat ctc gcg tac tcc cct cct ttc tac cct tcc	96
Val Ser Ala Lys Asp Asp Leu Ala Tyr Ser Pro Pro Phe Tyr Pro Ser	
20 25 30	

cca tgg gca gat ggt cag ggt gaa tgg gcg gaa gta tac aaa cgc gct	144
Pro Trp Ala Asp Gly Gln Gly Glu Trp Ala Glu Val Tyr Lys Arg Ala	
35 40 45	

gta gac ata gtt tcc cag atg acg ttg aca gag aaa gtc aac tta acg	192
Val Asp Ile Val Ser Gln Met Thr Leu Thr Glu Lys Val Asn Leu Thr	
50 55 60	

act gga aca gga tgg caa cta gag agg tgt gtt gga caa act ggc agt	240
Thr Gly Thr Gly Trp Gln Leu Glu Arg Cys Val Gly Gln Thr Gly Ser	
65 70 75 80	

gtt ccc aga ctc aac atc ccc agc ttg tgt ttg cag gat agt cct ctt	288
Val Pro Arg Leu Asn Ile Pro Ser Leu Cys Leu Gln Asp Ser Pro Leu	
85 90 95	

ggt att cgt ttc tcg gac tac aat tca gct ttc cct gcg ggt gtt aat	336
Gly Ile Arg Phe Ser Asp Tyr Asn Ser Ala Phe Pro Ala Gly Val Asn	
100 105 110	

gtc gct gcc acc tgg gac aag acg ctc gcc tac ctt cgt ggt cag gca	384
Val Ala Ala Thr Trp Asp Lys Thr Leu Ala Tyr Leu Arg Gly Gln Ala	
115 120 125	

atg ggt gag gag ttc agt gat aag ggt att gac gtt cag ctg ggt cct	432
Met Gly Glu Glu Phe Ser Asp Lys Gly Ile Asp Val Gln Leu Gly Pro	
130 135 140	
gct gct ggc cct ctc ggt gct cat ccg gat ggc ggt aga aac tgg gaa	480
Ala Ala Gly Pro Leu Gly Ala His Pro Asp Gly Gly Arg Asn Trp Glu	
145 150 155 160	
ggt ttc tca cca gat cca gcc ctc acc ggt gta ctt ttt gcg gag acg	528
Gly Phe Ser Pro Asp Pro Ala Leu Thr Gly Val Leu Phe Ala Glu Thr	
165 170 175	
att aag ggt att caa gat gct ggt gtc att gcg aca gct aag cat tat	576
Ile Lys Gly Ile Gln Asp Ala Gly Val Ile Ala Thr Ala Lys His Tyr	
180 185 190	
atc atg aac gaa caa gag cat ttc cgc caa caa ccc gag gct gcg ggt	624
Ile Met Asn Glu Gln Glu His Phe Arg Gln Gln Pro Glu Ala Ala Gly	
195 200 205	
tac gga ttc aac gta agc gac agt ttg agt tcc aac gtt gat gac aag	672
Tyr Gly Phe Asn Val Ser Asp Ser Leu Ser Ser Asn Val Asp Asp Lys	
210 215 220	
act atg cat gaa ttg tac ctc tgg ccc ttc gcg gat gca gta cgc gct	720
Thr Met His Glu Leu Tyr Leu Trp Pro Phe Ala Asp Ala Val Arg Ala	
225 230 235 240	
gga gtc ggt gct gtc atg tgc tct tac aac caa atc aac aac agc tac	768
Gly Val Gly Ala Val Met Cys Ser Tyr Asn Gln Ile Asn Asn Ser Tyr	
245 250 255	
ggt tgc gag aat agc gaa act ctg aac aag ctt ttg aag gcg gag ctt	816
Gly Cys Glu Asn Ser Glu Thr Leu Asn Lys Leu Leu Lys Ala Glu Leu	
260 265 270	
ggt ttc caa ggc ttc gtc atg agt gat tgg acc gct cat cac agc ggc	864
Gly Phe Gln Gly Phe Val Met Ser Asp Trp Thr Ala His His Ser Gly	
275 280 285	
gta ggc gct gct tta gca ggt ctg gat atg tcg atg ccc ggt gat gtt	912
Val Gly Ala Ala Leu Ala Gly Leu Asp Met Ser Met Pro Gly Asp Val	
290 295 300	
acc ttc gat agt ggt acg tct ttc tgg ggt gca aac ttg acg gtc ggt	960
Thr Phe Asp Ser Gly Thr Ser Phe Trp Gly Ala Asn Leu Thr Val Gly	
305 310 315 320	
gtc ctt aac ggt aca atc ccc caa tgg cgt gtt gat gac atg gct gtc	1008
Val Leu Asn Gly Thr Ile Pro Gln Trp Arg Val Asp Asp Met Ala Val	
325 330 335	
cgt atc atg gcc gct tat tac aag gtt ggc cgc gac acc aaa tac acc	1056
Arg Ile Met Ala Ala Tyr Tyr Lys Val Gly Arg Asp Thr Lys Tyr Thr	
340 345 350	
cct ccc aac ttc agc tcg tgg acc agg gac gaa tat ggt ttc gcg cat	1104
Pro Pro Asn Phe Ser Ser Trp Thr Arg Asp Glu Tyr Gly Phe Ala His	
355 360 365	

aac cat gtt tcg gaa ggt gct tac gag agg gtc aac gaa ttc gtg gac Asn His Val Ser Glu Gly Ala Tyr Glu Arg Val Asn Glu Phe Val Asp 370 375 380	1152
gtg caa cgc gat cat gcc gac cta atc cgt cgc atc ggc gcg cag agc Val Gln Arg Asp His Ala Asp Leu Ile Arg Arg Ile Gly Ala Gln Ser 385 390 395 400	1200
act gtt ctg ctg aag aac aag ggt gcc ttg ccc ttg agc cgc aag gaa Thr Val Leu Leu Lys Asn Lys Gly Ala Leu Pro Leu Ser Arg Lys Glu 405 410 415	1248
aag ctg gtc gcc ctt ctg gga gag gat gcg ggt tcc aac tcg tgg ggc Lys Leu Val Ala Leu Leu Gly Glu Asp Ala Gly Ser Asn Ser Trp Gly 420 425 430	1296
gct aac ggc tgt gat gac cgt ggt tgc gat aac ggt acc ctt gcc atg Ala Asn Gly Cys Asp Asp Arg Gly Cys Asp Asn Gly Thr Leu Ala Met 435 440 445	1344
gcc tgg ggt agc ggt act gcg aat ttc cca tac ctc gtg aca cca gag Ala Trp Gly Ser Gly Thr Ala Asn Phe Pro Tyr Leu Val Thr Pro Glu 450 455 460	1392
cag gcg att cag aac gaa gtt ctt cag ggc cgt ggt aat gtc ttc gcc Gln Ala Ile Gln Asn Glu Val Leu Gln Gly Arg Gly Asn Val Phe Ala 465 470 475 480	1440
gtg acc gac agt tgg gcg ctc gac aag atc gct gcg gct gcc cgc cag Val Thr Asp Ser Trp Ala Leu Asp Lys Ile Ala Ala Ala Ala Arg Gln 485 490 495	1488
gcc agc gta tct ctc gtg ttc gtc aac tcc gac tca gga gaa ggc tat Ala Ser Val Ser Leu Val Phe Val Asn Ser Asp Ser Gly Glu Gly Tyr 500 505 510	1536
ctt agt gtg gat gga aat gag ggc gat cgt aac aac atc act ctg tgg Leu Ser Val Asp Gly Asn Glu Gly Asp Arg Asn Asn Ile Thr Leu Trp 515 520 525	1584
aag aac ggc gac aat gtg gtc aag acc gca gcg aat aac tgt aac aac Lys Asn Gly Asp Asn Val Val Lys Thr Ala Ala Asn Asn Cys Asn Asn 530 535 540	1632
acc gtt gtc atc atc cac tcc gtc gga cca gtt ttg atc gat gaa tgg Thr Val Val Ile Ile His Ser Val Gly Pro Val Leu Ile Asp Glu Trp 545 550 555 560	1680
tat gac cac ccc aat gtc act ggt att ctc tgg gct ggt ctg cca ggc Tyr Asp His Pro Asn Val Thr Gly Ile Leu Trp Ala Gly Leu Pro Gly 565 570 575	1728
cag gag tct ggt aac tcc att gcc gat gtg ctg tac ggt cgt gtc aac Gln Glu Ser Gly Asn Ser Ile Ala Asp Val Leu Tyr Gly Arg Val Asn 580 585 590	1776
cct ggc gcc aag tct cct ttc act tgg ggc aag acc cgg gag tcg tat Pro Gly Ala Lys Ser Pro Phe Thr Trp Gly Lys Thr Arg Glu Ser Tyr 595 600 605	1824

ggt tct ccc ttg gtc aag gat gcc aac aat ggc aac gga gcg ccc cag	1872
Gly Ser Pro Leu Val Lys Asp Ala Asn Asn Gly Asn Gly Ala Pro Gln	
610 615 620	
tct gat ttc acc cag ggt gtt ttc atc gat tac cgc cat ttc gat aag	1920
Ser Asp Phe Thr Gln Gly Val Phe Ile Asp Tyr Arg His Phe Asp Lys	
625 630 635 640	
ttc aat gag acc cct atc tac gag ttt ggc tac ggc ttg agc tac acc	1968
Phe Asn Glu Thr Pro Ile Tyr Glu Phe Gly Tyr Gly Leu Ser Tyr Thr	
645 650 655	
acc ttc gag ctc tcc gac ctc cat gtt cag ccc ctg aac gcg tcc cga	2016
Thr Phe Glu Leu Ser Asp Leu His Val Gln Pro Leu Asn Ala Ser Arg	
660 665 670	
tac act ccc acc agt ggc atg act gaa gct gca aag aac ttt ggt gaa	2064
Tyr Thr Pro Thr Ser Gly Met Thr Glu Ala Ala Lys Asn Phe Gly Glu	
675 680 685	
att ggc gat gcg tcg gag tac gtg tat ccg gag ggg ctg gaa agg atc	2112
Ile Gly Asp Ala Ser Glu Tyr Val Tyr Pro Glu Gly Leu Glu Arg Ile	
690 695 700	
cat gag ttt atc tat ccc tgg atc aac tct acc gac ctg aag gca tcg	2160
His Glu Phe Ile Tyr Pro Trp Ile Asn Ser Thr Asp Leu Lys Ala Ser	
705 710 715 720	
tct gac gat tct aac tac ggc tgg gaa gac tcc aag tat att ccc gaa	2208
Ser Asp Asp Ser Asn Tyr Gly Trp Glu Asp Ser Lys Tyr Ile Pro Glu	
725 730 735	
ggc gcc acg gat ggg tct gcc cag ccc cgt ttg ccc gct agt ggt ggt	2256
Gly Ala Thr Asp Gly Ser Ala Gln Pro Arg Leu Pro Ala Ser Gly Gly	
740 745 750	
gcc gga gga aac ccc ggt ctg tac gag gat ctt ttc cgc gtc tct gtg	2304
Ala Gly Gly Asn Pro Gly Leu Tyr Glu Asp Leu Phe Arg Val Ser Val	
755 760 765	
aag gtc aag aac acg ggc aat gtc gcc ggt gat gaa gtt cct cag ctg	2352
Lys Val Lys Asn Thr Gly Asn Val Ala Gly Asp Glu Val Pro Gln Leu	
770 775 780	
tac gtt tcc cta ggc ggc ccg aat gag ccc aag gtg gta ctg cgc aag	2400
Tyr Val Ser Leu Gly Gly Pro Asn Glu Pro Lys Val Val Leu Arg Lys	
785 790 795 800	
ttt gag cgt att cac ttg gcc cct tcg cag gag gcc gtg tgg aca acg	2448
Phe Glu Arg Ile His Leu Ala Pro Ser Gln Glu Ala Val Trp Thr Thr	
805 810 815	
acc ctt acc cgt cgt gac ctt gca aac tgg gac gtt tcg gct cag gac	2496
Thr Leu Thr Arg Arg Asp Leu Ala Asn Trp Asp Val Ser Ala Gln Asp	
820 825 830	
tgg acc gtc act cct tac ccc aag acg atc tac gtt gga aac tcc tca	2544
Trp Thr Val Thr Pro Tyr Pro Lys Thr Ile Tyr Val Gly Asn Ser Ser	
835 840 845	

cgg aaa ctg ccg ctc cag gcc tcg ctg cct aag gcc cag taa 2586
 Arg Lys Leu Pro Leu Gln Ala Ser Leu Pro Lys Ala Gln
 850 855 860

<210> 2
 <211> 861
 <212> PRT
 <213> *Aspergillus oryzae*

<400> 2

Met Lys Leu Gly Trp Ile Glu Val Ala Ala Leu Ala Ala Ala Ser Val
 1 5 10 15

Val Ser Ala Lys Asp Asp Leu Ala Tyr Ser Pro Pro Phe Tyr Pro Ser
 20 25 30

Pro Trp Ala Asp Gly Gln Gly Glu Trp Ala Glu Val Tyr Lys Arg Ala
 35 40 45

Val Asp Ile Val Ser Gln Met Thr Leu Thr Glu Lys Val Asn Leu Thr
 50 55 60

Thr Gly Thr Gly Trp Gln Leu Glu Arg Cys Val Gly Gln Thr Gly Ser
 65 70 75 80

Val Pro Arg Leu Asn Ile Pro Ser Leu Cys Leu Gln Asp Ser Pro Leu
 85 90 95

Gly Ile Arg Phe Ser Asp Tyr Asn Ser Ala Phe Pro Ala Gly Val Asn
 100 105 110

Val Ala Ala Thr Trp Asp Lys Thr Leu Ala Tyr Leu Arg Gly Gln Ala
 115 120 125

Met Gly Glu Glu Phe Ser Asp Lys Gly Ile Asp Val Gln Leu Gly Pro
 130 135 140

Ala Ala Gly Pro Leu Gly Ala His Pro Asp Gly Gly Arg Asn Trp Glu
 145 150 155 160

Gly Phe Ser Pro Asp Pro Ala Leu Thr Gly Val Leu Phe Ala Glu Thr
 165 170 175

Ile Lys Gly Ile Gln Asp Ala Gly Val Ile Ala Thr Ala Lys His Tyr
 180 185 190

Ile Met Asn Glu Gln Glu His Phe Arg Gln Gln Pro Glu Ala Ala Gly
 195 200 205

Tyr Gly Phe Asn Val Ser Asp Ser Leu Ser Ser Asn Val Asp Asp Lys
 210 215 220

Thr Met His Glu Leu Tyr Leu Trp Pro Phe Ala Asp Ala Val Arg Ala
 225 230 235 240

Gly Val Gly Ala Val Met Cys Ser Tyr Asn Gln Ile Asn Asn Ser Tyr
 245 250 255

Gly Cys Glu Asn Ser Glu Thr Leu Asn Lys Leu Leu Lys Ala Glu Leu
 260 265 270

Gly Phe Gln Gly Phe Val Met Ser Asp Trp Thr Ala His His Ser Gly
 275 280 285

Val Gly Ala Ala Leu Ala Gly Leu Asp Met Ser Met Pro Gly Asp Val
 290 295 300

Thr Phe Asp Ser Gly Thr Ser Phe Trp Gly Ala Asn Leu Thr Val Gly
 305 310 315 320

Val Leu Asn Gly Thr Ile Pro Gln Trp Arg Val Asp Asp Met Ala Val
 325 330 335

Arg Ile Met Ala Ala Tyr Tyr Lys Val Gly Arg Asp Thr Lys Tyr Thr
 340 345 350

Pro Pro Asn Phe Ser Ser Trp Thr Arg Asp Glu Tyr Gly Phe Ala His
 355 360 365

Asn His Val Ser Glu Gly Ala Tyr Glu Arg Val Asn Glu Phe Val Asp
 370 375 380

Val Gln Arg Asp His Ala Asp Leu Ile Arg Arg Ile Gly Ala Gln Ser
 385 390 395 400

Thr Val Leu Leu Lys Asn Lys Gly Ala Leu Pro Leu Ser Arg Lys Glu
 405 410 415

Lys Leu Val Ala Leu Leu Gly Glu Asp Ala Gly Ser Asn Ser Trp Gly
 420 425 430

Ala Asn Gly Cys Asp Asp Arg Gly Cys Asp Asn Gly Thr Leu Ala Met
 435 440 445

Ala Trp Gly Ser Gly Thr Ala Asn Phe Pro Tyr Leu Val Thr Pro Glu
 450 455 460

Gln Ala Ile Gln Asn Glu Val Leu Gln Gly Arg Gly Asn Val Phe Ala
 465 470 475 480

Val Thr Asp Ser Trp Ala Leu Asp Lys Ile Ala Ala Ala Ala Arg Gln
 485 490 495

Ala Ser Val Ser Leu Val Phe Val Asn Ser Asp Ser Gly Glu Gly Tyr
 500 505 510

Leu Ser Val Asp Gly Asn Glu Gly Asp Arg Asn Asn Ile Thr Leu Trp
 515 520 525

Lys Asn Gly Asp Asn Val Val Lys Thr Ala Ala Asn Asn Cys Asn Asn
 530 535 540

Thr Val Val Ile Ile His Ser Val Gly Pro Val Leu Ile Asp Glu Trp
 545 550 555 560

Tyr Asp His Pro Asn Val Thr Gly Ile Leu Trp Ala Gly Leu Pro Gly
 565 570 575

Gln Glu Ser Gly Asn Ser Ile Ala Asp Val Leu Tyr Gly Arg Val Asn
 580 585 590

Pro Gly Ala Lys Ser Pro Phe Thr Trp Gly Lys Thr Arg Glu Ser Tyr
 595 600 605

Gly Ser Pro Leu Val Lys Asp Ala Asn Asn Gly Asn Gly Ala Pro Gln
 610 615 620

Ser Asp Phe Thr Gln Gly Val Phe Ile Asp Tyr Arg His Phe Asp Lys
 625 630 635 640

Phe Asn Glu Thr Pro Ile Tyr Glu Phe Gly Tyr Gly Leu Ser Tyr Thr
 645 650 655

Thr Phe Glu Leu Ser Asp Leu His Val Gln Pro Leu Asn Ala Ser Arg
 660 665 670

Tyr Thr Pro Thr Ser Gly Met Thr Glu Ala Ala Lys Asn Phe Gly Glu
675 680 685

Ile Gly Asp Ala Ser Glu Tyr Val Tyr Pro Glu Gly Leu Glu Arg Ile
690 695 700

His Glu Phe Ile Tyr Pro Trp Ile Asn Ser Thr Asp Leu Lys Ala Ser
705 710 715 720

Ser Asp Asp Ser Asn Tyr Gly Trp Glu Asp Ser Lys Tyr Ile Pro Glu
725 730 735

Gly Ala Thr Asp Gly Ser Ala Gln Pro Arg Leu Pro Ala Ser Gly Gly
740 745 750

Ala Gly Gly Asn Pro Gly Leu Tyr Glu Asp Leu Phe Arg Val Ser Val
755 760 765

Lys Val Lys Asn Thr Gly Asn Val Ala Gly Asp Glu Val Pro Gln Leu
770 775 780

Tyr Val Ser Leu Gly Gly Pro Asn Glu Pro Lys Val Val Leu Arg Lys
785 790 795 800

Phe Glu Arg Ile His Leu Ala Pro Ser Gln Glu Ala Val Trp Thr Thr
805 810 815

Thr Leu Thr Arg Arg Asp Leu Ala Asn Trp Asp Val Ser Ala Gln Asp
820 825 830

Trp Thr Val Thr Pro Tyr Pro Lys Thr Ile Tyr Val Gly Asn Ser Ser
835 840 845

Arg Lys Leu Pro Leu Gln Ala Ser Leu Pro Lys Ala Gln
850 855 860

<210> 3
<211> 32
<212> DNA
<213> *Aspergillus oryzae*

<400> 3
gcagatctac catgaagctt ggttgatcg ag

32

<210> 4
<211> 30

<212> DNA
<213> *Aspergillus oryzae*

<400> 4
gcctcgagtt actgggcctt aggcagcgag 30

<210> 5
<211> 29
<212> DNA
<213> *Trichoderma reesei*

<400> 5
aacgttaatt aaggaatcgt tttgtgttt 29

<210> 6
<211> 29
<212> DNA
<213> *Trichoderma reesei*

<400> 6
agtactagta gtcctgtggc gaaagcctg 29

<210> 7
<211> 31
<212> DNA
<213> *Escherichia coli*

<400> 7
ttgaattgaa aatagattga tttaaaactt c 31

<210> 8
<211> 25
<212> DNA
<213> *Escherichia coli*

<400> 8
ttgcatgcgt aatcatggtc atagc 25

<210> 9
<211> 26
<212> DNA
<213> *Saccharomyces cerevisiae*

<400> 9
ttgaattcat gggtaataac tgatat 26

<210> 10
<211> 32
<212> DNA
<213> *Saccharomyces cerevisiae*

<400> 10
aaatcaatct attttcaatt caattcatca tt 32

<210> 11
<211> 45
<212> DNA
<213> *Aspergillus niger*

<400> 11
ggatgctgtt gactccggaa atttaacggt ttggtcttgc atccc 45

<210> 12
<211> 44
<212> DNA
<213> *Aspergillus niger*

<400> 12
ggtattgtcc tgcagacggc aatttaacgg cttctgcgaa tcgc 44

<210> 13
<211> 29
<212> DNA
<213> *Humicola insolens*

<400> 13
aagcttaagc atgcgttcct cccccctcc 29

<210> 14
<211> 32
<212> DNA
<213> *Humicola insolens*

<400> 14
ctgcagaatt ctacaggcac tgatggtacc ag 32

<210> 15
<211> 32
<212> DNA
<213> *Humicola insolens*

<400> 15
ctgcagaatt ctacaggcac tgatggtacc ag 32

<210> 16
<211> 36
<212> DNA
<213> *Humicola insolens*

<400> 16
accgcggact gcgcatcatg cgttcctccc ccctcc 36

<210> 17
<211> 29
<212> DNA
<213> *Trichoderma reesei*

<400> 17 aaacgtcgcac cgaatgtagg attggtatc	29
<210> 18 <211> 17 <212> DNA <213> Trichoderma reesei	
<400> 18 gatgcgcagt ccgcggt	17
<210> 19 <211> 29 <212> DNA <213> Trichoderma reesei	
<400> 19 aaacgtcgcac cgaatgtagg attggtatc	29
<210> 20 <211> 36 <212> DNA <213> Trichoderma reesei	
<400> 20 ggagggggga ggaacgcatg atgcgcagtc cgcggt	36
<210> 21 <211> 29 <212> DNA <213> Trichoderma reesei	
<400> 21 aaacgtcgcac cgaatgtagg attggtatc	29
<210> 22 <211> 32 <212> DNA <213> Trichoderma reesei	
<400> 22 ctgcagaatt ctacaggcac tgatggtacc ag	32
<210> 23 <211> 46 <212> DNA <213> Aspergillus oryzae	
<400> 23 atagtcaacc gcggactgcg catcatgaag cttgggttga tcgagg	46
<210> 24 <211> 26	

<212> DNA
 <213> *Aspergillus oryzae*

 <400> 24
 actagttttac tgggccttag gcagcg 26

 <210> 25
 <211> 26
 <212> DNA
 <213> *Trichoderma reesei*

 <400> 25
 gtcgactcga agcccgaatg taggat 26

 <210> 26
 <211> 45
 <212> DNA
 <213> *Trichoderma reesei*

 <400> 26
 cctcgatcca accaagcttc atgatgcgca gtccgcggtt gacta 45

 <210> 27
 <211> 42
 <212> DNA
 <213> *Aspergillus oryzae*

 <400> 27
 tgccggtgtt ggcccttgcc aaggatgatc tcgctactc cc 42

 <210> 28
 <211> 28
 <212> DNA
 <213> *Aspergillus oryzae*

 <400> 28
 gactagtctt actgggcctt aggcagcg 28

 <210> 29
 <211> 63
 <212> DNA
 <213> *Humicola insolens*

 <400> 29
 atgcgttcct ccccccctcct ccgctccgcc gttgtggccg cactgccggt gttggccctt 60
 gcc 63

 <210> 30
 <211> 30
 <212> DNA
 <213> *Aspergillus oryzae*

 <400> 30

acgcgtcgac cgaatgtagg attggtatcc 30

<210> 31
<211> 42
<212> DNA
<213> Aspergillus oryzae

<400> 31
gggagtagcg gagatcatcc ttggcaaggg ccaacaccgg ca 42

<210> 32
<211> 40
<212> DNA
<213> Aspergillus oryzae

<400> 32
aatccgacta gtggatctac catgcgttcc tccccctcc 40

<210> 33
<211> 32
<212> DNA
<213> Aspergillus oryzae

<400> 33
gcgggcctcg agttactggg ccttaggcag cg 32

<210> 34
<211> 17
<212> DNA
<213> Aspergillus oryzae

<400> 34
agggtgaatg ggcggaa 17

<210> 35
<211> 20
<212> DNA
<213> Aspergillus oryzae

<400> 35
gacatttttg ctgtcagtca 20

<210> 36
<211> 20
<212> DNA
<213> Aspergillus oryzae

<400> 36
aatgttacat gcgtacacgc 20

<210> 37
<211> 17
<212> DNA

<213> Aspergillus oryzae
<400> 37
gtttcggctc aggactg 17

<210> 38
<211> 17
<212> DNA
<213> Aspergillus oryzae
<400> 38
acttccgccc attcacc 17

<210> 39
<211> 17
<212> DNA
<213> Aspergillus oryzae
<400> 39
agggtgaatg ggcggaa 17

<210> 40
<211> 17
<212> DNA
<213> Aspergillus oryzae
<400> 40
ggcggaaatg ctcttgt 17

<210> 41
<211> 18
<212> DNA
<213> Aspergillus oryzae
<400> 41
sggatggcgg tagaaact 18

<210> 42
<211> 17
<212> DNA
<213> Aspergillus oryzae
<400> 42
gcggtccaat cactcat 17

<210> 43
<211> 17
<212> DNA
<213> Aspergillus oryzae
<400> 43
gctacggttg cgagaat 17

<210> 44
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 44
ctcaaggga aggcacc 17

<210> 45
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 45
ggtgccttgc ccttgag 17

<210> 46
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 46
ttcgctgcgg tcttgac 17

<210> 47
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 47
gtggaagaac ggcgaca 17

<210> 48
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 48
cccagccgta gttagaa 17

<210> 49
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 49
cgtcccgata cactccc 17

<210> 50
<211> 17
<212> DNA
<213> *Aspergillus oryzae*

<400> 50

cctggagcgg cagtttc 17

<210> 51
<211> 18
<212> DNA
<213> Aspergillus oryzae

<400> 51
ggtcggtgtc cttaacgg 18

<210> 52
<211> 20
<212> DNA
<213> Aspergillus oryzae

<400> 52
actatcctgc aaacacaagc 20

<210> 53
<211> 16
<212> DNA
<213> Aspergillus oryzae

<400> 53
cctttcactt ggggca 16

<210> 54
<211> 20
<212> DNA
<213> Aspergillus oryzae

<400> 54
ggagttacca gactcctggc 20

<210> 55
<211> 20
<212> DNA
<213> Aspergillus oryzae

<400> 55
accttccgaa acatggttat 20

<210> 56
<211> 39
<212> DNA
<213> Aspergillus oryzae

<220>
<221> misc_feature
<222> (16)..(17)
<223> n is a, c, g, or t

<400> 56

ggtagaaact gggaannstt ctcaccagat ccagccctc

39

<210> 57
<211> 33
<212> DNA
<213> *Aspergillus oryzae*

<220>
<221> misc_feature
<222> (16)..(17)
<223> n is a, c, g, or t

<400> 57
gcctacgccg ctgtgnnsag cgtccaatc act

33

<210> 58
<211> 22
<212> DNA
<213> *Aspergillus nidulens*

<400> 58
gtgccccatg atacgcctcc gg

22

<210> 59
<211> 26
<212> DNA
<213> *Aspergillus nidulens*

<400> 59
gagtcgtatt tccaaggctc ctgacc

26

<210> 60
<211> 23
<212> DNA
<213> *Aspergillus nidulens*

<400> 60
ggaggccatg aagtggacca acg

23

<210> 61
<211> 45
<212> DNA
<213> *Aspergillus niger*

<400> 61
cacgctgaaa gccatgctct ttccttcgtg tagaagacca gacag

45

<210> 62
<211> 45
<212> DNA
<213> *Aspergillus niger*

<400> 62

ctggtcttct acacgaagga aagagcatgg ctttcacggg gtctg 45

<210> 63
<211> 44
<212> DNA
<213> *Aspergillus niger*

<400> 63
ctatatacac aactggattt accatggggc cgcggccgca gatc 44

<210> 64
<211> 44
<212> DNA
<213> *Aspergillus niger*

<400> 64
gatctgcggc cgcggggcca tggtaaattc agttgtgtat atag 44

<210> 65
<211> 30
<212> DNA
<213> *Aspergillus oryzae*

<400> 65
actggattta ccatgaagct tggttggatc 30

<210> 66
<211> 30
<212> DNA
<213> *Aspergillus oryzae*

<400> 66
agtcacctct agttattact gggccttagg 30

<210> 67
<211> 31
<212> DNA
<213> *Aspergillus fumigatus*

<400> 67
actggattta ccatgagatt cggttggctc g 31

<210> 68
<211> 31
<212> DNA
<213> *Aspergillus fumigatus*

<400> 68
agtcacctct agttactagt agacacgggg c 31

<210> 69
<211> 3060
<212> DNA

<213> *Aspergillus fumigatus*

<400> 69

atgagattcg gttggctcga ggtggccgct ctgacggccg cttctgtagc caatgccag	60
gtttgtgatg ctttcccgtc attgtttcgg atatagttga caatagtcac ggaaataatc	120
aggaattggc tttctctcca ccattctacc cttcgccttg ggctgatggc cagggagagt	180
gggcagatgc ccatcgacgc gccgtcgaga tcgtttctca gatgacactg gcggagaagg	240
ttaaccttac aacgggtact ggggtgggtg cgactttttt gttgacagtg agctttcttc	300
actgaccatc tacacagatg ggaaatggac cgatgcgtcg gtcaaaccgg cagcgttccc	360
aggtaagctt gcaattctgc aacaacgtgc aagtgtagtt gctaaaacgc ggtggtgcag	420
acttggtatc aactggggtc tttgtggcca ggattcccct ttgggtatcc gtttctgtga	480
gctatacccg cggagtcttt cagtccttgt attatgtgct gatgattgtc tctgtatagc	540
tgacctcaac tccgccttcc ctgctggtac taatgtcgcc gcgacatggg acaagacact	600
cgcctacctt cgtggcaagg ccatgggtga ggaattcaac gacaagggcg tggacatttt	660
gctggggcct gctgctggtc ctctcggcaa ataccggac ggcggcagaa tctgggaagg	720
cttctctcct gatccggttc tcaactggtg acttttcgcc gaaactatca agggatatca	780
agacgcgggt gtgattgcta ctgccaagca ttacattctg aatgaacagg agcatttccg	840
acaggttggc gagggcccagg gatatggtta caacatcacg gagacgatca gctccaacgt	900
ggatgacaag accatgcacg agttgtacct ttggtgagta gttgacactg caaatgagga	960
ccttgattga tttgactgac ctggaatgca ggccctttgc agatgctgtg cgcggtaaga	1020
ttttccgtag acttgacctc gcgacgaaga aatcgctgac gaaccatcgt agctggcggt	1080
ggcgtgtca tgtgttcta caatcaaate aacaacagct acggttgtca aaacagtcaa	1140
actctcaaca agctcctcaa ggctgagctg ggcttccaag gcttcgtcat gagtactgg	1200
agcgtctacc acagcgggtg cggcgtgcc ctcgctgggt tggatatgtc gatgcctgga	1260
gacatttcct tcgacgacgg actctccttc tggggcacga acctaactgt cagtgttctt	1320
aacggcaccg ttccagcctg gcgtgtcgat gacatggctg ttcgtatcat gaccgcgtac	1380
tacaagggtg gtcgtgaccg tcttcgtatt ccccctaact tcagctcctg gaccgggat	1440
gagtacggct gggagcattc tgctgtctcc gagggagcct ggaccaagggt gaacgacttc	1500
gtcaatgtgc agcgcagtca ctctcagatc atccgtgaga ttggtgccgc tagtacagt	1560
ctcttgaaga acacgggtgc tcttcctttg accggcaagg aggttaaagt ggggtgttctc	1620
ggtgaagacg ctggttccaa cccgtgggggt gctaacggct gccccgaccg cggctgtgat	1680
aacggcactc ttgctatggc ctggggtagt ggtactgcca acttccctta ccttgtcacc	1740

```

cccgagcagg ctatccagcg agaggatcatc agcaacggcg gcaatgtctt tgctgtgact 1800
gataacgggg ctctcagcca gatggcagat gttgcatctc aatccagggtg agtgcgggct 1860
cttagaaaaa gaacgttctc tgaatgaagt tttttaacca ttgcgaacag cgtgtctttg 1920
gtgtttgtca acgcccagctc tggagagggt ttcacagtg tgcacggcaa cgagggtgac 1980
cgcaaaaatc tcactctgtg gaagaacggc gagggcgtca ttgacactgt tgcagccac 2040
tgcaacaaca cgattgtggg tattcacagt gttgggcccg tcttgatcga ccggtggtat 2100
gataacccca acgtcactgc catcatctgg gccggccttc ccggtcagga gaggggcaac 2160
tccctggtcg acgtgctcta tggccgcgtc aaccccagcg ccaagacccc gttcacctgg 2220
ggcaagactc gggagtctta cggggctccc ttgctcaccg agcctaacaa tggcaatggg 2280
gctccccagg atgatttcaa cgagggcgtc ttcattgact accgtcactt tgacaagcgc 2340
aatgagaccc ccatttatga gtttggccat ggcttgagct acaccacctt tggttactct 2400
caccttcggg ttcaggccct caatagtctg agttcggcat atgtcccgc tagcggagag 2460
accaagcctg cgccaacctt tggtagatc ggtagtgccg ccgactacct gtatcccag 2520
ggtctcaaaa gaattaccaa gtttatctac ccttggctca actcgaccga cctcgaggat 2580
tcttctgacg acccgaacta cggctgggag gactcggagt acattcccga aggcgctagg 2640
gatgggtctc ctcaaccctt cctgaaggct ggccggcgtc ctgggtggtaa ccctaccctt 2700
tatcaggatc ttgttagggg gtcggccacc ataaccaaca ctggtaacgt cgccgggtat 2760
gaagtccctc aattggtgag tgaccgcgtt gttccttgcg ttgcaatttg gctaactcgc 2820
ttctagtatg tttcactggg cggaccgaac gagcctcggg tcgttctgcg caagtctgac 2880
cgaatcttcc tggctcctgg ggagcaaaag gtttggacca cgactcttaa ccgtcgtgat 2940
ctcgccaatt gggatgtgga ggctcaggac tgggtcatca caaagtaccc caagaaagtg 3000
cacgtcggca gctcctcgcg taagctgcct ctgagagcgc ctctgccccg tgtctactag 3060

```

<210> 70

<211> 863

<212> PRT

<213> *Aspergillus fumigatus*

<400> 70

```

Met Arg Phe Gly Trp Leu Glu Val Ala Ala Leu Thr Ala Ala Ser Val
1           5           10           15

```

```

Ala Asn Ala Gln Glu Leu Ala Phe Ser Pro Pro Phe Tyr Pro Ser Pro
20           25           30

```

Trp Ala Asp Gly Gln Gly Glu Trp Ala Asp Ala His Arg Arg Ala Val
 35 40 45
 Glu Ile Val Ser Gln Met Thr Leu Ala Glu Lys Val Asn Leu Thr Thr
 50 55 60
 Gly Thr Gly Trp Glu Met Asp Arg Cys Val Gly Gln Thr Gly Ser Val
 65 70 75 80
 Pro Arg Leu Gly Ile Asn Trp Gly Leu Cys Gly Gln Asp Ser Pro Leu
 85 90 95
 Gly Ile Arg Phe Ser Asp Leu Asn Ser Ala Phe Pro Ala Gly Thr Asn
 100 105 110
 Val Ala Ala Thr Trp Asp Lys Thr Leu Ala Tyr Leu Arg Gly Lys Ala
 115 120 125
 Met Gly Glu Glu Phe Asn Asp Lys Gly Val Asp Ile Leu Leu Gly Pro
 130 135 140
 Ala Ala Gly Pro Leu Gly Lys Tyr Pro Asp Gly Gly Arg Ile Trp Glu
 145 150 155 160
 Gly Phe Ser Pro Asp Pro Val Leu Thr Gly Val Leu Phe Ala Glu Thr
 165 170 175
 Ile Lys Gly Ile Gln Asp Ala Gly Val Ile Ala Thr Ala Lys His Tyr
 180 185 190
 Ile Leu Asn Glu Gln Glu His Phe Arg Gln Val Gly Glu Ala Gln Gly
 195 200 205
 Tyr Gly Tyr Asn Ile Thr Glu Thr Ile Ser Ser Asn Val Asp Asp Lys
 210 215 220
 Thr Met His Glu Leu Tyr Leu Trp Pro Phe Ala Asp Ala Val Arg Ala
 225 230 235 240
 Gly Val Gly Ala Val Met Cys Ser Tyr Asn Gln Ile Asn Asn Ser Tyr
 245 250 255
 Gly Cys Gln Asn Ser Gln Thr Leu Asn Lys Leu Leu Lys Ala Glu Leu
 260 265 270

Gly Phe Gln Gly Phe Val Met Ser Asp Trp Ser Ala His His Ser Gly
 275 280 285

Val Gly Ala Ala Leu Ala Gly Leu Asp Met Ser Met Pro Gly Asp Ile
 290 295 300

Ser Phe Asp Asp Gly Leu Ser Phe Trp Gly Thr Asn Leu Thr Val Ser
 305 310 315 320

Val Leu Asn Gly Thr Val Pro Ala Trp Arg Val Asp Asp Met Ala Val
 325 330 335

Arg Ile Met Thr Ala Tyr Tyr Lys Val Gly Arg Asp Arg Leu Arg Ile
 340 345 350

Pro Pro Asn Phe Ser Ser Trp Thr Arg Asp Glu Tyr Gly Trp Glu His
 355 360 365

Ser Ala Val Ser Glu Gly Ala Trp Thr Lys Val Asn Asp Phe Val Asn
 370 375 380

Val Gln Arg Ser His Ser Gln Ile Ile Arg Glu Ile Gly Ala Ala Ser
 385 390 395 400

Thr Val Leu Leu Lys Asn Thr Gly Ala Leu Pro Leu Thr Gly Lys Glu
 405 410 415

Val Lys Val Gly Val Leu Gly Glu Asp Ala Gly Ser Asn Pro Trp Gly
 420 425 430

Ala Asn Gly Cys Pro Asp Arg Gly Cys Asp Asn Gly Thr Leu Ala Met
 435 440 445

Ala Trp Gly Ser Gly Thr Ala Asn Phe Pro Tyr Leu Val Thr Pro Glu
 450 455 460

Gln Ala Ile Gln Arg Glu Val Ile Ser Asn Gly Gly Asn Val Phe Ala
 465 470 475 480

Val Thr Asp Asn Gly Ala Leu Ser Gln Met Ala Asp Val Ala Ser Gln
 485 490 495

Ser Ser Val Ser Leu Val Phe Val Asn Ala Asp Ser Gly Glu Gly Phe
 500 505 510

Ile Ser Val Asp Gly Asn Glu Gly Asp Arg Lys Asn Leu Thr Leu Trp
 515 520 525

Lys Asn Gly Glu Ala Val Ile Asp Thr Val Val Ser His Cys Asn Asn
 530 535 540

Thr Ile Val Val Ile His Ser Val Gly Pro Val Leu Ile Asp Arg Trp
 545 550 555 560

Tyr Asp Asn Pro Asn Val Thr Ala Ile Ile Trp Ala Gly Leu Pro Gly
 565 570 575

Gln Glu Ser Gly Asn Ser Leu Val Asp Val Leu Tyr Gly Arg Val Asn
 580 585 590

Pro Ser Ala Lys Thr Pro Phe Thr Trp Gly Lys Thr Arg Glu Ser Tyr
 595 600 605

Gly Ala Pro Leu Leu Thr Glu Pro Asn Asn Gly Asn Gly Ala Pro Gln
 610 615 620

Asp Asp Phe Asn Glu Gly Val Phe Ile Asp Tyr Arg His Phe Asp Lys
 625 630 635 640

Arg Asn Glu Thr Pro Ile Tyr Glu Phe Gly His Gly Leu Ser Tyr Thr
 645 650 655

Thr Phe Gly Tyr Ser His Leu Arg Val Gln Ala Leu Asn Ser Ser Ser
 660 665 670

Ser Ala Tyr Val Pro Thr Ser Gly Glu Thr Lys Pro Ala Pro Thr Tyr
 675 680 685

Gly Glu Ile Gly Ser Ala Ala Asp Tyr Leu Tyr Pro Glu Gly Leu Lys
 690 695 700

Arg Ile Thr Lys Phe Ile Tyr Pro Trp Leu Asn Ser Thr Asp Leu Glu
 705 710 715 720

Asp Ser Ser Asp Asp Pro Asn Tyr Gly Trp Glu Asp Ser Glu Tyr Ile
 725 730 735

Pro Glu Gly Ala Arg Asp Gly Ser Pro Gln Pro Leu Leu Lys Ala Gly
 740 745 750

Gly Ala Pro Gly Gly Asn Pro Thr Leu Tyr Gln Asp Leu Val Arg Val
 755 760 765

Ser Ala Thr Ile Thr Asn Thr Gly Asn Val Ala Gly Tyr Glu Val Pro
 770 775 780

Gln Leu Tyr Val Ser Leu Gly Gly Pro Asn Glu Pro Arg Val Val Leu
 785 790 795 800

Arg Lys Phe Asp Arg Ile Phe Leu Ala Pro Gly Glu Gln Lys Val Trp
 805 810 815

Thr Thr Thr Leu Asn Arg Arg Asp Leu Ala Asn Trp Asp Val Glu Ala
 820 825 830

Gln Asp Trp Val Ile Thr Lys Tyr Pro Lys Lys Val His Val Gly Ser
 835 840 845

Ser Ser Arg Lys Leu Pro Leu Arg Ala Pro Leu Pro Arg Val Tyr
 850 855 860

<210> 71
 <211> 2589
 <212> DNA
 <213> *Aspergillus fumigatus*

<400> 71
 atgagattcg gttggctcga ggtggccgct ctgacggccg cttctgtagc caatgccag 60
 gaattggctt tctctccacc attctaccct tcgccttggg ctgatggcca gggagagtgg 120
 gcagatgccc atcgacgcgc cgtcgagatc gtttctcaga tgacactggc ggagaaggtt 180
 aaccttaciaa cgggtactgg atgggaaatg gaccgatgcg tcggtcaaac cggcagcggt 240
 cccagacttg gtatcaactg gggctcttgt ggccaggatt cccctttggg tatccgtttc 300
 tctgacctca actccgcctt ccctgctggt actaatgtcg ccgcgacatg ggacaagaca 360
 ctgcctacc ttcgtggcaa ggccatgggt gaggaattca acgacaaggg cgtggacatt 420
 ttgctggggc ctgctgctgg tcctctcggc aaatacccg acggcggcag aatctgggaa 480
 ggcttctctc ctgatccggc tctcactggt gtacttttcg ccgaaactat caagggtatc 540
 caagacgcgg gtgtgattgc tactgccaaag cattacattc tgaatgaaca ggagcatttc 600
 cgacaggttg gcgaggccca gggatatggt tacaacatca cggagacgat cagctccaac 660
 gtggatgaca agaccatgca cgagttgtac ctttggccct ttgcagatgc tgtgcgcgct 720
 ggcgttggcg ctgtcatgtg ttctacaat caaatcaaca acagctacgg ttgtcaaaac 780

agtcaaactc tcaacaagct cctcaaggct gagctgggct tccaaggctt cgtcatgagt	840
gactggagcg ctcaccacag cgggtgctggc gctgccctcg ctggggttgga tatgtcgatg	900
cccggagaca tttccttcga cgacggactc tccttctggg gcacgaacct aactgtcagt	960
gttcttaacg gcaccgttcc agcctggcgt gtcgatgaca tggctgttcg tatcatgacc	1020
gcgtactaca aggttggtcg tgaccgtctt cgtattcccc ctaacttcag ctcttgacc	1080
cgggatgagt acggctggga gcattctgct gtctccgagg gagcctggac caaggtgaac	1140
gacttcgtca atgtgcagcg cagtcactct cagatcatcc gtgagattgg tgccgctagt	1200
acagtgtctt tgaagaacac ggggtgtctt cctttgaccg gcaaggaggt taaagtgggt	1260
gttctcggtg aagacgctgg ttccaacccg tggggtgcta acggctgccc cgaccgcggc	1320
tgtgataacg gcactcttgc tatggcctgg ggtagtggtg ctgccaaactt cccttacctt	1380
gtcacccccg agcaggctat ccagcgagag gtcacagca acggcggcaa tgtctttgct	1440
gtgactgata acggggctct cagccagatg gcagatgttg catctcaatc cagcgtgtct	1500
ttggtgtttg tcaacgccga ctctggagag ggtttcatca gtgtcgacgg caacgaggggt	1560
gaccgcaaaa atctcactct gtggaagaac ggcgaggccg tcattgacac tgttgtcagc	1620
cactgcaaca acacgattgt gggtattcac agtggtgggc ccgtcttgat cgaccggtgg	1680
tatgataacc ccaacgtcac tgccatcatc tgggccggct tgcccggta ggagagtggc	1740
aactccctgg tcgacgtgct ctatggccgc gtcaacccca gcgccaagac cccgttcacc	1800
tggggcaaga ctcgggagtc ttacggggct cccttgctca ccgagcctaa caatggcaat	1860
ggtgctcccc aggatgattt caacgagggc gtcttcattg actaccgtca ctttgacaag	1920
cgcaatgaga ccccatatta tgagtttggc catggcttga gctacaccac ctttggttac	1980
tctcaccttc gggttcaggc cctcaatagt tcgagttcgg catatgtccc gactagcgga	2040
gagaccaagc ctgcgccaac ctatggtgag atcggtagt cgcgcgacta cctgtatccc	2100
gagggctctca aaagaattac caagtttatt tacccttggc tcaactcgac cgacctcgag	2160
gattctttctg acgacccgaa ctacggctgg caggactcgg agtacattcc cgaaggcgt	2220
agggatgggt ctctcaacc cctcctgaag gctggcggcg ctctggtgg taacctacc	2280
ctttatcagg atcttgtag ggtgtcggc accataacca aactggtaa cgtcgcgggt	2340
tatgaagtcc ctcaattgta tgtttcattg ggcggaccga acgagcctcg ggtcgttctg	2400
cgcaagttcg accgaatctt cctggctcct ggggagcaaa aggtttggac cagcactctt	2460
aaccgtcgtg atctcgccaa ttgggatgtg gaggtcagg actgggtcat cacaagtac	2520
cccaagaaag tgcacgtcgg cagctcctcg cgtaagctgc ctctgagagc gcctctgccc	2580

cgtgtctac 2589

<210> 72
<211> 29
<212> DNA
<213> Aspergillus fumigatus

<400> 72
ggctcatgag attcggttgg ctcgaggtc 29

<210> 73
<211> 30
<212> DNA
<213> Aspergillus fumigatus

<400> 73
gccgttatca cagccgcggt cggggcagcc 30

<210> 74
<211> 30
<212> DNA
<213> Aspergillus fumigatus

<400> 74
ggctgccccg accgcggctg tgataacggc 30

<210> 75
<211> 35
<212> DNA
<213> Aspergillus fumigatus

<400> 75
gcttaattaa tctagtagac acggggcaga ggcgc 35

<210> 76
<211> 16
<212> DNA
<213> Aspergillus fumigatus

<400> 76
acactggcgg agaagg 16

<210> 77
<211> 18
<212> DNA
<213> Aspergillus fumigatus

<400> 77
gcccagggat atggttac 18

<210> 78
<211> 19

<212> DNA
<213> *Aspergillus fumigatus*

<400> 78
cgactctgga gagggtttc 19

<210> 79
<211> 19
<212> DNA
<213> *Aspergillus fumigatus*

<400> 79
ggactgggtc atcacaaag 19

<210> 80
<211> 17
<212> DNA
<213> *Aspergillus fumigatus*

<400> 80
gcgagaggtc atcagca 17

<210> 81
<211> 17
<212> DNA
<213> *Aspergillus fumigatus*

<400> 81
gtaaaacgac ggccagt 17

<210> 82
<211> 16
<212> DNA
<213> *Aspergillus fumigatus*

<400> 82
caggaaacag ctatga 16

<210> 83
<211> 69
<212> DNA
<213> *Aspergillus fumigatus*

<400> 83
cttcttggtta gtgcaatata atatagaagt catcgactag tggatctacc atgagattcg 60
gttggtctcg 69

<210> 84
<211> 61
<212> DNA
<213> *Aspergillus fumigatus*

<400> 84

gcgtgaatgt aagcgtgaca taactaatta catgactcga gctagtagac acgggggcaga 60

g 61

<210> 85

<211> 60

<212> DNA

<213> *Aspergillus fumigatus*

<400> 85

ccgctccgcc gttgtggccg cctgcccgt gttggccctt gccgaattgg ctttctctcc 60

<210> 86

<211> 17

<212> DNA

<213> *Aspergillus fumigatus*

<400> 86

ctggcgttgg cgctgtc 17

<210> 87

<211> 30

<212> DNA

<213> *Aspergillus fumigatus*

<400> 87

gcggcagaat ctgggaaagc ttctctcctg 30

<210> 88

<211> 30

<212> DNA

<213> *Aspergillus fumigatus*

<400> 88

caggagagaa gctttcccag attctgccgc 30

<210> 89

<211> 29

<212> DNA

<213> *Aspergillus fumigatus*

<400> 89

tgactggagc gctcaacaca gcggtgtcg 29

<210> 90

<211> 29

<212> DNA

<213> *Aspergillus fumigatus*

<400> 90

cgacaccgct gtgttgagcg ctccagtca 29

<210> 91

<211> 30
<212> DNA
<213> *Aspergillus fumigatus*

<400> 91
gaggattctt ctggcgaccc gaactacggc

30

<210> 92
<211> 30
<212> DNA
<213> *Aspergillus fumigatus*

<400> 92
gccgtagttc gggtcgccag aagaatcctc


30

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>108</u> , line <u>11</u> .	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet ☐	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit May 2, 2003	Accession Number B-30652
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
In respect of those designations in which a European and/or Australia Patent is sought, during the pendency of the patent application, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (Rule 28(4) EPC/Regulation 3.25 of Australia Statutory Rule 1991 No. 71).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

☒ This sheet was received with the international application
Authorized officer: 

For International Bureau use only

☐ This sheet was received with the International Bureau on:
Authorized officer